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A B S T R A C T
Background
This living systematic review is one of several Cochrane Reviews evaluating the medical management of patients with chronic
rhinosinusitis.
Chronic rhinosinusitis is common. It is characterised by inflammation of the nasal and sinus linings, nasal blockage, rhinorrhoea, facial
pressure/pain and loss of sense of smell. It occurs with or without nasal polyps. 
'Biologics' are medicinal products produced by a biological process. Monoclonal antibodies are one type, already evaluated in related
inflammatory conditions (e.g. asthma and atopic dermatitis).
Objectives
To assess the eKects of biologics for the treatment of chronic rhinosinusitis.
Search methods
The Cochrane ENT Information Specialist searched the Cochrane ENT Register; CENTRAL (2019, Issue 9); Ovid MEDLINE; Ovid Embase; Web
of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 16 September
2019.
Selection criteria
Randomised controlled trials (RCTs) with at least three months follow-up comparing biologics (currently, monoclonal antibodies) against
placebo/no treatment in patients with chronic rhinosinusitis.
Data collection and analysis
We used standard Cochrane methodological procedures. Our primary outcomes were disease-specific health-related quality of life (HRQL),
disease severity and serious adverse events (SAEs). The secondary outcomes were avoidance of surgery, extent of disease (measured by
endoscopic or computerised tomography (CT) score), generic HRQL and adverse events (nasopharyngitis, including sore throat). We used
GRADE to assess the certainty of the evidence for each outcome.
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Main results
We included eight RCTs. Of 986 adult participants, 984 had severe chronic rhinosinusitis with nasal polyps; 43% to 100% of participants
also had asthma. Three biologics, with diKerent targets, were evaluated: dupilumab, mepolizumab and omalizumab. All the studies were
sponsored or supported by industry.
Anti-IL-4Rα mAb (dupilumab) versusplacebo/no treatment (all receiving intranasal steroids)
Three studies (784 participants) evaluated dupilumab.
Disease-specific HRQL was measured with the SNOT-22 (score 0 to 110; minimal clinically important diKerence (MCID) 8.9 points). At 24
weeks, the SNOT-22 score was 19.61 points lower (better) in participants receiving dupilumab (mean diKerence (MD) -19.61, 95% confidence
interval (CI) -22.54 to -16.69; 3 studies; 784 participants; high certainty).
Symptom severity measured on a 0- to 10-point visual analogue scale (VAS) was 3.00 lower in those receiving dupilumab (95% CI -3.47 to
-2.53; 3 studies; 784 participants; moderate certainty).
The risk of serious adverse events may be lower in the dupilumab group (risk ratio (RR) 0.45, 95% CI 0.28 to 0.75; 3 studies; 782 participants;
low certainty).
The number of participants requiring nasal polyp surgery (actual or planned) during the treatment period  is probably lower in those
receiving dupilumab (RR 0.17, 95% CI 0.05 to 0.52; 2 studies; 725 participants; moderate certainty).
Change in the extent of disease using the Lund Mackay computerised tomography (CT) score (0 to 24, higher = worse) was -7.00 (95% CI
-9.61 to -4.39; 3 studies; 784 participants; high certainty), a large eKect favouring the dupilumab group.
The EQ-5D visual analogue scale (0 to 100, higher = better; MCID 8 points) was used to measure change in generic quality of life. The mean
diKerence favouring dupilumab was 8.59 (95% CI 5.31 to 11.86; 2 studies; 706 participants; moderate certainty).
There may be little or no diKerence in the risk of nasopharyngitis (RR 0.95, 95% CI 0.72 to 1.25; 3 studies; 783 participants; low certainty).
Anti-IL-5 mAb (mepolizumab) versusplacebo/no treatment (all receiving intranasal steroids)
Two studies (137 participants) evaluated mepolizumab.
Disease-specific HRQL measured with the SNOT-22 at 25 weeks was 13.26 points lower (better) in participants receiving mepolizumab
(95% CI -22.08 to -4.44; 1 study; 105 participants; low certainty; MCID 8.9).
It is very uncertain whether there is a diKerence in s ymptom severity: on a 0- to 10-point VAS symptom severity was -2.03 lower in those
receiving mepolizumab (95% CI -3.65 to -0.41; 1 study; 72 participants; very low certainty).
It is very uncertain if there is diKerence in the risk of serious adverse events (RR 1.57, 95% CI 0.07 to 35.46; 2 studies; 135 participants,
very low certainty).
It is very uncertain whether or not the overall risk that patients still need surgery at trial end is lower in the mepolizumab group (RR 0.78,
95% CI 0.64 to 0.94; 2 studies; 135 participants; very low certainty).
It is very uncertain whether mepolizumab reduces the extent of disease as measured by endoscopic nasal polyps score (scale range 0 to
8). The mean diKerence was 1.23 points lower in the mepolizumab group (MD -1.23, 95% -1.79 to -0.68; 2 studies; 137 participants; very
low certainty).
The diKerence in generic quality of life (EQ-5D) was 5.68 (95% CI -1.18 to 12.54; 1 study; 105 participants; low certainty), favouring the
mepolizumab group. This diKerence is smaller than the MCID of 8 points.
There may be little or no diKerence in the risk of nasopharyngitis (RR 0.73, 95% 0.36 to 1.47; 2 studies; 135 participants; low certainty).
Anti-IgE mAb (omalizumab) versus placebo/no treatment (all receiving intranasal steroids)
Three very small studies (65 participants) evaluated omalizumab. We are very uncertain about the eKect of omalizumab on disease-specific
HRQL, severe adverse events, extent of disease (CT scan scores), generic HRQL and adverse eKects.
Authors' conclusions
In adults with severe chronic rhinosinusitis and nasal polyps, using regular topical nasal steroids, dupilumab improves disease-specific
HRQL compared to placebo, and reduces the extent of the disease as measured on a CT scan. It probably also improves symptoms
and generic HRQL and there is no evidence of an increased risk of serious adverse events. It may reduce the need for further surgery. There
may be little or no diKerence in the risk of nasopharyngitis.
Biologics for chronic rhinosinusitis (Review)
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In similar patients, mepolizumab may improve both disease-specific and generic HRQL. It is uncertain whether it reduces the need for
surgery or improves nasal polyp scores. There may be little or no diKerence in the risk of nasopharyngitis.  It  is uncertain if there is a
diKerence in symptom severity and the risk of serious adverse events.
We are uncertain about the eKects of omalizumab.
P L A I N   L A N G U A G E   S U M M A R Y
Biologics for people with chronic rhinosinusitis
What is the aim of this review?
'Biologics' is the name given to a new type of drug. This type is increasingly being used to help people with diseases due to inflammation
of body tissues. The aim of this review is to see if any of these drugs are eKective in treating people with 'chronic rhinosinusitis'. These
patients have long-term problems with inflammation of the nose and sinuses. This leads to them having blocked, stuKy, runny noses and
pain in their cheeks. They oOen need to use long-term steroid nasal sprays. Some patients with chronic rhinosinusitis also get polyps in
their nose. These can make their symptoms worse.
Key message
One of the new biologics – called dupilumab – helps people with severe chronic rhinosinusitis who also have nasal polyps. It makes their
symptoms better and shrinks their polyps. It does not seem to cause any severe side eKects. Another similar drug – called mepolizumab
– may do the same but we are less certain about that.
What was studied in the review?
We looked for trials where patients with chronic rhinosinusitis had been given either one of the new biologic drugs or a placebo (dummy)
treatment. They needed to have been treated for at least three months. We looked for studies that measured the eKect of the drug on
people's symptoms and their general health.
What are the main results of the review?
Almost all the people studied in the trials had severe chronic rhinosinusitis with nasal polyps (so we can only draw conclusions about the
eKects of the drugs on people like this). We found eight studies, looking at three diKerent drugs. Most of the information we have comes
from two big trials (with nearly 800 patients) looking at the eKect of one drug – dupilumab.
Eect of dupilumab
AOer 24 weeks of treatment, people taking dupilumab have a better quality of life than those who do not and their polyps have shrunk
more. On average their symptoms are probably better too, and they do not have more severe side eKects than those taking placebo.
Eect of mepolizumab
The eKect of mepolizumab was studied in far fewer patients and so we are less certain about the results. We can say that this drug may have
similar eKects to dupilumab.
Eect of omalizumab
We found very little information about the use of this drug and cannot say whether it is eKective or not.
How up-to-date is this review?
The evidence is up-to-date to September 2019.
Biologics for chronic rhinosinusitis (Review)




























































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Anti-IL-4Rα mAb (dupilumab) compared to placebo (on top of topical steroids) for chronic
rhinosinusitis
Anti-IL-4Rα mAb (dupilumab) compared to placebo (on top of topical steroids) for chronic rhinosinusitis
Patients or population: patients with severe chronic rhinosinusitis with nasal polyps
Setting: tertiary care
Intervention: anti-IL-4Rα mAb (dupilumab)
Comparison: placebo (on top of topical steroids)




















Health-related quality of life
- disease-specific (SNOT-22,
range 0 to 110, lower = better)


















At up to 24 weeks, aspects of
health-related quality of life that
are directly impacted by chronic
rhinosinusitis were better in par-
ticipants who received dupilumab.
The size of the difference is clinical-
ly significant.
Disease severity - VAS (range 0
to 10, lower = better)


















symptoms were probably bet-
ter in participants who received
dupilumab.
Study populationSerious adverse events













Participants who had dupilumab
may have had fewer serious ad-
verse events than participants who
received placebo in 3 RCTs (26/470
with dupilumab versus 38/312 with
placebo), but we have limited con-
fidence in this estimate because
the sample size may be too small
to estimate this accurately, or cap-
ture the range of adverse events






















































































































er population or with longer fol-
low-up.
Study populationAvoidance of surgery - number
of patients who had surgery as
rescue treatment














Patients who had dupilumab may
have had a lower risk of requiring
surgery due to severe chronic rhi-
nosinusitis symptoms after 24 to 52
weeks of treatment. We have mod-
erate confidence in this estimate
as we are not sure which criteria
were used to determine the need
for 'rescue surgery'.
Extent of disease - CT scan
score (Lund Mackay, range 0 to
24, lower = better)
















At up to 24 weeks, the extent of dis-
ease as assessed by CT scan was
less severe in participants who re-
ceived dupilumab - the difference
is likely to be a large effect.
Health-related quality of life -
generic (EQ-5D visual analogue
scale, range 0 to 100, higher =
better)




— The mean gener-
ic health-related
quality of life score
without anti-IL-4Rα
mAb (dupilumab)











The overall quality of life or health
status, as assessed by the EQ-5D vi-
sual analogue scale was probably
slightly higher in participants who
received dupilumab. However, we
are not sure if the size of this differ-
ence is noticeable or would be con-
sidered important enough by most
patients.
Study populationAdverse events - nasopharyn-
gitis, including sore throat
(longest available data)














We are uncertain whether there is
an important difference in the risk
of nasopharyngitis. Adverse events
were reported by 94/470 partici-
pants who took dupilumab versus
66/313 who took placebo.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: confidence interval; CT: computerised tomography; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio; SNOT-22: Sino-Nasal Outcome Test-22; VAS:
visual analogue scale
GRADE Working Group grades of evidence






















































































































Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1Downgraded by one level due to study limitations: methods or criteria used in the measurement of the outcome were not validated.
2Downgraded by two levels due to imprecision and indirectness: small sample size for the outcome estimated resulting in an imprecise estimation of eKect size. Moreover, some
serious adverse events are relatively rare; a larger and more heterogenous population or longer periods of treatment and follow-up may be needed.
3Downgraded by one level due to serious limitations: the criteria used for requiring/not requiring 'rescue surgery' were unclear.
 
 
Summary of findings 2.   Anti-IL-5 mAb (mepolizumab) compared to placebo (on top of topical steroids) for chronic rhinosinusitis
Anti-IL-5 mAb (mepolizumab) compared to placebo (on top of topical steroids) for chronic rhinosinusitis
Patients or population: patients with severe chronic rhinosinusitis with nasal polyps
Setting: tertiary care
Intervention: anti-IL-5 mAb (mepolizumab)
Comparison: placebo (on top of topical steroids)


















Health-related quality of life - dis-





— The mean disease-spe-
cific health-related



























— The mean disease sever-
ity score without an-
ti-IL-5 mAb (mepolizum-
ab) was 6.21.



































































































































Study populationSevere adverse events













We are very un-
certain about






Study populationAvoidance of surgery - patients no
longer meeting the criteria for surgery





















Extent of disease - endoscopic score
Follow-up (range): 25 to 40 weeks
137
(2 RCTs)
— The mean endoscopic
score without anti-IL-5
mAb (mepolizumab)
ranged from 0 to -0.7.














Health-related quality of life - generic,
measured using the EQ-5D visual ana-
logue scale (range 0 to 100;  0 = worst





— The mean generic
health-related quality
of life score without an-
ti-IL-5 mAb (mepolizum-
ab) was 75.45










life or health sta-
tus, as assessed
by the EQ-5D vi-
sual analogue
scale.
Study populationAdverse events - nasopharyngitis, in-
cluding sore throat
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio; SNOT-22: Sino-Nasal Outcome Test-22; VAS: visual analogue scale
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1Downgraded by two levels due to imprecision: very small sample size resulting in a very imprecise estimation of eKect sizes.
2Downgraded by one level due to study limitations: methods or criteria used in the measurement of the outcome were not validated.
3Downgraded by one level due to indirectness: one study only assessed patients for two doses (Gevaert 2011). The other study evaluated six doses (24 weeks), but had a more
than 30% dropout rate (Bachert 2017). Therefore, the length of follow-up is inadequate and it is unclear whether this evidence related to safety is generalisable.
 
 
Summary of findings 3.   Anti-IgE mAb (omalizumab) compared to placebo (on top of topical steroids) for chronic rhinosinusitis
Anti-IgE mAb (omalizumab) compared to placebo (on top of topical steroids) for chronic rhinosinusitis
Patients or population: patients with chronic rhinosinusitis with nasal polyps
Setting: tertiary care
Intervention: anti-IgE mAb (omalizumab)
Comparison: placebo (on top of topical steroids)


















ty of life - RSOM-31 and
SNOT-20
Follow-up (range): 20




One study found a significant improvement in sleep (P = 0.03) and general
symptoms (P = 0.01) in the omalizumab group compared to baseline, where-
as in the placebo group no significant changes were seen.
A second study reported that the median change in SNOT-20 score was -1.05





We are very uncertain about
the impact of omalizumab on


























































































































One study reported that there was no statistically significant difference in
overall total nasal symptom score (measuring rhinorrhoea, nasal blockage,




We are very uncertain about
the impact of omalizumab on
the overall symptoms of chron-
ic rhinosinusitis.
Study populationSevere adverse events
Follow-up (range): 20








There is too little information -
we are very uncertain whether
there is a difference in severe
adverse events.
Avoidance of surgery — — — — — — None of the studies reported
this outcome.
Extent of disease - CT
















There is too little information -
we are very uncertain whether
there is a difference in the ex-
tent of disease with omalizum-
ab. There are inconsistencies
in the size and direction of ef-
fect. In the NCT01066104 study,
the results favoured the place-




life - generic (SF-36)
Follow-up (range): 20
weeks to 6 months
38
(2 RCTs)
One study found no significant differences (P > 0.05, all comparisons) except
for one domain, 'vitality' (omalizumab 9.4, placebo 12.5, P < 0.05).
A second study found that physical health was significantly improved in the
omalizumab group (P = 0.02) but not in the placebo group (P = 0.75). Mental




We are very uncertain about
the impact of omalizumab on
health-related quality of life.












There is too little information -
we are very uncertain whether
there is a difference in adverse
effects.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: confidence interval; CT: computerised tomography; RCT: randomised controlled trial; RSOM-31: Rhinosinusitis Outcome Measures-31; SMD: standardised mean differ-
ence; SNOT-22: Sino-Nasal Outcome Test-22























































































































High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1Downgraded by two levels due to imprecision: very small sample size.
2Downgraded by one level due indirectness: a limited number of doses (4 to 12) and duration of follow-up (16 to 24 weeks, with most patients followed up for about 4 months).
It is unclear how this information on adverse events is generalisable to others.
3Downgraded by one level due to study limitations: method of assessment not validated.
4Downgraded by one level due to inconsistency: high (unexplained) heterogeneity for the eKect sizes.
5Downgraded by one level due to inconsistency: high and unexplained heterogeneity as the size and direction of the eKect diKered between studies.
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B A C K G R O U N D
This review is one of a suite of Cochrane Reviews looking
at common management options for patients with chronic
rhinosinusitis (Chong 2016a; Chong 2016b; Chong 2016c; Head
2016a; Head 2016b; Head 2016c; Head 2018).
Description of the condition
Chronic rhinosinusitis represents a common source of ill health;
11% of UK adults reported chronic rhinosinusitis symptoms in a
worldwide population study (Hastan 2011). Symptoms including
nasal obstruction, nasal discharge, facial pain, anosmia (loss
of sense of smell) and sleep disturbance have a major impact
on quality of life, reportedly greater in several domains of the
SF-36 than angina or chronic respiratory disease (Gliklich 1995).
Acute exacerbations (worsening), inadequate symptom control and
respiratory disease exacerbation are common. Complications are
rare, but may include visual impairment and intracranial infection.
Two major phenotypes of chronic rhinosinusitis have been
described based on the presence or absence of nasal polyps on
examination. Nasal polyps are tumour-like hyperplastic swellings
of the nasal mucosa, most commonly originating from within the
ostiomeatal complex (Larsen 2004). Chronic rhinosinusitis with
nasal polyps (CRSwNP) is diagnosed when polyps are seen (on
direct or endoscopic examination) in the middle meatus or nasal
cavity. Chronic rhinosinusitis without nasal polyps (CRSsNP) is
diagnosed when no polyps are observed on examination.
Although the aetiology of chronic rhinosinusitis is not fully
understood, it may involve abnormalities in the host response
to irritants, commensal and pathogenic organisms and allergens,
obstruction of sinus drainage pathways, abnormalities of normal
mucociliary function, loss of the normal mucosal barrier or
infection. Chronic rhinosinusitis is a heterogenous group of
diseases, but three main patterns of inflammation have been
identified: type 1 driven, usually associated with chronic
rhinosinusitis without nasal polyps; type 2 driven, usually
associated with chronic rhinosinusitis with nasal polyps in
Caucasian patients; and type 17 driven, associated typically
with chronic rhinosinusitis with nasal polyps in Asian patients
(Smith 2018). There is some overlap between phenotypes and
inflammatory patterns and the current division of chronic
rhinosinusitis into two main phenotypes, with and without polyps,
is therefore likely to be inadequate for defining patient subgroups.
Endotyping, using measurable biomarkers, is increasingly being
performed but is not yet routinely incorporated into clinical
practice.
Despite the diKerences in aetiology and phenotype, in clinical
practice many treatments for chronic rhinosinusitis are initiated
without knowledge of a patient's 'polyp status'. Even when it is
known whether or not a patient with chronic rhinosinusitis has
polyps, this knowledge does not always suggest adjustments to
treatment. This review (and most of its companion reviews) will
consider patients with and without polyps together in the initial
evaluation of treatment eKects. However, as biologics are primarily
used in hospital settings and in well-defined patient populations,
we planned subgroup analyses to explore potential diKerences
between them (see below).
Description of the intervention
The term 'biologics' refers to medicinal products produced by
a biological process.  Monoclonal antibodies are one type of
biologic. They target specific inflammatory mediators or immune
cells in the pathophysiological pathways that produce chronic
inflammatory diseases.  Trials have evaluated these agents in
conditions such as asthma and atopic dermatitis leading to growing
interest in the possibility of using them to treat patients with
chronic rhinosinusitis.
How the intervention might work
Monoclonal antibodies work on diKerent target substances
or receptors in the inflammatory pathway.  The more we
understand about the inflammatory pathways involved in chronic
rhinosinusitis, the more we may be able to aKect those pathways
with biologics. DiKerent biologics are likely to have very diKerent
eKicacy in diKerent patient populations depending on the pattern
of inflammation in those patients. Recent trials in patients with
chronic rhinosinusitis with nasal polyps have focused on biologics
directed at the inflammatory mediators and receptors involved in
type 2 pathways. As yet none have investigated the eKectiveness of
biologics in type 1 or type 17 driven inflammation.
Currently, biologics are mainly used in patients with severe
chronic rhinosinusitis where pharmacological therapy does not
provide adequate symptom control, with the aim of reducing
those symptoms and leading to an improvement in their quality
of life. Some patients with severe chronic rhinosinusitis undergo
surgical treatment aimed at achieving these goals.  If patients
respond well to biologics, surgical intervention may be avoided. If
biologics are successful in reducing inflammation and reducing the
size of nasal polyps, this should also be visible using endoscopy
and computerised tomography (CT) scans. These changes can be
documented and quantified using the relevant scoring system.
Biologics are, however, associated with adverse reactions
that may be immune-related and can be serious - such as
anaphylaxis. Biologics are widely used in rheumatology and some
of the serious adverse events documented in those patients include
tuberculosis reactivation, lymphoma and severe infections (Singh
2011;  Tarp 2017). Another adverse reaction is pharyngitis, which
may be serious enough for patients to discontinue treatment.
The following are descriptions of a number of classes and
mechanisms of actions of monoclonal antibodies (mAb) with some
specific named biologics. This is not an exhaustive list. The field is
growing and our understanding of the mechanisms of action may
change over time. Biologics not listed here may be evaluated in this
review.
Anti-IL-4Rα mAb and anti-IL-13 mAb
Dupilumab, delivered by subcutaneous injection, is a human
monoclonal antibody of the IgG4 subclass that targets the
IL-4Rα subunit and disrupts IL-4 and IL-13 signalling.  This is
involved in the type 2 inflammatory pathway most typically
seen in patients with chronic rhinosinusitis with nasal polyps.
Trials of dupilumab in asthma have also shown improvement
in the symptoms of coexisting chronic rhinosinusitis (Wenzel
2016). Lebrikizumab and tralokinumab are anti-IL-13 monoclonal
antibodies.
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Anti-IL-5 mAb
Mepolizumab,  reslizumab  and  benralizumab  are delivered
subcutaneously or intravenously, and are human monoclonal
(IgG1) antibodies targeting interleukin 5 (IL-5) or the IL-5 receptor
α subunit on the surface of eosinophil white blood cells. IL-5
promotes eosinophil development survival, so targeting IL-5
reduces blood and tissue eosinophil counts. Mepolizumab is
currently approved by the UK's National Institute for Health and
Care Excellence (NICE) for the treatment of severe eosinophilic
asthma and as IL-5 has been suggested as a parallel marker for
the severity of both asthma and chronic rhinosinusitis with nasal
polyps, it has the potential to treat both simultaneously (Chupp
2017; Dasgupta 2017; Pavord 2012). Reslizumab and benralizumab
have had early success in patients with poorly controlled asthma
(DuBuske 2018; Máspero 2017).
Anti-IgE mAb
Omalizumab, also delivered subcutaneously, is a recombinant
DNA-derived humanised (IgG1k) monoclonal antibody that
specifically binds to free human immunoglobulin E (IgE) in the
blood and interstitial fluid, and to the membrane-bound form
of IgE (mIgE) on the surface of mIgE-expressing B-lymphocytes.
It therefore has the eKect of reducing the levels of IgE in the
serum and tissues, with a subsequent blocking of the IgE-mediated
inflammatory cascade. This anti-IgE treatment has to date been
shown to be eKective in allergic rhinitis and asthma (Casale
2001; Hanania 2011).
Further information about the mechanisms of action of biologics in
this field can be found in Kariyawasam 2019.
Why it is important to do this review
To date much of the literature around the role of these
new drugs has been focused on the allergy, asthma and
immunology subspecialties. As the role for biologic therapies in
chronic rhinosinusitis continues to be defined and pharmaceutical
companies are now targeting this condition, it is increasingly
important for practising otorhinolaryngologists, especially sub-
specialist rhinologists, to determine the place of biologics in the
treatment cascade by keeping up-to-date on their progression.
NICE is currently conducting a health technology appraisal of
the clinical and cost-eKectiveness of dupilumab for chronic
rhinosinusitis with nasal polyps (NICE 2019). This Cochrane Review
looks at the balance of benefits and harms for biologic drugs in the
treatment of patients with chronic rhinosinusitis. It also serves to
identify areas for future research, especially as the knowledge of
specific chronic rhinosinusitis endotypes increases.
This review is a living systematic review, whereby we will search
key databases monthly and update the review as and when new
important evidence is found. A living systematic review approach
is appropriate for this review because: 1) the topic is important
for health care decision-making; 2) there is uncertainty about the
existing evidence; and 3) this is a rapidly developing field where
new trials are being actively planned and completed. We will revisit
the scope (population, intervention, comparison, outcomes) of the
review yearly, or more frequently as appropriate, to ensure that
new agents or uses are included as this field develops. In addition
to having more data on safety and eKicacy, our understanding
of how biologics work, the best way to measure outcomes and
how outcomes are interpreted will very likely change as more
research is completed. Therefore, we will adapt our definition of
what outcomes to measure and how outcomes should be measured
and interpreted over time.
O B J E C T I V E S
Main objective
To assess the eKects of biologics for the treatment of chronic
rhinosinusitis.
Secondary objective
To maintain the currency of the evidence, using a living systematic
review approach.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials and quasi-randomised trials.
We only considered cross-over trials if there was suKicient evidence
to suggest that the condition of patients was stable and the
washout period was adequate. Otherwise, we only planned to use
the first phase of cross-over trials.
We only included studies where patients were followed up for at
least three months, to reflect the importance of focusing on long-
term outcomes for a chronic condition.
Types of participants
Patients with chronic rhinosinusitis, whether with polyps (CRSwNP)
or without polyps (CRSsNP).
We excluded studies that had included a majority of patients with:
• cystic fibrosis;
• allergic fungal sinusitis/eosinophilic fungal/mucinous
rhinosinusitis;
• antrochoanal polyps (benign polyps originating from the
mucosa of the maxillary sinus);
• malignant polyps;
• primary ciliary dyskinesia;




All monoclonal antibodies used for the treatment of chronic
rhinosinusitis. This included but was not limited to the following:
• anti-IL-4Rα mAb (dupilumab);
• anti-IL-13 (lebrikizumab, tralokinumab);
• anti-IL-5 mAb (reslizumab, benralizumab, mepolizumab);
• anti-IgE mAb (omalizumab).
These are the biologics identified in November 2019 as most
likely to be used in patients with chronic rhinosinusitis. Additional
monoclonal antibodies and other classes of biologics will also be
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included in this review when they are evaluated in patients with
chronic rhinosinusitis.
All routes of administration, doses and duration of treatment were
included. However, studies should have followed up participants
for three months or more.
Comparison
Placebo or no treatment. Surgery will be an alternative treatment
(comparison) when trials in the area become available.
Concurrent treatments
It was expected that most studies would have used intranasal
steroids as a concurrent treatment. There was no limitation on the
type of pharmacological concurrent treatments used.
Comparison pairs
The following  main comparison pairs  were proposed in the
protocol (Chong 2019):
• anti-IL-4Rα mAb plus intranasal steroids versus placebo/no
treatment plus intranasal steroids;
• anti-IL-13 plus intranasal steroids versus placebo/no treatment
plus intranasal steroids;
• anti-IL-5 mAb plus intranasal steroids versus placebo/no
treatment plus intranasal steroids;
• anti-IgE mAb plus intranasal steroids versus placebo/no
treatment plus intranasal steroids.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
Our primary intention was to assess the eKects of assignment,
rather than adherence to treatment.
Primary outcomes
• Health-related quality of life, using validated disease-specific
health-related quality of life scores, such as the Sino-
Nasal Outcome Test-22 (SNOT-22), Rhinosinusitis Outcome
Measures-31 (RSOM-31) and SNOT-20.
• Disease severity, as measured by validated patient-reported
symptom score (such as the Chronic Sinusitis Survey (CSS)
questionnaire and visual analogue scales). Where this was
unavailable, we considered including data measuring the
severity of individual symptoms (see below).
• Serious adverse events (SAEs), measured by the number
of participants aKected. A serious adverse event is defined
as "Death, a life-threatening adverse event, inpatient
hospitalisation or prolongation of existing hospitalisation, a
persistent or significant incapacity or substantial disruption of
the ability to conduct normal life functions, or a congenital
anomaly/birth defect. Important medical events that may not
result in death, be life-threatening, or require hospitalisation
may be considered serious when, based upon appropriate
medical judgment, they may jeopardize the patient or subject
and may require medical or surgical intervention to prevent one
of the outcomes listed in this definition" (FDA 2018).
Many studies within this suite of reviews (Chong 2016a; Chong
2016b; Chong 2016c; Head 2016a; Head 2016b; Head 2016c; Head
2018) did not use/present data using instruments that were either
validated or evaluated all four types of symptoms meeting the
EPOS 2012 diagnostic criteria in a composite score. If data from
a validated score were unavailable, we planned to analyse data
related to each of these individual symptoms, if presented.
Secondary outcomes
• Avoidance of surgery, measured by the number (proportion)
of participants who had, or did not have,  surgery for chronic
rhinosinusitis symptoms, or who no longer fulfilled the eligibility
criteria for surgery*. (See comments in Assessment of risk of bias
in included studies).
• Extent of disease as measured by either:
* endoscopic score (depending on population, either nasal
polyps size score or other such as Lund Kennedy); and/or
* computerised tomography (CT) scan score (e.g. Lund Mackay
with a range of 0 to 24, higher = worse).
• Health-related quality of life, using generic quality of life scores,
such as the SF-36, EQ-5D and other well-validated instruments.
• Adverse eKects: nasopharyngitis, including sore throat.
Outcomes were measured at 3 to 6 months, 6 to 12 months and
more than 12 months. For adverse events, we analysed data from
the longest time periods.
*We recorded and tabulated the eligibility criteria for surgery used
in the included studies.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 16 September 2019.
Electronic searches
The Information Specialist searched:
• the Cochrane ENT Register (searched via the Cochrane Register
of Studies 18 September 2019);
• the Cochrane Central Register of Controlled Trials (CENTRAL
2019, Issue 9) (searched via the Cochrane Register of Studies);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to 16 September 2019);
• Ovid EMBASE (1974 to 16 September 2019);
• Web of Science (1945 to 16 September 2019);
• ClinicalTrials.gov, www.clinicaltrials.gov (searched via the
Cochrane Register of Studies to 18 September 2019);
• ClinicalTrials.gov, www.clinicaltrials.gov (searched via
www.clinicaltrials.gov to date 18 September 2019);
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (searched via the Cochrane Register of
Studies to 18 September 2019);
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (searched 18 September 2019).
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The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL, Ovid
MEDLINE and Ovid Embase. Where appropriate, they were
combined with subject strategy adaptations of the highly sensitive
search strategy designed by Cochrane for identifying randomised
controlled trials and controlled clinical trials (as described in the
Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0, Box 6.4.b. (Handbook 2011). Search strategies for major
databases including CENTRAL are provided in Appendix 1.
Living systematic review considerations
As a living systematic review, the Information Specialist will
conduct monthly searches of:
• the Cochrane ENT Trials Register (search via the Cochrane
Register of Studies to date);
• the Cochrane Central Register of Controlled Trials (CENTRAL)
(search via the Cochrane Register of Studies to date);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to date);
• Ovid Embase (1974 to date);
• Web of Knowledge, Web of Science (1945 to date);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies to date);
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (search via the Cochrane Register of
Studies to date).
To facilitate these searches the Information Specialist will set up
monthly auto-alerts where available and appropriate.
The Information Specialist will also conduct quarterly searches of
the following sources, and prior to publication of any update:
• ClinicalTrials.gov (search via www.clinicaltrials.gov to date);
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (search to date).
A summary of trials identified versus reports obtained will be
published in the review.
Biologics are a new class of intervention. The search strategy
developed is highly sensitive, in order to try to capture new
interventions as they are introduced. The Information Specialist
will review the search methods (the sources and search frequency)
and the search terms (index terms and free text terms) on an annual
basis. The aim will be to include new terms for new interventions
as they are introduced, and remove terms to increase precision as
interventions are removed or withdrawn.
Searching other resources
We scanned the reference lists of identified publications for
additional trials and contacted trial authors where necessary. In
addition, the Information Specialist searched Ovid MEDLINE to
retrieve existing systematic reviews relevant to this systematic
review, so that we could scan their reference lists for additional
trials.
We did not perform a separate search for adverse eKects. We
considered adverse eKects described in included studies only.
Clinical study reports (CSRs) and other sources of evidence
This review meets many of the 18 criteria for considering clinical
study reports as a source of evidence (JeKerson 2018). In particular,
there is a concern about publication bias with a new class of drugs
for this current condition. Moreover, these are very costly agents
that are already marketed for other conditions and there is a risk of
oK-label use.
There are no established search procedures to identify clinical
study reports at the time of publication. We attempted to identify
unpublished studies and clinical study reports. The Information
Specialist searched:
1. Regulatory bodies: We searched the websites of the:
a. US Food and Drug Administration (FDA) (http://www.fda.gov
and https://www.fda.gov/about-fda/about-website/fdagov-
archive) (searched 11 December 2019);
b. European Medicines Agency (EMEA) (http://
www.emea.europa.eu) (searched 18 November 2019);
c. European Union Clinical Trials Register (EUCRT) (https://
www.clinicaltrialsregister.eu/) (searched 15 November 2019).
2. Manufacturer-specific clinical trial repositories and data
sharing platforms:
• Novartis Clinical Trial Results Database (https://
www.novctrd.com) (searched 18 November 2019);
• GSK Study Register (https://www.gsk-studyregister.com)
(searched 18 November 2019).
3. Direct requests to manufacturers: We did not identify
additional trials and therefore did not write to the manufacturer/
sponsors. We plan to contact the principal investigators/
manufacturers/sponsors of each of the known trials individually
to ask for additional data as part of the planned update of this
living systematic review. We did identify one clinical study report
(Bachert 2017) and additional data from ClinicalTrials.gov and
EUCTR for five included  studies (Bachert 2016; Bachert 2017;
LIBERTY SINUS 24; LIBERTY SINUS 52; NCT01066104), which
were identified as part of the regular electronic searches.
Living systematic review considerations
As a living systematic review, the Information Specialist will
conduct quarterly searches to retrieve existing systematic reviews
relevant to this systematic review and monthly searches of the Web
of Knowledge Science Citation Index for articles referencing the
published review and its included studies. Google Scholar searches
will be conducted on an annual basis. We will review on an ongoing
basis (and at least every six months) the various sources to search
for clinical study reports, updating the list of sources searched
and when as required. We will make contact with the principal
investigators of ongoing trials and ask them to advise when results
are available, or to share early or unpublished data.
We have a number of plans to investigate further the identification
of clinical study reports and other sources of evidence. These are
detailed in DiKerences between protocol and review.
Data collection and analysis
Selection of studies
The Cochrane ENT Information Specialist used Cochrane's
Screen4Me workflow to help assess the initial search results for the
first iteration of this living systematic review because of the high
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number of results retrieved from the database searches. Screen4Me
comprises three components: 1) known assessments – a service
that matches records in the search results to records that have
already been screened in Cochrane Crowd and been labelled as
'a RCT' or as 'not a RCT'. 2) The machine learning classifier (RCT
model) (Wallace 2017), available in the Cochrane Register of Studies
(CRS-Web), assigns a probability of being a true RCT (from 0 to
100) to each citation. For citations that are assigned a probability
score below the cut-point at a recall of 99% we have assumed these
to be non-RCTs. For those that score on or above the cut-point
we either manually dual screened these results or sent them to 3)
Cochrane Crowd for screening (Cochrane's citizen science platform
where the Crowd help to identify and describe health evidence). For
more information about Screen4Me and the evaluations that have
been done, please go to the Screen4Me website on the Cochrane
Information Specialist's portal and see Marshal 2018, McDonald
2017, Noel-Storr 2018 and Thomas 2017.
At least two review authors  (LYC/PP), or the Cochrane ENT
Information Specialist (SC) acting as one screener, independently
screened the remaining titles and abstracts to identify potentially
relevant studies. At least two review authors (MB/PP/SS)
independently evaluated the full text of each potentially relevant
study to determine whether it met the inclusion/exclusion criteria
for this review.
We resolved any diKerences by discussion and consensus, with the
involvement of a third author (KS) for clinical and/methodological
input where necessary.
Living systematic review considerations
We will immediately collate and screen any new citations retrieved
by the monthly searches using the approach outlined above
including, as a first step in monthly screening, applying the
Screen4Me workflow starting with the RCT model.
Data extraction and management
One  review author  (MB) and one of two
Cochrane ENT methodologists (AT/KW, listed in the
Acknowledgements)  independently extracted outcome data from
each study using a standardised data collection form (see Appendix
2). Whenever a study had more than one publication, we retrieved
all publications to ensure complete extraction of data. Where
there were discrepancies in the data extracted by diKerent review
authors, we checked these against the original reports and resolved
diKerences by discussion and consensus, with the involvement of
a third author (MB) or a methodologist (LYC) where appropriate.
We contacted the original study authors for clarification or for
missing data whenever possible. If diKerences were found between
publications of a study, we contacted the original authors for
clarification. We used data from the main paper(s) if no further
information was found.
In addition, we also compared trials identified through study
registers with identified publications. If an unpublished trial was
identified (registered in trial registry, but more than 12 months
since completion of recruitment and no data/incomplete data
published), we contacted the contact person listed in the trial
registry websites for information. Whenever clinical study reports
or data from regulatory bodies are available, we will compare these
against the journal reports and use them as the primary source of
data if there is a discrepancy in the information. However, current
experience with the use of clinical study reports suggests that there
is oOen a considerable time lag between requesting these data and
obtaining them. Therefore, we will make use of data from journal
reports as the main source of evidence as a starting point and then
check the data against the clinical study reports and regulatory data
as and when these are available.
We included key characteristics of the studies, such as study design,
setting, sample size, population and how outcomes were defined
or collected in the studies. In addition, we also collected baseline
information on prognostic factors or eKect modifiers. For this
review, this included:
• presence or absence of nasal polyps;
• polyp score (where applicable);
• whether the patient has had previous sinus surgery.
The primary eKect of interest is the eKect of treatment assignment,
which reflects the outcomes of treatment for people who were
prescribed the intervention rather than per protocol analysis (the
eKect on people who completed the full course of treatment as
planned). For the outcomes of interest to the review, we extracted
the findings from the studies on an available case analysis basis,
i.e. we included available data from all participants at the time
points based on the treatment randomised whenever possible,
irrespective of compliance or whether patients had received the
treatment as planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we extracted the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations and
number of patients for each treatment group. Where endpoint
data were not available, we extracted the values for change from
baseline. We analysed data from measurement scales such as
SNOT-22 and EQ-5D as continuous data.
• For binary data: the number of participants experiencing an
event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appeared to be approximately
normally distributed or if the analysis that the investigators
performed suggested parametric tests were appropriate, then
we treated the outcome measures as continuous data.
Alternatively, if data were available, we planned to convert into
binary data.
We prespecified the time points of interest for the outcomes in this
review. While studies may report data at multiple time points, we
only extracted the longest available data within the time points of
interest. For example, for 'short' follow-up periods, our time point
was defined as three to six months post-randomisation. If a study
reported data at three, four and six months, we only extracted and
analysed the data for the six-month follow-up.
Assessment of risk of bias in included studies
Two Cochrane ENT methodologists  (AT/KW, listed in the
Acknowledgements) independently assessed the risk of bias of
each included study.
In the first version of the review, we used the original version of the
Cochrane 'Risk of bias' tool (ROB-1) (Handbook 2011). For future
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versions of this living systematic review, we anticipate using the
Cochrane 'Risk of bias 2.0' tool (ROB-2) (Sterne 2019), according
to the guidance in the latest version of the Cochrane Handbook for
Systematic Reviews of Interventions (version 6; Handbook 2019).
When using the ROB-1 tool, we followed the guidance
in the  Cochrane Handbook for Systematic Reviews of
Interventions (version 5; Handbook 2011). We assessed the risk of
bias as 'low', 'high' or 'unclear' for each of the following six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessment;
• incomplete outcome data;
• selective reporting;
• other sources of bias (if required).
In future iterations of this living systematic review, we plan to apply
the ROB-2 tool (rather than ROB-1) according to the guidance in
the latest version of the Cochrane Handbook for Systematic Reviews
of Interventions (Handbook 2019). We will assess the risk of bias
as 'low', 'high' or 'some concerns' for each of the following five
domains:
• risk of bias arising from the randomisation process;
• risk of bias due to deviations from the intended interventions;
• risk of bias due to missing outcome data;
• risk of bias in measurement of outcome;
• risk of bias in selection of the reported result.
For ROB-2, we will only assess the outcomes included in the
'Summary of findings' table.
For the outcome 'disease severity, as measured by validated
patient-reported symptom score' we will only conduct a ROB-2
assessment if this is reported. If only the results from individual
symptoms, or non-validated scores, are reported we will not
individually assess these, as the risk of bias is likely to be present
due to the choice of outcome measure and selective reporting of
only certain aspects of the condition.
There is a particular risk of bias in assessing  the outcome
'avoidance of surgery', as there are no widely accepted criteria
to determine when patients should or should not have surgery.
Unless studies explicitly specify what criteria are used for making
judgements and both the investigator (oKering/deciding on the
surgery) and participants were blinded, there are potential biases in
the decision-making process of the study personnel in determining
whether or not a  participant  fulfils the criteria for surgery and/
or whether they should be oKered the option of surgery. We
assessed this in the 'Blinding, outcomes assessment' domain using
the ROB-1 tool and we will assess this in the 'Risk of bias in the
measurement of outcome' domain when we are using the ROB-2
tool.
Measures of treatment eAect
We summarised the eKects of dichotomous outcomes (e.g.
proportion of patients with symptom resolution) as risk ratios
(RR) with 95% confidence intervals (CIs). For the key outcomes
that we presented in the 'Summary of findings' tables, we also
expressed the results as absolute numbers based on the pooled
results and compared to the assumed risk. If appropriate, we would
also have considered calculating the number needed to treat to
benefit (NNTB) using the pooled results. The assumed baseline
risk is typically either (a) the median of the risks of the control
groups in the included studies, this being used to represent a
'medium-risk population' or, alternatively, (b) the average risk of
the control groups in the included studies is used as the 'study
population' (Handbook 2019). If a large number of studies are
available, and where appropriate, we may also present additional
data based on the assumed baseline risk in (c) a low-risk population
and (d) a high-risk population.
For continuous outcomes, we expressed treatment eKects as
a mean diKerence (MD) with standard deviation (SD) or as a
standardised mean diKerence (SMD) if diKerent scales had been
used to measure the same outcome. We provided a clinical
interpretation of the SMD values using either Cohen's d or by
conversion to a recognised scale if possible.
Unit of analysis issues
Cross-over trials and cluster-randomised trials are unlikely for this
review topic. We did not plan to use data from phase II of cross-
over studies (unless there was suKicient evidence to suggest that
the condition of patients was stable and the washout period was
adequate). If these trial designs are found and deemed suitable
to use in the future, we will seek advice from the Cochrane Bias
Methods Group and use the latest version of the ROB-2 tool for
cross-over and cluster-randomised trials.
We expected that studies would take multiple measurements
or observations of a single outcome in the same patients
(repeated measurements). In these situations, we only extracted
and analysed the data point for the longest available follow-up
specified in our protocol (Chong 2019).
Dealing with missing data
We tried to contact study authors via email whenever the outcome
of interest was not reported, if the methods of the study suggest
that the outcome had been measured. We did the same if not
all data required for meta-analysis had been reported, unless the
missing data were standard deviations. If standard deviation data
were not available, we approximated these using the standard
estimation methods from P values, standard errors or 95%
CIs where reported, as detailed in the Cochrane Handbook for
Systematic Reviews of Interventions (Handbook 2019). If it was
impossible to estimate these, we planned to contact the study
authors.
Apart from imputations for missing standard deviations, we
conducted no other imputations. We will extracted and analysed all
data using the available case analysis method.
Assessment of heterogeneity
We assessed clinical heterogeneity (which may be present even in
the absence of statistical heterogeneity) by examining the included
trials for potential diKerences between studies in the types of
participants recruited, interventions or controls used and the
outcomes measured.
We assessed statistical heterogeneity by visually inspecting the
forest plots and by considering the Chi2 test (with a significance
level set at P value < 0.10) and the I2 statistic, which calculates the
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percentage of variability that is due to heterogeneity rather than
chance (Handbook 2019).
Assessment of reporting biases
We assessed reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We assessed within-study reporting bias by comparing the
outcomes reported in the published report against the study
protocol, whenever this could be obtained. If the protocol or
trial registry entry was not available, we compared the outcomes
reported to those listed in the methods section. If results are
mentioned but not reported adequately in a way that allows
analysis (e.g. the report only mentions whether the results were
statistically significant or not), bias in a meta-analysis is likely to
occur. We sought further information from the study authors. If
no further information could be found, we planned to note this as
being a 'high' risk of bias when the ROB-1 tool was used. If there was
insuKicient information to judge the risk of bias we noted this as an
'unclear' risk of bias (Handbook 2011). When the ROB-2 tool is used
in the future, we will assess selective reporting bias in a similar way,
according to the signalling questions in the 'risk of bias in selection
of the reported result' domain (Handbook 2019). However, we will
assess selective non-reporting bias at the synthesis level, using the
latest tools (e.g. ROB-ME) if available.
Publication bias (between-study reporting bias)
We planned to assess funnel plots if suKicient studies (more than
10) were available for an outcome. If we had observed asymmetry
of the funnel plot, we would have conducted more formal
investigation using the methods proposed by Egger 1997. We
also report on whether there were any studies identified through
trial registries and other sources (Searching other resources), with
unpublished reports.
Data synthesis
We conducted all meta-analyses using RevMan Web (RevMan Web
2019). For dichotomous data, we planned to analyse treatment
diKerences as a risk ratio (RR) calculated using the Mantel-Haenszel
methods.
For continuous outcomes, if all the data were from the same
scale, we pooled mean values obtained at follow-up with change
outcomes and reported this as a MD. However, if the SMD had to be
used as an eKect measure, we did not pool change and endpoint
data.
We proposed using a random-eKects model since it was likely
that there would be clinical heterogeneity in the response to
diKerent  types of biologics or diKerent types of monoclonal
antibodies. However, we also planned to undertake a sensitivity
analysis to examine the eKects of using the alternative fixed-eKect
model.
Living systematic review considerations
When new evidence will be incorporated into the living systematic
review
Whenever new evidence (meaning studies, data or information)
relevant to the review is identified, we will extract the data and
assess risk of bias, as appropriate. We will immediately incorporate
any important new evidence into the review.
We will not adjust the meta-analyses to account for multiple testing,
given that the methods related to frequent updating of meta-
analyses are under development (Simmonds 2017). We will not use
sequential methods for updated meta-analyses (Handbook 2019).
Subgroup analysis and investigation of heterogeneity
When studies had a mixed group of patients, we planned to analyse
the study as one subgroup (rather than as a mixed group) if more
than 80% of patients belonged to one category. For example, if
81% of patients had chronic rhinosinusitis without nasal polyps, we
would analyse the study as that subgroup.
We planned to conduct subgroup analyses based on the
phenotypes of patients (whether patients had chronic
rhinosinusitis with or without nasal polyps, are a mixed group
or the status of polyps is not known or not reported) regardless
of whether statistical heterogeneity was observed, as these are
widely suspected to be potential eKect modifiers. Although there
appears to be a considerable overlap between the two forms of
chronic rhinosinusitis with regards to inflammatory profile, clinical
presentation and eKect of treatment (Cho 2012; DeMarcantonio
2011; Ebbens 2010; EPOS 2007; Ragab 2004; Ragab 2010; van
Drunen 2009), there is some evidence pointing to diKerences in
the respective inflammatory profiles (Kern 2008; Keswani 2012; Tan
2011; Tomassen 2011; Zhang 2008; Zhang 2009), and potentially
even diKerences in treatment outcome (Ebbens 2011).
We planned to present this as the main subgroup analysis for
eKectiveness outcomes in this review. We planned to present all
other subgroup analysis results in tables.
In addition to subgrouping by phenotype, we planned to conduct
the following subgroup analyses in the presence of statistical
heterogeneity:
• Patients with asthma as a comorbidity. Patients with asthma
may have diKerent inflammatory markers and respond
diKerently. In addition to chronic rhinosinusitis symptoms, they
may also benefit from better control of asthma symptoms.
However, there are no clear data to tell us which patients will
benefit more or less from certain types of biologics, therefore the
direction of eKects is unclear.
• Patients with non-steroidal anti-inflammatory drug (NSAID)-
exacerbated respiratory disease (N-ERD). The rationale is similar
to that for patients with asthma as a comorbidity.
• Treatment regimens.  For agents acting on the same target
substance or  receptor,  treatment regimens  such as dose and
frequency of initial treatment and maintenance treatment are
likely to be important. However, at the preparation of the
protocol in 2019 there was not enough information to inform
how these subgroups should be defined. We will revisit this
question as part of our regular re-evaluation of the review
methods, as and when more data are available from trials.
Sensitivity analysis
We planned to carry out sensitivity analyses to determine whether
the findings are robust to the decisions made in the course of
identifying, screening and analysing the trials. We planned to
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conduct sensitivity analysis for the following factors, if there were
relevant data to do so:
• risk of bias of included studies: excluding studies with high risk
of overall bias for the results, as assessed using the Cochrane
ROB-1 and ROB-2 tools;
• impact of model chosen: fixed-eKect versus random-eKects
model;
• how outcomes were measured: we planned to investigate the
impact of including data where the validity of the measurement
was unclear.
If any of these investigations found a diKerence in the size of the
eKect or heterogeneity, we would mention this in the 'EKects of
interventions' section. However, there were insuKicient studies and
data meeting these criteria and these analysis were not required.
Summary of findings and assessment of the certainty of the
evidence
We used the GRADE approach to rate the overall certainty
of evidence for each outcome using the GDT tool (https://
gradepro.org/) for the main comparison pairs listed in the Types of
interventions section. The certainty of evidence reflects the extent
to which we are confident that an estimate of eKect is correct
and we applied this in the interpretation of results. There are four
possible ratings: 'high', 'moderate', 'low' and 'very low'. A rating
of 'high' certainty evidence implies that we are confident in our
estimate of eKect and that further research is very unlikely to
change our confidence in the estimate of eKect. A rating of 'very
low' certainty implies that any estimate of eKect obtained is very
uncertain.
The GRADE approach rates evidence from RCTs that do not have
serious limitations as high certainty. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
The 'Summary of findings' tables present only the seven top
priority outcomes (primary outcomes: disease-specific health-
related quality of life, disease severity as measured by validated
patient-reported symptom score, serious adverse events (SAEs)
and secondary outcomes: avoidance of surgery, extent of disease
as measured by endoscopic score or CT scan score, generic health-
related quality of life and other adverse eKects).
Methods for future updates
We will review the scope and methods of this review approximately
yearly (or more frequently if appropriate) in the light of potential
changes in the topic area, or the evidence being included in
the review (for example, additional comparisons, interventions or
outcomes, or new review methods available).
Conditions under which the review will no longer be maintained as a
living systematic review
The review will no longer be maintained as a living systematic
review once there is high-certainty evidence obtained for the
primary eKectiveness outcomes of the review; new studies are not
expected to be conducted regularly for the interventions included
in this review; or the review topic is no longer a priority for health
care decision-making.
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 4914 references. This reduced
to 3341 aOer the removal of duplicates. The Cochrane ENT
Information Specialist sent all 3341 references to the Screen4Me
workflow. The Screen4Me workflow identified 399 references
as  having been previously assessed: 179 had been rejected as
not RCTs and 220 had been assessed as possible RCTs. The RCT
classifier rejected an additional 1253 references as not RCTs (with
a 99% sensitivity). The Cochrane Crowd assessed the remaining
1689 references, rejecting 1046 as not RCTs and identifying 643
as possible RCTs. Following this process, the Screen4Me workflow
had therefore identified 863 possible RCTs for title and abstract
screening.
The results of this process are detailed in the PRISMA flow
diagram (Figure 1) and summarised in the table below.
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Figure 1.   PRISMA flow diagram for initial search (September 2019).
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Figure 1.   (Continued)
 
 
  Possible RCTs Rejected
 Known assessments  220 179
 RCT classifier   1253
 Cochrane Crowd  643 1046
 Total  863 2478
 
We subsequently identified six additional duplicates, leaving 857
references to screen.
For further details of this process please see Selection of studies in
the Methods section.
We screened the title and abstracts of the remaining 857 references.
We discarded 778  references and assessed 79  full-text articles.
We discarded three additional references at the full-text screening
stage and identified one additional duplicate. We excluded 30 of
these references (19 studies) with reasons recorded in the review
(see Excluded studies).
We included eight completed studies, where results were
available  (31  references) (Bachert 2016; Bachert 2017; Gevaert
2011; Gevaert 2013; LIBERTY SINUS 24; LIBERTY SINUS 52;
NCT01066104; Pinto 2010). NCT01066104 is an unpublished study
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(no journal publications or abstracts found), but the results of the
study were available on the clinicaltrials.gov website.
There is one reference to one study that completed in March 2017
where the results have not yet been published and no information
on the findings are available on clinicaltrials.gov (NCT02772419).
The study was conducted by Kyowa Kirin Co. Ltd. The company
confirmed on 7 January 2019 that the study is complete and that
they are considering publication of the results. We requested access
to the study results or clinical study report on 7 January 2019. The
response from Kyowa Kirin is shown in Appendix 4. This study is
classified as ongoing.
We identified another seven studies (13 references) that we
classified as ongoing. Five studies were due to be completed in
December 2019 and during 2020 (NCT02799446; NCT03450083;
NCT03614923; OSTRO; SYNAPSE). An additional two studies were
completed in 2019 and are due to publish their results in 2020
(POLYP 1; POLYP 2).
See Characteristics of ongoing studies for further details of all eight
studies.
A flow chart of study retrieval and selection is provided in Figure 1.
Included studies
We found a total of eight completed RCTs (Bachert 2016; Bachert
2017; Gevaert 2011; Gevaert 2013; LIBERTY SINUS 24; LIBERTY
SINUS 52; NCT01066104; Pinto 2010).   All the studies were
sponsored or supported by industry.
A summary of key participant characteristics, interventions,
comparison pairs and outcomes measured and reported is
provided in Table 1.
Study design
All studies were double-blind RCTs and used a placebo. The shortest
planned duration was eight weeks (Gevaert 2011), the longest was
52 weeks (LIBERTY SINUS 52). One study was stopped early and only
had 14 participants (Pinto 2010). Some studies were phase II or
proof of concept studies and had  fewer than 30 patients in each
treatment arm (Gevaert 2011; Gevaert 2013; NCT01066104; Pinto
2010).
Participants
A total of 986 participants were included. With the exception of
two participants in one study (Pinto 2010), all the  participants
were adults with chronic rhinosinusitis with nasal polyps and
a significant number of participants (43% to 100%) also had asthma
as a co-morbidity.
Interventions and comparisons
Studies were available to evaluate  three of our four proposed
comparison pairs.  (No studies assessed the comparison anti-
IL-13 plus intranasal steroids versus placebo/no treatment plus
intranasal steroids). All studies compared a biologic against
placebo and all participants received intranasal corticosteroids.
Comparison 1: Anti-IL-4Rα mAb versus placebo/no treatment (all
receiving intranasal steroids)
Three RCTs (784 participants)  investigated dupilumab 300 mg
versus placebo.
• LIBERTY SINUS 24 (276 participants) gave 300 mg
(subcutaneous, SC) dupilumab every two weeks and followed
up patients for 24 weeks.
• LIBERTY SINUS 52 (448 participants) randomised patients 1:1:1
into three arms (two dupilumab arms and one placebo arm):
300 mg SC dupilumab every two weeks for 52 weeks, or 300 mg
SC dupilumab every two weeks for 24 weeks followed by 300
mg SC dupilumab every four weeks for another 28 weeks. The
total period of follow-up was 52 weeks and results were reported
for both week 24 and 52. The study had prespecified that some
of the data would be pooled across both studies and/or both
treatment arms of dupilumab, and did not report the results of
the individual trials separately. For the purpose of this review,
we combined the results of the diKerent dupilumab arms in
the LIBERTY SINUS 52 study, but reported the results of SINUS-52
and SINUS-24 independently by using the data presented in trial
registries whenever possible.
• Bachert 2016 (60 participants) gave a 500 mg SC loading dose of
dupilumab followed by 300 mg SC weekly for 15 weeks.
Comparison 2: Anti-IL-5 mAb versus placebo/no treatment (all
receiving intranasal steroids)
Two RCTs were found for this comparison.
• Bachert 2017 (107 participants).
• Gevaert 2011 (30 participants).
Both studied mepolizumab 750 mg intravenously every four weeks
for 24 weeks.
Comparison 3: Anti-IgE mAb versus placebo/no treatment (all
receiving intranasal steroids)
Three very small studies were found.
• Gevaert 2013 (24 participants).
• NCT01066104 (27 participants).
• Pinto 2010 (14 participants).
All studied subcutaneous omalizumab, at a dose dependent on
the participants' weight and other characteristics, every two or four
weeks for between 16 weeks and six months.
Outcomes
1. Health-related quality of life (HRQL), using validated disease-
specific HRQL scores
Most studies  measured and reported  the SNOT-22. Two did
not: Gevaert 2011 and NCT01066104. SNOT-22 has a range of 0 to
110 and the minimal clinically important diKerence (MCID) is 8.9
points (Hopkins 2009).
2. Disease severity, as measured by validated patient-reported
symptom score (such as the CSS questionnaire or visual analogue
scales)
LIBERTY SINUS 24 used a 0 to 10 cm visual analogue scale (VAS)
to measure overall (global) symptoms ("How troublesome are
your symptoms?", 0 = "not troublesome", 10 = "worst thinkable
Biologics for chronic rhinosinusitis (Review)









Cochrane Database of Systematic Reviews
troublesome").  Other studies either did not provide details or
reported some variation in how the question was asked. Bachert
2017  reported using a VAS of 0 to 10 with the question, "How
troublesome are your symptoms of nasal polyposis?",  0 = "not
troublesome", 10 = "worst possible". These studies generally made
reference to the recommendation in EPOS 2007 to use a VAS, but did
not report whether or not the format or wording of the questions
they used in the trials had been validated.
Other measures such as  "total symptom score" with a scale
range of 0 to 9 points were used by some studies. However, this
scale only measured symptoms of rhinitis (posterior and anterior
rhinorrhoea) and nasal blockage rather than the overall symptom
score of chronic rhinosinusitis, and other individual symptom
scores, and there was no evidence of validation. Data from these
scales, and on those relating to specific, individual symptoms, are
not considered in our meta-analysis as they are not global symptom
scores.
3. Severe adverse events
Most studies used the definition of treatment-emergent severe
adverse events, where the events and participants were accounted
for according to the treatment actually received (rather than
by randomised group) and at least one dose was taken.
4. Avoidance of surgery
A few studies attempted to measure the degree of improvement
(or non-improvement) experienced by participants, by identifying
those participants who required some form of surgery to alleviate
their symptoms. This took the form of determining the number of
patients who required some form of 'rescue surgery', or the number
of patients who met (or no longer met) the criteria for surgery.
There are many issues and potential risks of bias associated with
this measure. Table 2  summarises information for each included
study about (a) whether or not the eligibility for surgery was defined
at randomisation, and (b) in studies where  the need for surgery
was an 'outcome',  what were the criteria for surgery in those
circumstances?
In the two largest studies (724 participants), no specific criteria were
given; it was stated that surgery was performed "when there was
worsening of signs and/or symptoms during the study" (LIBERTY
SINUS 24; LIBERTY SINUS 52).
In Bachert 2017, a set of criteria was used at randomisation and
a diKerent set at the trial's endpoint, to determine "eligibility for
surgery". The criteria used were hypothetical; it is unclear how
many participants were oKered or underwent surgery. Moreover,
whether or not these criteria correlate  with  actual patients'
decisions to accept (and undergo) surgery (if oKered) is unclear.
It is also uncertain whether patients fulfilling these criteria would
actually benefit from surgery (i.e. whether surgery is appropriate in
these cases).
Therefore, although we identified a number of attempts by trialists
to provide an indicator of whether biologics could reduce the need
for surgery in patients, none of the studies used a validated method
that can provide conclusive answers.
5a. Extent of disease: endoscopic score
A number of studies reported using   "endoscopic nasal polyps
score"  (NPS) or total polyps  score (TPS) and referenced  Gevaert
2013, whereas the protocol for  Bachert 2016  referenced a non-
related paper. These had the same scoring system, utilising the total
scores from both sides (bilateral, range 0 to 8).  Unlike the Lund
Kennedy and other scales with reported validation, these scales
focused on the size of polyps, and not other factors such as the
presence of inflammation and secretions/mucus.
Table: Scoring system for endoscopic nasal polyps score (NPS), or total
polyps score (TPS)
 
Polyp score Polyp size
0 No polyps
1 Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate
2 Polyps reaching below the lower border of the middle turbinate
3 Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle
turbinate
4 Large polyps causing complete obstruction of the inferior nasal cavity
 
5b. Extent of disease: computerised tomography (CT) scan score
All studies (other than Bachert 2017) used the Lund Mackay score.
6. Health-related quality of life (HRQL), using generic HRQL scores
Generic health-related quality of life data were available from five
studies. Data on the overall health status measured using the EQ-5D
visual analogue scale were commonly reported and were used in
our meta-analysis. A minimal clinically important diKerence (MCID)
of 8 points has been reported by Hoehle 2019. Data from studies
using the SF-36 are reported narratively, as incompleteness of
the information did not allow data analysis. 
7. Adverse eAects: nasopharyngitis, including sore throat
Most studies reported this outcome.
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Excluded studies
We excluded 19 studies (30  references) aOer reviewing the full
text. Further details of the reasons for exclusion can be found in
the Characteristics of excluded studies table.
We excluded five studies due to the population (Castro 2011;
Liberty Asthma Quest; MUSCA; NCT01285323; NCT02170337).
NCT01285323 and MUSCA were in asthma patients. NCT02170337
was a safety study in healthy patients. Liberty Asthma Quest and
Castro 2011 were studies in asthma patients with a subset of
chronic rhinosinusitis patients. The chronic rhinosinusitis patients
did not meet our inclusion criteria.
We excluded one study due to the intervention (Gevaert 2006). In
this safety study a single dose of biologic was given, rather than a
course of treatment.
We excluded 12 studies that were not RCTs (Boguniewicz 2019; De
Schryver 2015; Gevaert 2008; Gonzalez-Diaz 2014; Hellings 2017;
Laidlaw 2019; Naclerio 2017; NCT02743871; Perez De Llano 2018;
Tajiri 2013; Zangrilli 2019).
Two studies were withdrawn (NCT00603785; NCT02734849).
Risk of bias in included studies
We included eight studies in this review. Overall the risk of bias was
low or unclear for most domains.
See Figure 2 for the 'Risk of bias' graph (our judgements about
each risk of bias item presented as percentages across all included
studies) and Figure 3 for the 'Risk of bias' summary (our judgements
about each risk of bias item for each included study).
 
Figure 2.   'Risk of bias graph': review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
The risk of selection bias was low or unclear in the majority of
studies. We considered the risk of bias to be low for both random
sequence generation and allocation concealment in four studies
(Bachert 2016; Bachert 2017; LIBERTY SINUS 24; LIBERTY SINUS
52), and the risk in both of these domains to be unclear for three
studies (Gevaert 2011; NCT01066104; Pinto 2010). We considered
the Gevaert 2013 study to be at low risk of bias for random sequence
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generation, but at high risk for allocation concealment, because a
randomisation list was used.
Blinding
We considered seven of the eight studies to be at low risk of
performance bias, since all participants and personnel were blind
to treatment allocation. Both the investigator and participants were
blinded in the Gevaert 2013 study, but it is not clear whether or
not the study personnel were also blind. We therefore marked this
domain as being at unclear risk of bias.
In five of the studies it was clear that people who were blind
to treatment allocation assessed outcomes, so we considered
these to be at low risk of detection bias (Bachert 2016; Bachert
2017; LIBERTY SINUS 24; LIBERTY SINUS 52; NCT01066104). We
considered the remaining three studies to be at unclear risk of bias
(Gevaert 2011; Gevaert 2013; Pinto 2010). Although Gevaert 2013
and Pinto 2010 mentioned that the CT scans were read by blinded
assessors, it was not clear whether or not the nasal endoscopy
outcome assessment was blind.
Incomplete outcome data
We assessed four of the studies to be at high risk of attrition
bias (Bachert 2016; Bachert 2017; Gevaert 2011; LIBERTY SINUS
52), mostly due to high rates of discontinuation in these small
studies. We assessed LIBERTY SINUS 52 to be at high risk
because, although the investigators used a last observation carried
forward (LOCF) imputation method, there were proportionally
more discontinuations in the placebo arm. We assessed Gevaert
2013 and NCT01066104 to be at low risk of attrition bias, and
considered LIBERTY SINUS 24 and Pinto 2010 to be at unclear risk
of bias for this domain.
Selective reporting
We only considered one of the studies to be at low risk of selective
reporting (Bachert 2017). There were diKerences between the NCT
trial registration and reported outcomes for Gevaert 2013 and
NCT01066104, so we assessed these to be at high risk of reporting
bias. We found the other trials to be at unclear risk of reporting bias.
Other potential sources of bias
There are concerns about whether or not appropriate and validated
tools were used for some outcomes. None of the studies reported
using validated methods for their endoscopic scoring systems. All of
the studies either did not provide details of the method used or had
reported using a scoring system that took into account only the size
of the polyps and we did not find any references to the validation
of this system. Similarly, whilst many studies reported using a VAS
for overall symptom score, they made no reference to validation.
Although a VAS is a well-used type of scale, its validity needs to
be confirmed  in each  specific population and for each outcome
measured; factors such as the clarity of questions and the definition
used for the 'best' and 'worst' points in the scale could aKect a
scale's validity.
The assessment of 'avoidance of surgery' (outcome 4  above)  is
fraught with diKiculty; there is a high risk of bias in the included
studies. Only a small number of studies defined eligibility for
surgery at baseline. However, these studies did not use the same
criteria for assessment of surgical eligibility at the trial's endpoint.
Moreover, there is an absence of generally accepted or validated
criteria as to what constitutes a situation which is 'severe' enough
for patients to be willing to undergo surgery, or to benefit from
it. Therefore, it is particularly unclear how these criteria were
determined and/or the basis on which criteria were changed
between entry and the endpoint of a study.
In those studies without any predefined or explicit criteria for
surgery, it is even less clear how decisions were made to oKer
'rescue surgery'. See Table 2 for further details.
EAects of interventions
See: Summary of findings for the main comparison Anti-IL-4Rα
mAb (dupilumab) compared to placebo (on top of topical steroids)
for chronic rhinosinusitis; Summary of findings 2 Anti-IL-5 mAb
(mepolizumab) compared to placebo (on top of topical steroids)
for chronic rhinosinusitis; Summary of findings 3 Anti-IgE mAb
(omalizumab) compared to placebo (on top of topical steroids) for
chronic rhinosinusitis
Comparison 1: Anti-IL-4Rα mAb plus intranasal steroids versus
placebo/no treatment plus intranasal steroids
Three studies (784 participants) investigated dupilumab (Bachert
2016;  LIBERTY SINUS 24;  LIBERTY SINUS 52). See Summary of
findings for the main comparison.
1. Health-related quality of life, using validated disease-specific
health-related quality of life scores
Disease-specific health-related quality of life was measured with
the Sino-Nasal Outcome Test-22 (SNOT-22, range 0 to 110, minimal
clinically important diKerence (MCID) 8.9 points).
At 24 weeks,  the SNOT-22 score was 19.61 points lower (better)
in participants who received dupilumab (mean diKerence (MD)
-19.61, 95% confidence interval (CI) -22.54 to -16.69; 3 studies; 784
participants; I2 = 0%; high-certainty evidence; Analysis 1.1).
This eKect was also seen at 52 weeks (MD -22.38, 95% CI -27.10 to
-17.66; 1 study; 303 participants), but the certainty of evidence is
moderate due to imprecision (Analysis 1.1).
2. Disease severity, as measured by validated patient-reported
symptom score
All of the studies used a 0 to 10 cm visual analogue scale
(VAS) score to measure overall chronic rhinosinusitis symptoms.
For the  LIBERTY SINUS 24  and  LIBERTY SINUS 52  studies (724
participants), the question asked was "How troublesome are your
symptoms?". We found no evidence to indicate that this tool
has been validated.
The pooled mean diKerence is -3.00 favouring the groups receiving
dupilumab (95% CI -3.47 to -2.53; 3 studies; 784 participants; I2 =
0%; moderate-certainty evidence; Analysis 1.2). This is likely to be
clinically significant.
3. Serious adverse events
The incidence  of serious adverse events was measured over
diKerent periods:  up to 16 weeks in  Bachert 2016, 24 weeks
in LIBERTY SINUS 24 and 52 weeks in LIBERTY SINUS 52. The risk
seems to be lower in the treatment group (risk ratio (RR) 0.45,
95% CI 0.28 to 0.75; 3 studies; 782 participants; I2  = 0%; low-
certainty evidence; Analysis 1.3). There were discrepancies in the
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numbers reported in the diKerent publications reporting the results
of  LIBERTY SINUS 24. Therefore, we used  the data that matched
those reported in clinicaltrials.gov in this analysis.
4. Avoidance of surgery
Two studies reported the number of participants requiring "nasal
polyps surgery (actual or planned) during the treatment period".
The proportion may be lower in the groups that received
dupilumab (RR 0.17, 95% CI 0.05 to 0.52; 2 studies; 725 participants;
I2= 28%; moderate-certainty evidence; Analysis 1.4). However,
between baseline and endpoint there were changes in the criteria
that determined whether or not a participant qualified for surgery.
It was unclear how many qualified for surgery compared with
how many actually received surgery, and the specific factors that
determined whether or not a patient received 'rescue' surgery
during follow-up. See Table 2 for more details on how this outcome
was measured.
5a. Extent of disease: endoscopy score
All studies used a nasal polyps score, which summed the scores
for both nostrils (0 to 8 points; 0 = no polyp, 4 = large polyps, for
each nostril, with a lower score indicating smaller-sized polyps).
The diKerences between the intervention arms were large (Cohen's
eKect size > 0.7 = large eKect), favouring the dupilumab group.
At 24 weeks follow-up the mean diKerence  was -1.80 (95% CI
-2.25 to -1.35; 3 studies; 784 participants; I2  = 65%; moderate-
certainty evidence; Analysis 1.5), with a corresponding eKect size of
standardised mean diKerence (SMD) -1.05 (95% CI -1.29 to -0.82).
We found no evidence to indicate that this scoring system has been
validated.
At 52 weeks, the mean diKerence was -2.34 (95% CI -2.77 to -1.91;
1 study; 303 participants; low-certainty evidence; Analysis 1.5), and
the corresponding eKect size was SMD -1.24 (95% CI -1.48 to -0.99).
5b. Extent of disease: computerised tomography (CT) scan score
We pooled data from 16 weeks to 52 weeks as data were only
available from one time point from each study.
The changes in the extent of disease were evaluated using a  CT
scan and scored using the Lund Mackay scale (0 to 24, higher =
worse). The mean diKerence was -7.00 (95% CI -9.61 to -4.39; 3
studies; 784 participants; I2 = 92%; high-certainty evidence; Analysis
1.6),  showing  a large eKect favouring the dupilumab group. The
corresponding SMD was -1.50 (95% CI -1.84 to -1.15; Cohen's eKect
size > 0.7 = large eKect). We considered the certainty of the evidence
to be high despite the large I2 value;  there is no inconsistency in
terms of direction or size of eKects between the three studies.
6. Health-related quality of life, using generic health-related
quality of life scores
Two studies used the EQ-5D visual analogue scale (0 to 100, higher
= better) to measure the change in generic health-related quality
of life (overall health state). The pooled MD of two studies was 8.59
points (95% CI 5.31 to 11.86; 2 studies; 706 participants; I2 = 100%;
moderate-certainty evidence; Analysis 1.7). This eKect size is similar
to the size of the MCID (8 points, as suggested by Hoehle 2019)
and therefore there is probably a clinically important improvement
in this outcome. We noted the high I2 value, however the two
pooled studies are LIBERTY SINUS 24 and LIBERTY SINUS 52 and the
direction of eKect is the same in both studies despite the diKering
time periods for outcome assessment (24 weeks and 52 weeks),
therefore we considered this to be more a statistical quirk than an
issue of concern.
7. Adverse e5ects: nasopharyngitis, including sore throat
The pooled results indicate that there is probably little or no
diKerence  in the risk of nasopharyngitis, but larger sample sizes
are needed for a more precise estimate (RR 0.95, 95% CI 0.72 to 1.25;
3 studies; 783 participants; I2 = 0%; low-certainty evidence; Analysis
1.8).
Comparison 2: Anti-IL-5 mAb plus intranasal steroids versus
placebo/no treatment plus intranasal steroids
Two studies evaluated mepolizumab (Bachert 2017; Gevaert 2011).
See Summary of findings 2.
1. Health-related quality of life, using validated disease-specific
health-related quality of life scores
Data on disease-specific health-related quality of life as measured
with the SNOT-22 were only available from one study (Bachert 2017:
data from  the EudraCT  website). The mean diKerence  of  -13.26
lower (better) with mepolizumab (95% CI -22.08 to -4.44; 1 study;
105 participants; low-certainty evidence; Analysis 2.1) is greater
than the MCID of 8.9 points.
2. Disease severity, as measured by validated patient-reported
symptom score
Bachert 2017 reported using a VAS of 0 to 10 with the question "How
troublesome are your symptoms of nasal polyposis?" (0 = "not
troublesome", 10 = "worst possible"). The MD was -2.03  (95% CI
-3.65 to -0.41; 1 study; 72 participants; very low-certainty evidence;
Analysis 2.2). We are very uncertain about these data due to the very
small sample size and the absence of evidence that a validated tool
was used.
3. Serious adverse events (SAEs)
It is uncertain whether or not there is a diKerence in the risk
of serious adverse events (RR 1.57, 95% CI 0.07 to 35.46; 2 studies;
135 participants; I2 = 0%; very low-certainty evidence; Analysis 2.3).
4. Avoidance of surgery
Each  study  applied diKerent criteria for assessing the need  for
surgery (see Table 2). While Bachert 2017 reported the number of
patients who still met the criteria for surgery at the end of trial,
Gevaert 2011 reported the number that required surgery during the
period of the trial. It is very uncertain whether or not the overall
risk that patients still need surgery at the end of trial is lower in the
mepolizumab group (RR 0.78, 95% CI 0.64 to 0.94; 2 studies; 135
participants; I2 = 0%; very low-certainty evidence; Analysis 2.4).
5a. Extent of disease: endoscopic score
The mean diKerence in the change of the nasal polyps score was
1.23 points lower in the mepolizumab group (MD -1.23, 95% -1.79
to  -0.68; 2 studies; 137 participants;   I2  = 0%; very low-certainty
evidence; Analysis 2.5). This corresponds to a moderate eKect size
(SMD -0.69, 95% -1.04 to -0.34; low-certainty evidence). We found
no evidence to indicate that this scoring system has been validated.
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5b. Extent of disease: computerised tomography (CT) scan score
Gevaert 2011  did not report the numerical values of the CT
scan scores, but stated that at week eight the scores "were
not significantly diKerent between groups". Bachert 2017 did not
measure CT scan scores. The evidence for this outcome was of very
low certainty.
6. Health-related quality of life, using generic quality of life
scores
The mean diKerence on the EQ-5D visual analogue scale was 5.68
in one study (95% CI -1.18 to 12.54; 1 study; 105 participants; low-
certainty evidence; Analysis 2.6), favouring the mepolizumab group
(Bachert 2017). This diKerence is smaller than the MCID of 8 points.
7. Adverse e5ects: nasopharyngitis, including sore throat
There may be little or no diKerence in the risk of nasopharyngitis
(RR 0.73, 95% 0.36 to 1.47; 2 studies; 135 participants; I2 = 0%; low-
certainty evidence; Analysis 2.7).
Comparison 3: Anti-IgE mAb plus intranasal steroids versus
placebo/no treatment plus intranasal steroids
We identified  three very small studies evaluating  omalizumab
(Gevaert 2013; NCT01066104; Pinto 2010). See Summary of findings
3.
1. Health-related quality of life, using validated disease-specific
health-related quality of life scores
A narrative summary was reported in  Gevaert 2013  (24
participants): "On the basis of the 31-item Rhinosinusitis Outcome
Measuring Instrument (RSOM-31), sleep (P =0.03) and general
symptoms (P = 0.01) showed a significant improvement in the
omalizumab group, whereas in the placebo group no significant
changes were seen".
Pinto 2010 reported that the median change in SNOT-20 score was
-1.05 for the omalizumab group and -0.20 for the placebo group (P
< 0.78 for the diKerence between groups).
The evidence for this outcome was of very low certainty.
2. Disease severity, as measured by validated patient-reported
symptom score
Pinto 2010 reported that "The median TNSS for each month did
not vary between visits by analysis of variance for either group (P
> 0.05, all comparisons), with no significant net diKerence across
treatments (omalizumab –1, placebo 0, P < 0.21)".
3. Serious adverse events (SAEs)
Although all three studies collected data on severe adverse events,
no event was reported (very low-certainty evidence). In total, the
treatment groups across three studies had 35 participants, while
the placebo group had 29 participants; this number is too small to
properly assess severe adverse events (Analysis 3.1).
4. Avoidance of surgery
None of the studies reported this outcome.
5a. Extent of disease: endoscopic score
Two studies evaluated and reported nasal polyps  scores (0 to 8
points, higher = worse). Although the pooled mean diKerence of
-1.63 (95% CI -3.73 to 0.47; 2 studies; 47 participants; I2 = 81%)
corresponds to a large eKect size (SMD -1.51, 95% CI -4.22 to 1.21;
Analysis 3.2), there is inconsistency because the eKect sizes seen
in the two studies are very diKerent. One study showed a large
eKect size with an SMD of nearly 3 (Gevaert 2013); in the other study
both arms had similar scores (NCT01066104). The evidence for this
outcome is of very low certainty.
Pinto 2010 reported that "There were no significant changes within
in endoscopy scores for either group (data not shown). Net change
across treatments were not significantly diKerent (omalizumab 0,
placebo –0.5, P < 0.58)". There was no information about what
scoring system was used or whether one or both sides of the nose
were assessed and scored. The paper reported using a 0- to 4-point
score, but referenced a paper using a 0- to 3-point scale.
5b. Extent of disease: computerised tomography (CT) scan score
Gevaert 2013 reported the Lund Mackay scores at the endpoint
whereas NCT01066104 reported the percentage change compared
to baseline using a modification of the Lund Mackay score (no
reports of validation). In both studies, lower scores mean a better
outcome for the patients. The observed pooled results correspond
to a small eKect size (SMD -0.20, 95% CI -1.55 to 1.14; 2 studies; 47
participants; I2 = 80%; Analysis 3.3). 
Statistical heterogeneity is high and there are inconsistencies in the
size and direction of eKect. In the NCT01066104 study, the results
favoured the placebo group, while in Gevaert 2013 they favoured
the intervention group. The evidence for this outcome was of very
low certainty.
6. Health-related quality of life, using generic quality of life
scores
Two studies used the SF-36 to measure health-related quality
of life.  Pinto 2010  reported that "Across treatments, there were
also no significant diKerences (P > 0.05, all comparisons) except
for one domain, Vitality (omalizumab 9.4, placebo 12.5, P <
0.05)." Gevaert 2013  reported, "AOer 16 weeks, the Short-Form
Health Questionnaire (SF-36) for physical health was significantly
improved in the omalizumab group (P = 0.02) but not in the placebo
group (P = 0.75). Unlike physical health, mental health did not
significantly improve in either treatment group." The evidence for
this outcome was of very low certainty.
7. Adverse e5ects: nasopharyngitis, including sore throat
No nasopharyngitis was reported in any of the three studies in
either intervention arm. The total sample size (35 participants in the
intervention group, 29 in the placebo group) is probably too small
to detect adverse events (very low-certainty evidence).
D I S C U S S I O N
Summary of main results
We identified randomised controlled trials (RCTs) evaluating the
eKectiveness of three diKerent drugs, representing three diKerent
types of monoclonal antibodies. These were dupilumab (an anti-
Biologics for chronic rhinosinusitis (Review)









Cochrane Database of Systematic Reviews
IL-4Rα mAb), mepolizumab (an anti-IL-5 mAb) and omalizumab (an
anti-IgE mAb).
The first two  drugs were evaluated in  adults with chronic
rhinosinusitis and nasal polyps who were also using regular topical
nasal steroids. In these patients, we found high-certainty evidence
from three studies (with nearly 800 participants) that dupilumab
improves disease-specific health-related quality of life (HRQL)
compared to placebo, and reduces the extent of the disease as
measured on a computerised tomography (CT) scan. Moderate-
certainty evidence shows that it probably also improves
symptoms,  generic HRQL as measured by overall health status
and size of polyps as measured by nasal polyp scores. It  may
reduce the need for further surgery but it is diKicult to interpret
the clinical implications of this finding due to methodological
limitations. There is probably little or no diKerence in the risk of
nasopharyngitis.
Mepolizumab has been evaluated in similar patients but the
certainty of evidence is either low or very low. It may improve both
disease-specific and generic HRQL, and improve nasal polyp scores.
As with dupilumab, it may reduce the need for surgery, but there
are important limitations of the methodology that limit the clinical
interpretation of the data. There may be little or no diKerence in the
risk of nasopharyngitis. It is very uncertain if there is a diKerence in
the risk of serious adverse events.
We are very uncertain about the eKects of omalizumab because the
evidence is very limited and of low or very low certainty.
Overall completeness and applicability of evidence
There are four  major limitations pertaining to the completeness
and applicability of the evidence:
1. All but one study (Pinto 2010) recruited patients with moderate
to severe chronic rhinosinusitis with nasal polyps, as defined
by polyp size and need for systemic steroids and/or surgery,
and at least half of the participants also had asthma as a
comorbidity.  Therefore, there is no evidence on whether or
not patients with less severe disease (with or without nasal
polyposis or asthma) would benefit as much or at all.
2. All studies were in adults. There are no data for children.
3. There is a lack of long-term evidence.  Whilst treatment with
biologics is arguably a lifetime commitment, there was only one
study with a 52-week follow-up. It was not always possible to
compare the mid-term (24-week) data with the longer-term data
in this study. However, where data were published (SNOT-22 and
endoscopy score) the eKect size was maintained (LIBERTY SINUS
52).
4. The sample sizes were insuKicient and the length of follow-up
too short to comprehensively and adequately assess the risks of
side eKects.
Quality of the evidence
The primary reason for downgrading the quality of the available
evidence was imprecision, where sample sizes were too small to
provide a precise estimate.
In addition, the  lack of evidence that validated scales or scoring
systems were used was also a concern, especially for symptom
scores and endoscopy scores.  As in other studies found in this
series of Cochrane Reviews, the lack of use of a globally validated
symptom score scale, which focuses on overall disease severity,
continues to be a problem. It is diKicult to compare 'the overall
improvement' of symptoms across trials or reviews if studies
use diKerent scales, with diKerent weightings given to diKerent
types of symptoms.  Although  there have been improvements in
methodology compared to previous studies, in the sense that
studies attempted to use  visual analogue scales, there was no
evidence that these scales had been validated and that they
are comparable across studies. In addition, many studies also used
a scoring system for nasal endoscopy that only takes into account
the size of polyps. There is no reference to how this scale has been
validated against patient outcomes.
All but one study (Pinto 2010) focused (sometimes solely) on
recruiting patients who had comorbid asthma and more severe
nasal polyposis. However, notwithstanding this we did not further
downgrade studies based on applicability.
It should also be noted that the evidence available is relatively
short-term; only one study was conducted for more than  six
months. We did not downgrade the evidence for indirectness due
to the relatively short follow-up.
Potential biases in the review process
None of the studies reported using a validated  overall symptom
score measure to assess changes in patients' symptom severity.
Some studies reported specific types of chronic rhinosinusitis
symptoms using diKerent tools, for  many of which there was
no evidence of validation.
To provide the best possible picture of overall symptoms, we
examined each reported tool carefully and used data from
questions/questionnaires that asked about overall symptoms. We
avoided using data from tools that only measured one or two
specific symptoms of chronic rhinosinusitis. For example, we did
not use data from  the 'total symptom score' (TSS); this only
measured symptoms of anterior and posterior rhinorrhoea and
nasal blockage. The symptoms of loss of sense of smell and facial
pain were not measured.
Whenever an overall symptom assessment was reported using
a visual analogue scale, we recorded  and used those data  even
though there were slight variations between studies in how the
questions were worded.
Agreements and disagreements with other studies or
reviews
No previous systematic reviews have included the two largest trials
(LIBERTY SINUS 24;  LIBERTY SINUS 52), published in November
2019, which evaluate the eKects of dupilumab and  together
contribute 724 or 986 participants to the current review and meta-
analysis.
A systematic review, Tsetsos 2018, reported five trials that we also
included in this Cochrane Review (Bachert 2016; Bachert 2017;
Gevaert 2011; Gevaert 2013; Pinto 2010) and one that we excluded
(Gevaert 2006). Their primary outcome was total nasal endoscopic
polyp score. They did not perform a meta-analysis.
Rivero 2017 included randomised and non-randomised studies in
their systematic review and meta-analysis. Three of our included
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studies were also included in their review (Gevaert 2011; Gevaert
2013; Pinto 2010). Nasal polyp score was their primary outcome
of interest. The diKerences in the study types means that is not
appropriate to compare the results of their meta-analyses with
those in this review.
An earlier systematic review, Hong 2015, only identified two RCTs
(Gevaert 2013; Pinto 2010).
In summary, there are no systematic reviews or meta-analyses with
which it is appropriate to compare the results of the present review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Patients with chronic rhinosinusitis, with and without nasal polyps,
oOen need long-term treatment. Many have surgery and revision
surgery is common, with a 10-year revision rate in excess of
15% in a large population study (Smith 2019), and with over
50% of patients in a UK epidemiological study reporting previous
surgery for chronic rhinosinusitis with nasal polyps (CRSwNP)
(Philpott 2015). Patients with chronic rhinosinusitis with nasal
polyps and comorbid asthma are at a higher risk of undergoing
revision surgery, and many of these patients experience poor
symptom control, the need for repeated systemic steroids and
multiple surgeries. The majority of trials included in this review
have selected patients with severe chronic rhinosinusitis with nasal
polyps, as defined by polyp size and the need for systemic steroids
and/or surgery, both of which carry a risk of significant adverse
eKects. These severely aKected patients, who had eKectively failed
other treatment options, experienced significant improvements
in health-related quality of life and reduced disease severity on
radiological imaging. Importantly, there does not appear to be any
increased risk of severe adverse events, at least in the short term.
This has the potential, therefore, to be a 'game-changer'  in the
management of patients with severe disease, allowing them to
avoid other treatments associated with higher risk.
We are currently unable to predict which patients will respond
to biologics. The included studies report response rates between
50% and 70%, and therefore not all patients will respond to these
drugs.  Nor is it clear how to choose the optimum biologic, and
when to consider these drugs, particularly with regards to using
them before or aOer surgery. We also do not know if these drugs are
eKective in patients with less severe disease so we must highlight
the potentially limited generalisability of the reported findings to
the wider population of patients with chronic rhinosinusitis.
Finally, although not considered in this review, currently these
drugs are high-cost compared to conventional treatment with
topical and systemic corticosteroids and surgery, and patients
require ongoing treatment with them. Both health economic
analysis and long-term eKectiveness studies are required to help
guide usage and balance the societal costs with the needs of
individual patients as the costs of  long-term treatment with
biologics, at current drug price levels, will be substantial.
Implications for research
Trials continue to use a heterogenous group of outcomes and do
not include  the recently published core outcome set for chronic
rhinosinusitis (Hopkins 2018). There is an urgent need to validate
or refine the nasal polyp scoring system and to ensure that it is
uniformly applied.
Further data analysis is required to report response rates and future
trials should aim to identify biomarkers that will predict response
and allow selection of the 'best' biologic in each individual patient,
in what is likely to be a growing field of diKerent biologics. It will
also be important to evaluate response rates and eKectiveness in
diKerent subgroups as outlined above.
In many healthcare settings, the current high cost of biologics,
and the fact that their eKicacy has only been demonstrated in
severely aKected patients, will likely limit their use only to these
patients at the present time.  Studies are required to evaluate
their eKectiveness in patients with a less severe disease burden
and in patients with chronic rhinosinusitis without nasal polyps.
We also need comparative studies to evaluate diKerent biologics
and to compare them with conventional therapies, as well as
studies that evaluate the optimum timing of use of diKerent
interventions.  For example, studies are needed to determine if
biologics can be disease-modifying if given early in the disease
process (and therefore may be discontinued without relapse)
or whether ongoing usage is required regardless of when the
treatment is initiated.  Also, studies are required to determine
whether there is any diKerence in eKectiveness if biologics are used
before or aOer surgery. Finally, long-term observational studies are
required to determine if biologics lose eKectiveness over time, for
example due to the development of neutralising antibodies, or
whether there are any late adverse events.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Double-blind, parallel-group RCT with 16 weeks of treatment/follow-up
Participants Setting: multicentre; 13 hospitals/clinical centres in the USA and Europe (Belgium, Spain and Sweden)
Sample size: 60
• Number randomised: 60
• Number completed: 51 (28 in intervention group, 23 in comparator)
Participant (baseline) characteristics
• Age: mean 47.4 years dupilumab group; mean 49.3 years placebo group
• Gender: 60% male dupilumab group, 53.3% male placebo group
• Main diagnosis: chronic sinusitis with nasal polyps
• Polyps status: bilateral nasal polyp score (range 0 to 8, higher = worse) 5.9 (1.0) dupilumab group; 5.7
(0.9) placebo group
• Previous sinus surgery status: 53.3% had ≥ 1 previous surgery for nasal polyps in dupilumab group;
63.3% of placebo group
• Previous courses of steroids: excluded if received oral corticosteroids within past 2 months
• Aspirin sensitivity: 20% of dupilumab group and 30% of placebo group
• Asthma: 53.3% dupilumab group and 63.3% placebo group
• Need for surgery: no information provided regarding whether participants were deemed to require
surgery at baseline (no surgical outcomes reported)
Inclusion criteria:
• A minimum bilateral nasal polyp score of 5 out of a maximum score of 8 for both nostrils (with at least
a score of 2 for each nostril) despite completion of a prior INCS treatment for at least 8 weeks before
screening; and
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• Presence of at least 2 of the following symptoms prior to screening: nasal blockade/obstruction/con-
gestion or nasal discharge (anterior/posterior nasal drip); facial pain/pressure; reduction or loss of
smell.




• Patients < 18 or > 65 years of age
• SNOT-22 score of < 7
• Patients who have taken other investigational drugs or the following prohibited therapy within 2
months before screening or 5 half-lives, whichever is longer
* Burst of oral corticosteroids (OCS) or intranasal corticosteroid drops within the 2 months before
screening or are scheduled to receive OCS during the study period for another condition
* Monoclonal antibody (mAb) and immunosuppressive treatment
* Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days of Visit 1
* Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days
prior to Visit 1
• Patients who have undergone nasal surgery within 6 months before screening or have had more than
2 surgeries in the past for nasal polyps
• Patients with conditions/concomitant diseases making them non-evaluable for the primary efficacy
endpoint, such as:
* Antrochoanal polyps
* Nasal septal deviation that would occlude at least one nostril
* Acute sinusitis, nasal infection or upper respiratory infection at screening or in the 2 weeks before
screening
* Ongoing rhinitis medicamentosa
* Churg-Strauss syndrome, Young's syndrome, Kartagener’s syndrome or dyskinetic ciliary syn-
dromes, concomitant cystic fibrosis
* Signs or a CT scan suggestive of Allergic fungal rhinosinusitis
• Patients with co-morbid asthma are excluded if one of the following criteria is met:
* Patients with FEV1 < 60% (of predicted normal);
* Patients with an asthma exacerbation requiring systemic (oral and/or parenteral) steroid treat-
ment or hospitalisation for > 24 hours for treatment of asthma, within 3 months prior to screening
or are on a dose of greater than 1000 μg fluticasone or an equivalent inhaled corticosteroid.
Interventions Intervention (n = 30):
• 600 mg loading dose of subcutaneous dupilumab, followed by 300 mg every week for 15 weeks
Control (n = 30):
• Placebo given subcutaneously every week for 16 weeks
Use of additional medication (common to both groups): 100 µg mometasone furoate nasal spray in
each nostril twice daily given during the 4-week run-in period and continued at a stable dose through-
out the trial. Inhaled asthma controller therapies could be continued.
Outcomes Primary outcomes (relevant to this review):
All reported at 16 weeks
• Disease specific health-related quality of life (SNOT-22 score)
• Disease severity symptom score (VAS score for "how troublesome are your symptoms?"; individual
symptoms severity scores for nasal congestion/obstruction, anterior/posterior rhinorrhoea, loss of
sense of smell, nocturnal awakenings)
• Severe adverse events
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Secondary outcomes (relevant to this review):
All reported at 16 weeks
• Endoscopic polyp score (change in bilateral score, range 0 to 8, each nostril scored between 0 and 4;
higher = larger polyps)
• CT scan score (Lund Mackay CT score, range 0 to 24, higher = worse)
• Adverse events (nasopharyngitis)
Other outcomes reported by the study:
All reported at 16 weeks
• UPSIT smell test
• Peak nasal inspiratory flow
• Patient-rated nasal congestion/obstruction
• Anterior and posterior rhinorrhoea (score 0 to 3)
• Loss of sense of smell (score 0 to 3)
• Nocturnal awakening (score 0 to 3)
Funding sources Sanofi and Regeneron Pharmaceuticals
Declarations of interest Trial authors employed/received funding from Sanofi and Regeneron Pharmaceuticals. Sanofi and Re-
generon Pharmaceuticals Inc, in collaboration with the academic clinical investigators, provided input
on the design and conduct of the study; oversaw the collection, management and statistical analysis of
data; and contributed to the interpretation of the data and the preparation, review and submission of
the manuscript. The final decision on manuscript submission was made by the authors; the sponsors
did not have the right to veto or require submission or publication.
Notes A prespecified enrolment goal was that 50% of the patients had comorbid asthma. Recruitment of




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A randomized treatment kit number list will be generated centrally by
Sanofi. The investigational product (dupilumab or placebo) will be packaged
in accordance with this list.
The Sanofi Clinical Supplies team will provide the randomized treatment
kit number list and the Study Biostatistician will provide the randomization
scheme to the centralized treatment allocation system. This centralized treat-
ment allocation system will generate the patient randomization list according
to which it will allocate the treatments to the patients."
Comment: central randomisation using computer software
Allocation concealment
(selection bias)
Low risk Quote: "This centralized treatment allocation system will generate the patient
randomization list according to which it will allocate the treatments to the pa-
tients". "The Investigator obtains treatment kit numbers at randomization and
subsequent scheduled visits via an Interactive Voice Response System/Interac-
tive Web Response System (IVRS/IWRS) that will be available 24 hours a day." -
page 36 protocol
Comment: central allocation, separate to enrolment of participants
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Low risk Quote: "Dupilumab and placebo were provided in identical and indistinguish-
able treatment kits, and study patients, investigators, and site personnel were
blinded to study treatment."
Comment: double-blind
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "In accordance with the double-blind design, study patients, investiga-
tors, and study site personnel will remain blinded to study treatment and will
not have access to the randomization (treatment codes)." "Video recordings of






High risk Quote: "There were 23 patients in the placebo group who completed the 16-
week treatment period and 28 in the dupilumab group."




Unclear risk Comment: all primary and secondary endpoints assessed and reported. Pub-
lished protocol. Some lack of clarity in protocol regarding choice of measure-
ment tool (original trial record states "patient reported symptoms of sinusitis"




Methods Double-blind, parallel-group RCT with 24 weeks of treatment/follow-up
Participants Setting: multicentre study at 6 sites in Europe (Belgium, the Netherlands and the UK)
Sample size:
• Number randomised: 107
• Number completed: 74 (42 in intervention group, 32 in comparator)
Participant (baseline) characteristics:
• Age: mean 51 years mepolizumab group; mean 50 years placebo group
• Gender: 76% male mepolizumab group; 67% male placebo group
• Main diagnosis: severe recurrent bilateral nasal polyposis requiring surgery
• Polyps status: bilateral nasal polyp score mean 6.28 mepolizumab group; 6.31 placebo group (range
0 to 8, higher = worse)
• Previous sinus surgery status: all participants had at least one previous surgery (inclusion criterion)
• Previous courses of steroids: refractory to standard-of-care steroid therapy (received INCS for ≥ 3
months and/or received a short course of oral steroids) at the time of enrollment
• Asthma: 81% mepolizumab group; 75% placebo group
• Need for surgery: all participants were deemed to require surgery at baseline, according to the inclu-
sion criteria (see above)
Inclusion criteria:
• Diagnosis of severe bilateral nasal polyposis at the screening visit and Visit 1 (i.e. at end of run-in peri-
od), which meets the definition of the situation indicative of the need for surgery (an endoscopic nasal
polyposis score of 3 or greater and a symptom score of greater than 7 on a VAS)
• At least one previous surgery for the removal of nasal polyps
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• History of refractory response to steroid therapy as shown by being deemed potentially eligible for
surgery despite having been on a regular/continuous course of nasal corticosteroids for the treatment
of nasal polyposis for at least 3 months and/or have received a short course of oral steroids in the past
for nasal polyp treatment
• Male or female between 18 and 70 years of age, inclusive
• BMI within the range 19.0 to 31.0 kg/m2 (inclusive)
• Free of any clinically significant disease that would interfere with the study schedule or procedures
or compromise his/her safety
• Concurrent asthma must be maintained on no more than 10 mg/day of prednisolone or the equivalent
• Adequate contraception
Exclusion criteria:
• Requiring oral corticosteroids at a dose greater than 10 mg prednisolone or equivalent during the
study
• Asthma exacerbation requiring admission to hospital within 4 weeks of screening
• Immunotherapy within the previous 12 months
• Positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include am-
phetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
• Known medical history of hepatitis B, hepatitis C or HIV infection
• History or suspicion of drug abuse or alcohol abuse within the last 6 months
• Currently receiving, or have received within 3 months prior to first mepolizumab dose, chemotherapy,
radiotherapy or investigational medications/therapies
• One or more of the following abnormal laboratory values:
* serum creatinine ≥ 3 times institutional upper limit of normal;
* AST or/ALT ≥ 5 times institutional upper limit of normal;
* Platelet count < 50,000/μL
• History of sensitivity to any of the study medications, or components thereof or a history of drug or
other allergy that contraindicates their participation. Aspirin-sensitive participants were acceptable.
• History of allergic reaction to anti-IL-5 or other antibody therapy
• Positive serum pregnancy test at screening or positive urine pregnancy test prior to each dosing oc-
casion
• Breastfeeding/lactating
• Current smoker or smoked in the last 6 months
Interventions Intervention (n = 54):
• 750 mg intravenous infusion of mepolizumab every 4 weeks for 24 weeks (6 doses in total)
Control (n = 53):
• Placebo given intravenously every 4 weeks for 24 weeks (6 doses in total)
Use of additional medication (common to both groups): 100 µg fluticasone propionate nasal spray in
each nostril daily given during a 10- to 14-day run-in period and continued this dose throughout the tri-
al. Inhaled asthma controller therapies could be continued.
Outcomes Primary outcomes (relevant to this review):
All reported at 25 weeks
• Disease-specific health-related quality of life (SNOT-22 score)
• Disease severity symptom score (VAS score range 0 to 10, "how troublesome are your symptoms of
nasal polyposis?", individual VAS scores for four symptoms (rhinorrhoea, mucus in the throat, nasal
blockage and loss of smell))
• Severe adverse events
Secondary outcomes (relevant to this review):
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All reported at 25 weeks
• Avoidance of surgery (number of participants who no longer met the criteria for requiring surgery)
• Endoscopic nasal polyp score (range 0 to 8, higher = worse)
• Health-related quality of life, generic (EQ-5D scores, scale 0 to 100, higher = better)
• Nasopharyngitis
Other outcomes reported by the study:
All reported at 25 weeks
• Sense of smell – Sniffin' Sticks Screening-12
• Lung function assessments
Funding sources GlaxoSmithKline
Declarations of interest GlaxoSmithKline, in collaboration with the academic clinical investigators, provided input on the de-
sign and conduct of the study; oversaw the collection, management and statistical analysis of data;
and contributed to the interpretation of the data and the preparation, review and submission of the
manuscript. All authors had roles in the conception, design and interpretation of the analysis. All au-
thors participated in the development of the manuscript and had access to the data from the study.
The decision to submit for publication was that of the authors alone. The final decision on manuscript
submission was made by the authors. The sponsors did not have the right to veto publication.
Notes Trial registration number NCT01362244
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A randomization schedule was generated before the start of the study
by using validated internal software. Patients were randomized with the Glax-
oSmithKline IVRS system RAMOS. Site staK called the RAMOS system to regis-
ter the patient on the system and allocated a randomization number. The ran-
domization schedule used by the RAMOS system was generated by the Glax-
oSmithKline study statistician before the start of the study using validated in-
ternal software. A center-based randomization schedule was used, with block-
ing (block size 4)."
Comment: central randomisation using computer software
Allocation concealment
(selection bias)
Low risk Quote: "site staK (except for the unblinded pharmacist), GlaxoSmithKline
study staK (except for the independent statistician who analyzed the interim
data), and bioanalytical staK (placebo-treated subjects were not assayed for
PK concentrations) had no access to the random codes until after completion
of the study."





Low risk Quote: "The patients and treating doctors were blind to treatment."
Comment: double-blind
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Blinding was strictly maintained until all data had been collected and
cleaned and Database Freeze had been declared."
Comment: blinded study, outcomes collected prior to unmasking
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High risk Quote: "[for placebo] 32 (63%) completed treatment phase to Week 25. [for
mepolizumab] 42 (78%) completed treatment phase to Week 25."
Comment: high dropout (> 20%) in both arms, > 10% difference between the
groups. There were high rates of discontinuation, with imbalance between
arms (19 (37%) of placebo group and 12 (22%) of mepolizumab population dis-
continued), which may impact on results.
Selective reporting (re-
porting bias)




Methods Double-blind, parallel-group RCT with 8 weeks of treatment and 40 weeks of follow-up
Participants Setting: single centre within Europe (Belgium)
Sample size: 30
• Number randomised: 30
• Number completed: 10 (9 in intervention group, 1 in comparator)
Participant (baseline) characteristics:
• Age: mean 50.0 years mepolizumab group; mean 45.9 years placebo group
• Gender: 70% male mepolizumab group, 80% male placebo group
• Main diagnosis: chronic sinusitis with primary nasal polyps (grades 3 or 4) or recurrent nasal polyps
(grade 1 to 4)
• Polyps status: bilateral nasal polyp score mean 5.2 mepolizumab group; mean 5.5 placebo
group(range 0 to 8, higher = worse)
• Previous sinus surgery status: 75% had ≥ 1 previous surgery for nasal polyps in mepolizumab group;
80% in placebo group
• Previous courses of steroids: (excluded if received oral corticosteroids within past month)
• 50% mepolizumab group and 30% of placebo group reported comorbid asthma
• 25% of mepolizumab group and 0% of placebo group reported aspirin sensitivity
• Need for surgery: no information provided regarding whether participants were deemed to require
surgery at baseline (no surgical outcomes reported)
Inclusion criteria:
• Chronic rhinosinusitis with primary nasal polyps grade 3 to 4 (each nostril scored 0 to 4, higher = worse)
or recurrent nasal polyps after surgery (grade 1 to 4); and
• Failure of standard care for chronic rhinosinusitis with nasal polyps.
Exclusion criteria:
• Use of systemic corticosteroids/surgery in the month before recruitment
• Use of nasal corticosteroids, nasal antihistamines, nasal atropine, nasal cromolyn, nasal saline or an-
tibiotic treatment for 2 months after first dosing
Interventions Intervention (n = 20):
• 2 doses of 750 mg dose of intravenous mepolizumab given 28 days apart
Control (n = 10):
• Placebo given IV 28 days apart in 2 doses
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Use of additional medication (common to both groups): use of systemic corticosteroids and surgical in-
tervention was not allowed from 1 month before treatment until the end of the study, and participants
were not permitted to use nasal corticosteroids, nasal antihistamines, nasal atropine, nasal cromolyn,
nasal saline or antibiotic treatment for 2 months after first dosing.
Outcomes Primary outcomes (relevant to this review):
• Disease severity symptom scores (4 individual symptoms, anterior rhinorrhoea, nasal obstruction,
postnasal drip and loss of sense of smell, each scored with range 0 to 3, higher = worse) (reported at
8 weeks)
• Serious adverse events (reported at 48 weeks)
Secondary outcomes (relevant to this review):
• Endoscopy (reduction in nasal polyp score) (reported at 8 weeks)
• Change in CT scan score (improvement versus worsening or no change) (reported at 8 weeks)
• Pharyngitis (reported at 48 weeks)
Other outcomes reported by the study:
All reported at 8 weeks
• Nasal peak inspiratory flow
• Blood and serum markers (eosinophils, serum IL-5Rα, eosinophil cationic protein)
Funding sources Study was supported by GlaxoSmithKline (GSK), who also provided the study drug
Declarations of interest 2 trial authors were employed by GSK and a further 2 authors received funding from GSK
Notes Trial registration number: not available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Subjects were randomized to receive…"
Comment: no further details given, therefore unclear how randomisation was
performed or by whom.
Although not statistically significant, more participants in the intervention arm
had asthma and/or aspirin intolerance
Allocation concealment
(selection bias)





Low risk Quote: "The study was double blind up to 48 weeks"
Comment: described as double-blind and placebo injection was used
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: no comment on blinding of outcome assessors. Some subjective




High risk Quote: "At the end of the study there was a considerable drop out rate in both
the mepolizumab and placebo arms."
Comment: high dropout (30%) in placebo arm versus 10% in intervention arm
by week 8
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Selective reporting (re-
porting bias)
Unclear risk Comment: no published protocol available. Insufficient detail in methods to
judge adequacy of reporting. Some outcome measures reported narrative-
ly (e.g. symptom scores), with no data to support the description. No online




Methods Double-blind, parallel-group, 2-arm RCT with 16 weeks duration of treatment and 4 weeks follow-up
Participants Setting: 2 centres in European hospitals (Belgium)
Sample size: 24
• Number randomised: 24
• Number completed: 23 (15 in intervention group, 8 in comparator)
Participant (baseline) characteristics:
• Age, median (IQR): 50 (44 to 56) omalizumab group; 45 (42 to 54) placebo group
• Gender, men/women (n): 12/3 omalizumab group; 4/4 placebo group
• Main diagnosis: chronic rhinosinusitis with nasal polyps
• Polyps status (total nasal endoscopic polyp score) median (IQR): 6 (4 to 6) omalizumab group; 6 (6 to
8) placebo group
• Previous sinus surgery status; n (%) with previous surgery: 13 (87) omalizumab group; 6 (75) placebo
group
• Previous courses of steroids: not reported
• Aspirin hypersensitivity: 12/24 patients
• Asthma: all participants had asthma
• Need for surgery: no information provided regarding whether participants were deemed to require
surgery at baseline (no surgical outcomes reported)
Inclusion criteria:
• Chronic rhinosinusitis (according to the European Position Paper on Rhinosinusitis and Nasal Polyps
guidelines) and comorbid asthma (based on Global Initiative for Asthma guidelines and diagnosed by
a respiratory physician) for more than 2 years
• Total serum IgE levels between 30 and 700 kU/mL
Exclusion criteria:
• None stated and none available in online repository
Interventions Intervention (n = 15):
• Subcutaneous treatment with anti-IgE (omalizumab). The dose and dosing frequency (every 2
weeks/8 injections in total or every month/4 injections in total) of omalizumab were based on total
serum IgE levels and body weight, with a maximum dose of 375 mg. After screening, 10 visits were
scheduled every 2 weeks over 20 weeks.
Control (n = 8):
• Placebo injection, schedule as above
Use of additional medication (common to both groups): maintenance treatment for asthma was stan-
dardised and controlled by a respiratory physician. During the study, participants were not permit-
ted to use systemic corticosteroids, an inhaled corticosteroid (doses of greater than 1000 μg/day be-
clomethasone dipropionate or equivalent), antibiotic treatment, leukotriene receptor antagonists or
nasal decongestants.
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Outcomes Primary outcomes (relevant to this review):
• Disease-specific health-related quality of life (RSOM-31, AQLQ) (at 16 weeks)
• Disease severity symptom score, nasal and asthma symptoms (patient-reported, daily "absent, mild,
moderate or severe" (scores 0, 1, 2, 3) (at 16 weeks)
• Significant adverse effects (unclear time frame, presumed to be at 20 weeks)
Secondary outcomes (relevant to this review):
All reported at 16 weeks
• Health-related quality of life, generic (SF-36)
• Endoscopy (polyps size or overall score) (total nasal endoscopic polyp score (primary outcome) at 16
weeks)
• CT scan (change in Lund Mackay CT scores)
Other outcomes reported by the study:
All reported at 16 weeks
• FEV1 and PEFV (percentage of predicted)
• Peripheral blood eosinophil counts, serum total IgE levels and measurement of cytokines and medi-
ators in sera and nasal secretions
Funding sources This study received an unrestricted grant from Novartis, and Novartis provided the study medication
 
Research grants from Ghent University and the Flemish Scientific Research Board; the Interuniversi-
ty Attraction Poles program (IUAP)–Belgian state–Belgian Science Policy P6/35, and the Global Allergy
and Asthma European Network
Declarations of interest Gevaert, Calus, Van Zele, Blomme, De Ruyck and Bachert were provided with medication by Novartis.
The rest of the authors declare that they have no relevant conflicts of interest.
Notes Trial registration number: NCT01393340
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer-generated randomization list "
Allocation concealment
(selection bias)
Unclear risk Quote: "computer-generated randomization list"
Comment: states "list" with no further information. No details on separation of





Unclear risk Quote: "Both the investigator and the subject were blind to study treatment."
Comment: low risk if the investigator is also the care provider, but this is not
clear from the publication.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Polyps were evaluated on each side by means of nasal endoscopy at
each visit and graded based on polyp size."
Comment: unclear whether assessors were blinded to treatment group. Not
stated whether investigator (blinded) was also responsible for outcome mea-
surement. Blinding of assessor is clearly stated for other outcomes (CT scan),
but not mentioned for this, the primary outcome for the study.
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Low risk Quote "All patients completed all study visits."
Comment: 1 dropout prior to medication being given (omalizumab group). All
other participants completed follow-up (although some discontinued medica-
tion – ITT analysis).
Selective reporting (re-
porting bias)
High risk Comment: trial registration NCT01393340 had week 20 as the endpoint but




Methods Double-blind, parallel-group RCT with 24 weeks of treatment and 24 weeks of follow-up
Participants Setting: multicentre study based in 67 hospitals or clinical centres in 13 countries (Bulgaria, Czechia,
France, Germany, Hungary, Italy, the Netherlands, Poland, Romania, Ukraine, Russia, the UK and the
USA)
Sample size: 276
• Number randomised: 276
• Number completed: 262 (138 in intervention group, 124 in comparator)
Participant (baseline) characteristics:
• Age: mean 52 years dupilumab group; mean 50 years placebo group
• Gender: 62% male dupilumab group, 63% male placebo group
• Main diagnosis: bilateral nasal polyps and symptoms of chronic rhinosinusitis despite intranasal cor-
ticosteroid therapy before randomisation
• Polyps status: 100 % with polyps. Bilateral endoscopic polyp score 5.64 for dupilumab group, 5.86 for
placebo group (scale 0 to 8, higher = worse)
• Previous sinus surgery status: 69% of dupilumab group had previous sinus surgery, 74% of placebo
group had previous sinus surgery. Time since most recent surgery, mean 5.93 years for dupilumab
group, 5.54 years for placebo group.
• Previous courses of steroids: 64% of dupilumab group had a course of systemic corticosteroids in the
preceding 2 years, 65% of the placebo group
• Asthma was diagnosed in 57% of dupilumab group, 59% of placebo group
• NSAID-exacerbated respiratory disease was diagnosed in 32% of dupilumab group, 29% of placebo
group
• Other type 2 medical history (non-asthma/NSAID-exacerbated disease) was reported in 57% of
dupilumab group and 56% of placebo group
• Need for surgery: no information provided regarding whether participants were deemed to require
surgery at baseline
Inclusion criteria:
• ≥ 18 years of age
• Chronic rhinosinusitis with bilateral nasal polyps
• Prior treatment with systemic glucocorticoids within the last 2 years (or a medical contraindication or
intolerance to systemic glucocorticoids), prior surgery for nasal polyps, or both
• Endoscopic bilateral nasal polyp score of at least 5 (out of 8), with a minimum score of 2 in each nasal
cavity
• Ongoing symptoms for at least 8 weeks prior to study entry, including:
* nasal congestion, blockage or obstruction with moderate or severe symptom severity (score 2 or
3) and a weekly average severity score of at least 1 (range 0 to 3) at randomisation; and
* at least one other symptom, such as partial loss of smell (hyposmia), total loss of smell (anosmia),
or anterior or posterior rhinorrhoea
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• Patients with concomitant asthma had to be stable in the previous 6 weeks using their regular asthma
treatment
Exclusion criteria:
• Previous participation in a dupilumab study
• Received biologic therapy/systemic immunosuppressant to treat inflammatory or autoimmune dis-
ease within 2 months of study entry or 5 half-lives, whichever is longer
• Received experimental monoclonal antibody treatment within 5 half-lives or 6 months of study entry
• Received anti-IgE therapy within 130 days prior to study entry
• Received leukotriene antagonist/modifier treatment unless continuous treatment was received ≥ 30
days prior to study entry
• Any sinus intranasal surgery (including nasal polypectomy) within 6 months before visit 1
• Patients with a forced expiratory volume in 1 second (FEV1) ≤ 50% of predicted normal (for comorbid
asthma patients)
• Presence of antrochoanal nasal polyps; acute rhinosinusitis; upper respiratory infection; allergic gran-
ulomatous angiitis/eosinophilic granulomatosis with polyangiitis; granulomatosis with polyangiitis;
cystic fibrosis; fungal rhinosinusitis; Young syndrome; Kartagener syndrome; or dyskinetic cilia syn-
drome
Interventions Intervention (n = 143):
• 300 mg subcutaneous dupilumab every 2 weeks for 24 weeks
Control (n = 133):
• Placebo given subcutaneously every 2 weeks for 24 weeks
Use of additional medication (common to both groups): 100 µg mometasone furoate nasal spray in
each nostril twice daily given during the 4-week run-in period and throughout the trial. Saline nasal
lavage, systemic antibiotics, short-course systemic corticosteroids or sinonasal surgery were permitted
as needed during the treatment and follow-up periods.
Outcomes Primary outcomes (relevant to this review):
All reported at 24 weeks
• Disease-specific health-related quality of life (SNOT-22 score)
• Disease severity symptom score (VAS for rhinosinusitis, scored 0 to 10 cm for the questions "how trou-
blesome are your symptoms of rhinosinusitis?"; patient-reported total symptoms score (composite
severity score including symptoms of nasal congestion, loss of smell and anterior/posterior rhinor-
rhoea, each scored 0 to 30) with range 0 to 9, higher = worse)
• Serious adverse events
Secondary outcomes (relevant to this review):
All reported at 24 weeks
• Number of participants requiring surgery
• Endoscopic nasal polyp score (range 0 to 8, higher = worse)
• CT scan score (change from baseline in sinus opacification, assessed by Lund Mackay CT score, range
0 to 24, higher = worse)
• Generic health-related quality of life (EQ-5D score, range 0 to 100, higher = better)
• Nasopharyngitis
Other outcomes reported by the study:
All reported at 24 weeks
• Rescue treatment use of corticosteroids (participants with ≥ 1 event by week 24)
• Change from baseline in nasal peak inspiratory flow
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• FEV1 and Asthma Control Questionnaire-6 for patients with asthma
• UPSIT score
Funding sources Sanofi and Regeneron Pharmaceuticals
Declarations of interest Trial authors employed/received funding from Sanofi and Regeneron Pharmaceuticals
Notes Trial registration number: NCT02912468
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomly assigned centrally with a permuted block
randomisation schedule by Interactive Voice Response System or Interactive
Web Response System. Randomisations and allocations were done with use of
ClinPhone from Parexel (Waltham, MA, USA), which generated the patient ran-
domisation list and treatment assignment."
Comment: central randomisation using computer software.
Allocation concealment
(selection bias)
Low risk Quote: "Randomisations and allocations were done with use of ClinPhone
from Parexel (Waltham, MA, USA), which generated the patient randomisation
list and treatment assignment. […]The sponsor provided the randomisation
scheme to the centralised treatment allocation system and treatments were
allocated to the patients accordingly."





Low risk Quote: "both patients and investigators were masked to the assigned drug,
with active drug or matching placebo used in identical prefilled syringes la-
belled with a treatment kit number."
Comment: double-blind
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Treatment group information was masked in data transfers from
Parexel to the sponsor until database lock. […] Once all data were clean and
approved by the site, the database was extracted and locked, and data were
transferred to the SAS environment for statistical analysis."





Unclear risk Quote: "We did efficacy analyses in the intention-to-treat population, defined
as all patients who were randomly assigned; data were analysed according to
assigned intervention, whether received or not.[…] 12 (4%) of 276 patients dis-
continued treatment before week 24, and 13 (5%) patients discontinued from
the study; one patient was randomly assigned, but not treated, and the prima-
ry reason for discontinuation was occurrence of adverse events."
Comment: reasons for dropouts are explicit; < 10% loss, balanced across
groups. Trialists used WOCF and multiple imputation methods to include in
the analysis participants who discontinued. Although similar numbers of par-
ticipants discontinued due to adverse effects before week 24, 25/133 (18.8%)
placebo group had systemic corticosteroid or surgery before week 24, com-
pared with 10/143 (7%) dupilumab group, resulting in imbalance between the
groups in follow-up data.
Selective reporting (re-
porting bias)
Unclear risk Comment: majority of outcomes are reported in full. Some outcome data are
missing from the publication, including the specific number of participants
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who required surgery (only reported as pooled data with another trial). Some
reported outcomes do not appear to have been pre-specified in the original tri-




Methods Double-blind, 3-arm parallel-group RCT with 52 weeks of treatment and follow-up
Participants Setting: 117 hospitals or clinical centres in 14 countries (Argentina, Australia, Belgium, Canada, Chile,
Israel, Mexico, Portugal, Russia, Spain, Sweden, Turkey, Japan and the USA)
Sample size: 448
• Number randomised: 448
• Number completed: 428 (142 in intervention arm A, 146 in intervention arm B, 140 in comparator)
Participant (baseline) characteristics:
• Age: mean 53 years dupilumab (2-weekly, decreasing to 4-weekly group); mean 51 years dupilumab
(2-weekly group); mean 53 years placebo group
• Gender: 60% male dupilumab (2-weekly, decreasing to 4-weekly group); 65% male dupilumab (2-
weekly group); 62% male placebo group
• Main diagnosis: bilateral nasal polyps and symptoms of chronic rhinosinusitis despite intranasal cor-
ticosteroid therapy before randomisation
• Polyps status: 100% with polyps. Mean bilateral endoscopic polyp score 6.29 for dupilumab (2-weekly,
decreasing to 4-weekly group), 6.07 for dupilumab (2-weekly group), 5.96 for placebo group (scale 0
to 8).
• Previous sinus surgery status: 59% of dupilumab (2-weekly, decreasing to 4-weekly group) had pre-
vious sinus surgery, 59% of dupilumab (2-weekly group) had previous sinus surgery, 58% of placebo
group had previous sinus surgery. Time since most recent surgery, mean 8.41 years for dupilumab
(2-weekly, decreasing to 4-weekly group); 7.54 years for dupilumab (2-weekly group); 8.77 years for
placebo group
• Previous courses of steroids: 80% of dupilumab (2-weekly, decreasing to 4-weekly) group had a course
of systemic corticosteroids in the preceding 2 years; 81% of dupilumab (2-weekly) group; 80% of the
placebo group
• Asthma: diagnosed in 63% of dupilumab (2-weekly, decreasing to 4-weekly group); 57% of dupilumab
(2-weekly) group; 59% of placebo group
• NSAID-exacerbated respiratory disease: diagnosed in 28% of dupilumab (2-weekly, decreasing to 4-
weekly) group; 23% of dupilumab (2-weekly) group and 29% of placebo group.
• Other type 2 medical history: (non-asthma/NSAID-exacerbated disease) was reported in 68% of
dupilumab (2-weekly, decreasing to 4-weekly) group, 64% of dupilumab (2-weekly) group and 64%
of placebo group
• Need for surgery: no information provided regarding whether participants were deemed to require
surgery at baseline
Inclusion criteria:
• ≥ 18 years of age
• Chronic rhinosinusitis with bilateral nasal polyps
• Prior treatment with systemic glucocorticoids within the last 2 years (or a medical contraindication or
intolerance to systemic glucocorticoids), prior surgery for nasal polyps, or both
• Endoscopic bilateral nasal polyp score of at least 5 (out of 8), with a minimum score of 2 in each nasal
cavity
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• Ongoing symptoms for at least 8 weeks prior to study entry, including:
* Nasal congestion, blockage or obstruction with moderate or severe symptom severity (score 2 or
3) and a weekly average severity score of at least 1 (range 0 to 3) at randomisation; and
* At least one other symptom, such as partial loss of smell (hyposmia), total loss of smell (anosmia),
or anterior or posterior rhinorrhoea
• Patients with concomitant asthma had to be stable in the previous 6 weeks using their regular asthma
treatment
Exclusion criteria:
• Previous participation in a dupilumab study
• Received biologic therapy/systemic immunosuppressant to treat inflammatory or autoimmune dis-
ease within 2 months of study entry or 5 half-lives, whichever is longer
• Received experimental monoclonal antibody treatment within 5 half-lives or 6 months of study entry
• Received anti-IgE therapy within 130 days prior to study entry
• Received leukotriene antagonist/modifier treatment unless continuous treatment was received ≥ 30
days prior to study entry
• Any sinus intranasal surgery (including nasal polypectomy) within 6 months before visit 1
• Patients with a forced expiratory volume in 1 second (FEV1) ≤ 50% of predicted normal (in comorbid
asthma patients)
• Presence of antrochoanal nasal polyps; acute rhinosinusitis; upper respiratory infection; allergic gran-
ulomatous angiitis/eosinophilic granulomatosis with polyangiitis; granulomatosis with polyangiitis;
cystic fibrosis; fungal rhinosinusitis; Young syndrome; Kartagener syndrome; or dyskinetic cilia syn-
drome
Interventions Intervention (n = 295)
• Arm A: 300 mg subcutaneous dupilumab every 2 weeks for 24 weeks, followed by every 4 weeks until
a total of 52 weeks (n = 145); or
• Arm B: 300 mg subcutaneous dupilumab every 2 weeks for 52 weeks (n = 150)
Control (n = 153)
• Placebo given subcutaneously every 2 weeks for 52 weeks
Use of additional medication (common to both groups): 100 µg mometasone furoate nasal spray in
each nostril twice daily given during the 4-week run-in period and throughout the trial. Saline nasal
lavage, systemic antibiotics, short-course systemic corticosteroids or sinonasal surgery were permitted
as needed during the treatment and follow-up periods.
Outcomes Primary outcomes (relevant to this review):
• Disease-specific health-related quality of life (SNOT-22 score) (reported at 24 and 52 weeks)
• Disease symptom severity score (VAS scored 0 to 10 cm, for the question "how troublesome are your
symptoms of rhinosinusitis?"; patient-reported total symptoms score (including nasal congestion,
loss of smell and anterior/posterior rhinorrhoea, each scored as 0 to 3), range 0 to 9, higher = worse)
(reported at 24 weeks)
• Serious adverse events (reported at 52 weeks)
Secondary outcomes (relevant to this review):
• Number of participants requiring surgery (reported at 24 weeks)
• Endoscopic nasal polyp score (range 0 to 8, higher = worse) (reported at 24 weeks)
• CT scan score (change from baseline in sinus opacification, assessed by Lund Mackay CT score, range
0 to 24, higher = worse) (reported at 24 weeks)
• Nasopharyngitis, including sore throat (reported at 52 weeks)
Funding sources Sanofi and Regeneron Pharmaceuticals
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomly assigned centrally with a permuted block
randomisation schedule by Interactive Voice Response System or Interactive
Web Response System. Randomisations and allocations were done with use of
ClinPhone from Parexel (Waltham, MA, USA), which generated the patient ran-
domisation list and treatment assignment."
Comment: central randomisation using computer software.
Allocation concealment
(selection bias)
Low risk Quote: "Randomisations and allocations were done with use of ClinPhone
from Parexel (Waltham, MA, USA), which generated the patient randomisation
list and treatment assignment.[…] The sponsor provided the randomisation
scheme to the centralised treatment allocation system and treatments were
allocated to the patients accordingly."





Low risk Quote: "both patients and investigators were masked to the assigned drug,
with active drug or matching placebo used in identical prefilled syringes la-
belled with a treatment kit number."
For intervention group which switched to four weekly injections: "After Week
24, dupilumab administration was alternated with matched placebo injection
every other week up to Week 50."
Comment: study stated as double-blind
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Treatment group information was masked in data transfers from
Parexel to the sponsor until database lock. […] Once all data were clean and
approved by the site, the database was extracted and locked, and data were
transferred to the SAS environment for statistical analysis."





High risk Quote: "We did efficacy analyses in the intention-to-treat population, defined
as all patients who were randomly assigned; data were analysed according to
assigned intervention, whether received or not.[…] 29 (6%) of 448 patients dis-
continued treatment before week 24, and 49 (11%) patients discontinued from
the study; one patient was randomly assigned, but not treated"
Comment: there were disproportionately more discontinuations in the place-
bo arm (19/148 (13%) versus 3/145 (2%) and 7/150 (5.6%) for placebo versus
dupilumab groups) at week 24. 44/153 (28.8%) of the placebo group had sys-
temic corticosteroids or surgery before week 24, compared with 10/145 (6.9%)
and 16/150 (10.6%) for dupilumab groups. 20% dropouts in placebo arm (dis-
continued treatment before week 52), as compared to 3% and 9% in interven-
tion arms. Trialists used WOCF and multiple imputation methods to include in
the analysis participants who discontinued.
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Selective reporting (re-
porting bias)
Unclear risk Comment: no outcomes reported for 24- to 52-week follow-up for partici-
pants who decreased dupilumab dose to 4-weekly. Some data only report-





Methods Triple-blind, parallel-group, 2-arm RCT with 5-month (approximately 22 weeks) duration of treat-
ment/follow-up
Participants Setting: single-centre study in the USA
Sample size: 27
• Number randomised: 27
• Number completed: 24 (12 in intervention group, 12 in comparator)
Participant (baseline) characteristics:
• Age: range 18 to 65
• Gender: 7/24 (29%) female, 17/24 (71%) male
• Main diagnosis: chronic rhinosinusitis with nasal polyps
• Polyps status: no information
• Previous sinus surgery status: no information
• Previous courses of steroids: no information
• Other important effect modifiers, if applicable (e.g. aspirin sensitivity, comorbidities of asthma): no
information
• Need for surgery: no information provided regarding whether participants were deemed to require
surgery at baseline (no surgical outcomes reported)
Inclusion criteria:
• Age ≥ 18 years
• Criteria for chronic rhinosinusitis: participants must have (1) at least 2 major criteria (facial pain/pres-
sure or headache, nasal congestion, anterior or posterior nasal drainage, hyposmia/anosmia) for at
least 3 consecutive months; (2) an abnormal sinus CT scan in at least 2 sinus areas documented within
3 months of entry or endoscopic evidence of disease
• Participants must have bilateral polypoid disease demonstrated either by CT or endoscopy with evi-
dence of nasal polyps or polypoid mucosa on examination in at least 2 of the following areas: right
maxillary sinus, leO maxillary sinus, right anterior ethmoid sinus, leO anterior ethmoid sinus plus a
minimal polyp/polypoid score of 4 on the baseline rhinoscopic examination. (Nasal polyps are defined
as discreet polyps visible in the middle meatus area.)
• Positive skin test or in vitro reactivity to a perennial aeroallergen
• Meeting study drug-dosing table eligibility criteria (serum IgE level ≥ 30 to ≤ 1500 IU/mL and body
weight ≥ 30 to ≤ 150 kg)
• Minimum total symptom score of 5 (range of scores 0 to 15) at baseline
Exclusion criteria:
• Women who are pregnant/nursing/not using approved contraception
• Not meeting clinical criteria for omalizumab
• Taking a beta blocker
• Known sensitivity to Xolair (omalizumab)
• Evidence of acute bacterial exacerbation of rhinosinusitis requiring antibiotics
• Having received antibiotics within 3 weeks of the screening visit
NCT01066104 
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• Uncontrolled moderate to severe asthma with a recent exacerbation requiring use of systemic
steroids burst within 6 weeks of study enrolment (participants receiving a maintenance dose of pred-
nisone of 5 mg/day or less will be allowed provided the dose of prednisone is not changed during the
study)
• Uncontrolled recurrent epistaxis within the past 6 weeks
• History of hypogammaglobulinaemia, cystic fibrosis, bronchiectasis, immotile cilia syndrome, sys-
temic granulomatous disease, malignancy (or strong family history of malignancy)
• History of recent cocaine use; cigarette smoking in the past 3 years
• Other serious medical problems or major surgery within 3 months of the screening visit
• Any significant history of non-compliance
• Alcohol or drug abuse/dependence within the past 3 months
• Persistent abnormalities of hepatic, renal or haematologic function, defined as: total bilirubin, SGOT
and SGPT > 1.5 x upper limit of normal, creatinine > 2.0 x upper limit of normal, absolute neutrophil
count < 1.5 x 109/L, platelets < 100 x 109/L
• Using oral or systemic steroid burst within 6 weeks of study enrolment, or any other investigational
agent in the 30 days prior to enrolment
Interventions Intervention (n = 13)
• Xolair (omalizumab), administered subcutaneously, every 2 to 4 weeks depending on the patient's
baseline serum total IgE level (IU/mL) and body weight (kg). Doses > 150 mg are divided among more
than one injection site to limit injections to not more than 150 mg per site. Treatment is for 5 months.
Control (n = 14)
• Xolair placebo 150 mg to 375 mg, administered as above
Use of additional medication (common to both groups): no information provided
Outcomes Primary outcomes (relevant to this review):
Reported at 18 weeks (4 months)
• Serious adverse events
Secondary outcomes (relevant to this review):
Reported at 18 weeks (4 months)
• CT scan (scored using the Zinreich modification of the Lund Mackay scoring system)
• Nasal polyp score
Other outcomes reported by the study:
• None reported
Funding sources Massachusetts General Hospital (study sponsor)
Genentech, Inc. (collaborator)
Declarations of interest Quote: "Principal Investigators are NOT employed by the organization sponsoring the study. There IS
an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's
rights to discuss or publish trial results after the trial is completed"
Notes Trial registration number: NCT01066104
Risk of bias
Bias Authors' judgement Support for judgement
NCT01066104  (Continued)
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Random sequence genera-
tion (selection bias)









Low risk Quote: "Placebo of similar volume and frequency, administered by subcuta-
neous injection."
Comment: triple masking included participants and care providers; placebo
was matching injection
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment: triple masking (participant, care provider, investigator); not clear if
"investigator" included outcome assessors, but matching placebo used so un-




Low risk Comment: low attrition, similar between groups: 1/13 in omalizumab group
and 1/14 in placebo group withdrew due to adverse effects, and one person in
placebo group withdrew due to a protocol violation
Selective reporting (re-
porting bias)
High risk Quote: "Total symptom score (TSS) recorded daily. CRS Facial Pain/Headache
questionnaire at each visit."
Comment: methods section states that these outcomes will be collected, but





Methods Double-blind, parallel-group RCT with 26 weeks treatment/follow-up
Participants Setting: single-centre study in the USA
Sample size: 14
• Number randomised: 14
• Number completed: 14 (7 in intervention group, 7 in comparator)
Participant (baseline) characteristics:
• Age (mean ± SD): omalizumab 43.1 ± 9.8; placebo 48.6 ± 9.1
• Gender (% male (n/N)): omalizumab 43% (3/7) 100% (7/7); placebo 100% (7/7)
• Main diagnosis: chronic rhinosinusitis
• Polyps status: 7/7 in omalizumab and 5/7 in placebo had nasal polyposis
• Previous sinus surgery status: 100% had undergone endoscopic sinus surgery
• Previous courses of steroids:
• Intranasal steroids: omalizumab group: 71% (4/7); placebo group 71% (5/7)
• Systemic steroids omalizumab group: 43% (3/7); placebo group 0% (0/7)
• Inhaled asthma therapy taken by 72% (5/7) in omalizumab group and 43% (3/7) in placebo group
• Need for surgery: all participants had undergone endoscopic sinus surgery (no surgical outcomes re-
ported)
Inclusion criteria:
• Chronic rhinosinusitis was defined by symptoms (nasal obstruction, nasal discharge, facial pain, hy-
posmia) for greater than 12 weeks, confirmatory findings on nasal endoscopy, and evidence of inflam-
mation on sinus CT scan
Pinto 2010 
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• Age 18 to 75 years
• Chronic sinusitis, as defined by symptoms for greater than 12 weeks, despite treatment
• Paranasal sinus CT scan showing evidence of chronic sinusitis
• Positive skin or RAST test to an inhalant allergen
• Serum total IgE between 30 and 700 IU/mL
• Body weight less than 150 kg
• Impaired quality of life, as measured by the Rhinosinusitis Disability Index (RSDI)
Exclusion criteria:
• Women who are breastfeeding or of childbearing potential not using a contraception method
• Known sensitivity to Xolair
• Patients with severe medical condition(s)
• Use of any other investigational agent in the last 30 days
• No measurable disability on the RSDI
• Immunocompromised patients or patients with ciliary disorders
Interventions Intervention (n = 7):
• Omalizumab administered subcutaneously, once or twice monthly (dose dependent on participant
weight and serum IgE level), for 6 months
Control (n = 7):
• Placebo subcutaneous injection, dosing as for omalizumab
Use of additional medication (common to both groups): rescue medications permitted (trial reported
use of courses of systemic steroids, antibiotics and added adjunctive medications (anti-leukotrienes,
antihistamines or intranasal steroids)
Outcomes Primary outcomes (relevant to this review):
All reported at 26 weeks
• Health-related quality of life, disease specific: SNOT-20, recorded monthly for 6 months; Rhinosinusitis
Disability Index (RSDI) recorded monthly for 6 months
• Disease severity symptom score: participants recorded symptoms daily (nasal obstruction, nasal dis-
charge, facial pain and hyposmia) each recorded on a 4-point scale (0 = none, 1 = mild, 2 = moderate,
3 = severe); total scores were summed for a TNSS)
Secondary outcomes (relevant to this review):
All reported at 26 weeks
• Health-related quality of life, generic: SF-36 at 6 months
• Endoscopy (polyps size or overall score): nasal endoscopy score at 6 months
• CT scan – mucosal thickness on CT scan at 6 months (primary outcome)
• Adverse events
Other outcomes reported by the study:
• Number of sinusitis exacerbations requiring additional treatment at 6 months
• Nasal peak inspiratory flow at 6 months
• Nasal lavage eosinophils at 6 months
• University of Pennsylvania Smell Identification Test (UPSIT) at 6 months
Funding sources Quote: "Supported in part by a grant from Genentech and the McHugh Otolaryngology Research Fund.
JMP was supported by a Dennis W. Jahnigen Career Development Award from the American Geriatrics
Society."
Pinto 2010  (Continued)
Biologics for chronic rhinosinusitis (Review)









Cochrane Database of Systematic Reviews
NCT record also lists Novartis Pharmaceuticals as a collaborator.
Declarations of interest Quote: "The investigators had full access to all the data in the study and JMP takes responsibility for
the integrity of the data and the accuracy of the data analysis."
Notes Study terminated early. "Patients were monitored after each injection based on prevailing guidelines.
These changed during the study to the current recommendation which is 2 hours of observation follow-
ing the first 3 injections due to new FDA warnings regarding the possible risk of anaphylaxis … This re-
quirement ended recruitment because of the time commitment required for participation in the study
by volunteers."
Comment: early termination resulted in very low number of participants (only 14/50 planned number).
Trial registration number: NCT00117611
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "... randomized to omalizumab or placebo groups"
Comment: no further details given
Allocation concealment
(selection bias)





Low risk Quote: "Subjects were randomized and followed throughout the trial in a
blinded fashion." (main paper); "Masking: Double (Participant, Investiga-
tor)" (NCT record)
Comment: placebo used and trial described as double-blind
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote "All CT scan (sic) were read blinded to treatment category."
Comment: no comment on blinding for nasal endoscopy outcome. Insufficient




Unclear risk Comment: 0 withdrawals, but 1/7 placebo participant's CT scans could not
be analysed for technical reasons. Given the low number of participants, this
could introduce bias for the primary outcome.
Selective reporting (re-
porting bias)
Unclear risk Comment: outcomes mostly match those in NCT trial registration. RSDI (listed
on NCT) does not appear to have been reported. Report states that no side ef-
fects or adverse events occurred, but no information given on how these were
detected.
Pinto 2010  (Continued)
AQLQ: Asthma Quality of Life Questionnaire
AST: aspartate transaminase
ALT: alanine transaminase
BMI: body mass index
CT: computerised tomography







NPIF: nasal peak inspiratory flow
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NSAID: non-steroidal anti-inflammatory drug
OCS: oral corticosteroids
PEFV: partial expiratory flow volume
RAST: radioallergosorbent test
RCT: randomised controlled trial
RSDI: Rhinosinusitis Disability Index
RSOM-31: Rhinosinusitis Outcome Measures-31
SD: standard deviation
SGOT: serum glutamic oxaloacetic transaminase
SGPT: serum glutamic pyruvic transaminase
SNOT-22: Sino-Nasal Outcome Test-22
TNSS: total nasal symptom score
UPSIT: University of Pennsylvania Smell Identification Test
VAS: visual analogue scale
WOCF: worst observation carried forward
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Boguniewicz 2019 STUDY DESIGN: not a RCT
Castro 2011 POPULATION: less than half had chronic rhinosinusitis and not stratified for chronic rhinosi-
nusitis at randomisation
De Schryver 2015 STUDY DESIGN: not a RCT
Gevaert 2006 INTERVENTION: single dose, not a course of treatment
Gevaert 2008 STUDY DESIGN: not a RCT
Gonzalez-Diaz 2014 STUDY DESIGN: not a RCT
Hellings 2017 STUDY DESIGN: not a RCT
Laidlaw 2019 STUDY DESIGN: not a RCT
Liberty Asthma Quest POPULATION: chronic rhinosinusitis diagnosis was self-reported and less than half had it
MUSCA POPULATION: asthma
Naclerio 2017 STUDY DESIGN: not a RCT
NCT00603785 Study withdrawn
NCT01285323 POPULATION: asthma
NCT02170337 POPULATION: safety study in healthy patients
NCT02734849 Study withdrawn
NCT02743871 STUDY DESIGN: not a RCT
Perez De Llano 2018 STUDY DESIGN: not a RCT
Tajiri 2013 STUDY DESIGN: not a RCT
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Study Reason for exclusion
Zangrilli 2019 STUDY DESIGN: not a RCT
RCT: randomised controlled trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A phase 2, double-blind, placebo-controlled study of benralizumab (KHK4563) in patients with
eosinophilic chronic rhinosinusitis
Methods Double-blind, parallel-group, randomised controlled trial
Participants Adults (20 to 75 years) with:
• Eosinophilic chronic rhinosinusitis with a total score of ≥ 11 according to the diagnosis of
eosinophilic chronic rhinosinusitis at enrollment
• A minimum bilateral nasal polyp score of 3 out of the maximum score of 8 (with a score of at least
1 out of the maximum score of 4 for each nostril) at screening and at enrollment
Interventions Benralizumab
Outcomes Primary outcome measures:
1. The change from baseline in nasal polyp score at week 12 (time frame: baseline and 12 weeks
post-dose)
Secondary outcome measures:
1. The change from baseline in nasal polyp score (time frame: pre-dose and 4, 8, 12, 16, 20, 24 weeks
post-dose)
2. The change from baseline in computed tomography (CT) score (time frame: baseline and 12 weeks
post-dose)
3. Number of participants discontinued from the study due to aggravation of eosinophilic chronic
rhinosinusitis (time frame: up to 24 weeks after dosing)
4. Time to discontinuation (days) from the study due to aggravation of eosinophilic chronic rhinos-
inusitis (time frame: up to 24 weeks after dosing)
5. The change from baseline in blood eosinophil count (time frame: pre-dose and 4, 8, 12, 16, 20, 24
weeks post-dose)
6. The change from baseline in nasal airway resistance (time frame: pre-dose and 4, 8, 12, 24 weeks
post-dose). Nasal airway resistance (Pa/cm3/s).
7. The change from baseline in the averaged values of the olfactory thresholds (time frame: pre-
dose and 4, 8, 12, 24 weeks post-dose); olfactory thresholds are assessed by T&T Olfactometer
Test Score (5 kinds of smell with eight (5 to -2) phases)
8. The change from baseline in the improvement of olfactory dysfunction (time frame: pre-dose and
4, 8, 12, 24 weeks post-dose); olfactory dysfunction (1 to 5) is calculated by the olfactory thresholds
9. The change from baseline in Sino-Nasal Outcome Test-2 (SNOT-22) (time frame: pre-dose and 4, 8,
12, 16, 20, 24 weeks post-dose); symptom scores are assessed by VAS (nasal congestion, anterior
and posterior nasal drip, loss of the sense of smell, headache and impairment in activities of daily
living)
10.The change from baseline in symptom score by visual analogue scale (VAS) (time frame: pre-dose
and 4, 8, 12, 16, 20, 24 weeks post-dose); symptom scores are assessed by VAS (nasal congestion,
anterior and posterior nasal drip, loss of the sense of smell, headache and impairment in activities
of daily living)
NCT02772419 
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11.Incidence of treatment-emergent adverse events (TEAEs) or drug-related TEAEs and their nature
(time frame: up to 24 weeks after dosing)
Starting date —
Contact information —
Notes Actual completion date: March 2017
Expected publication date: unknown
Company contacted 6 January 2020. Response: publication planned. Company response: unable to




Trial name or title NCT02799446
Methods Randomised controlled trial
Participants Adults (18 to 75 years) and a diagnosis of chronic rhinosinusitis according to the clinical practice
guideline (update) of the American Academy of Otolaryngology - Head and Neck Surgery
Interventions Reslizumab 3 mg/kg intravenous (IV)
Outcomes Primary outcome measures:
1. Change in computed tomography (CT) score (time frame: 24 weeks)
Secondary outcome measures:
1. Quality of life questionnaire (time frame: 24 weeks)
2. Smell test (time frame: 24 weeks)
3. Endoscopy score (time frame: 24 weeks)
4. Adverse events by body system (time frame: 24 weeks)
Starting date June 2016
Contact information —
Notes Expected study completion date: July 2019
Expected publication: July 2020




Trial name or title NCT03450083
Methods Randomised controlled trial
Participants Adults (18 to 75 years) with:
• Severe bilateral nasal polyps with average endoscopic score of at least 5
NCT03450083 
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• At least 1000 mg prednisone (or equivalent) over the previous 12 months to control symptoms
• At least 1 prior nasal surgical polypectomy
Interventions 30 mg benralizumab will be delivered subcutaneously
Outcomes Primary outcome measures:
1. Nasal polyp size (time frame: 24 weeks); reduction in endoscopic nasal polyp score after 6 months
of treatment
Secondary outcome measures:
1. Nasal polyp size by CT (time frame: 24 weeks). Lund Mackay (LM) CT scan of sinus will be used to
determine nasal polyp size. Each of 4 sinuses are graded 0 to 3 on each side (total range 0 to 24;
0 no abnormality)
a. (partial opacification); or
b. (complete opacification).
2. Clinical survey (time frame: 24 weeks). Sino-nasal Outcome Test (SNOT-22) nasal symptoms score;
22 questions each scored 0 to 5 (no problem - as bad as it can be) for a total range of 0 to 110
3. Smell test (time frame: 24 weeks). UPSIT smell test; 40 questions with 4 choices each - number of
correct answers range 0 to 40
4. Blood test (time frame: 24 weeks). Complete blood count (CBC) to determine absolute eosinophil
count; range 30 to 300/µL
5. Rescue medication use (time frame: up to 24 weeks). Rescue medication score; rescue medica-
tions include triamcinolone twice daily and prednisone 20 mg for 5 days, which will be given only
as needed periodically. Score ranges from 0 to 20 (0 = none, 5 = triamcinolone nasal daily, 10 =
triamcinolone nasal twice daily, 20 = prednisone 20 mg for 5 days)
6. Time to surgery (time frame: 24 weeks). Time to nasal polyp surgery; measured in months starting
after last injection
7. Dropout rate (time frame: up to 24 weeks). Dropout rate; calculated continuously throughout the
study up to 24 weeks
Starting date July 2017
Contact information —
Notes Expected completion date: December 2019
Expected publication date: December 2020




Trial name or title NCT03614923
Methods Randomised controlled trial
Participants Adults (18 to 65 years) with:
• Clinically confirmed diagnosis of chronic rhinosinusitis with nasal polyps
• Nasal polyp score ≥ 5 out of a maximum score for both nostrils (with at least a score of 2 for each
nostril)
• SNOT-22 score > 7
NCT03614923 
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• Presence of at least 2 of the following symptoms prior to screening: nasal blockade/obstruc-
tion/congestion or nasal discharge (anterior/posterior nasal drip); facial pain/pressure; reduction
or loss of smell
Interventions Etokimab
Outcomes Primary outcome measures:
1. Change from baseline in nasal polyp score (NPS) to week 16 (time frame: week 16). Total scoring
0 to 8, scoring of 0 to 4 (0 = no polyps, 4 = large polyps causing complete obstruction) bilateral
2. Change from baseline in Sino-Nasal Outcome Test -22 (SNOT-22). Score from week 16 (time frame:
week 16); total scoring 0 to 110, scoring of 0 to 5 (0 = no problem, 5 = problem as bad as it can
be) (22 items)
Secondary outcome measures;
1. Change from baseline in smell test from week 16 (time frame: week 16)
2. Change from baseline in nasal peak inspiratory flow from week 16 (time frame: week 16)
3. Change in sinus opacification as assessed by CT scan using the Lund Mackay score (time frame:
week 16). Total scoring of 0 to 24, ostiomeatal complex 0 or 2 (obstructed) for each sinus group
(6), bilateral
Starting date December 2018
Contact information —
Notes Expected completion date: December 2019
Expected publication date: December 2020




Trial name or title OSTRO (NCT03401229)
Methods Randomised controlled trial
Participants Adults (18 to 75 years):
1. Patients with bilateral sinonasal polyposis that, despite treatment with a stable dose of intranasal
corticosteroids (INCS) for at least 4 weeks prior to V1, in addition to history of treatment with sys-
temic corticosteroids (SCS - oral, parenteral) or prior surgery for nasal polyposis (NP), have sever-
ity consistent with a need for surgery as described by: a minimum total Nasal Polyp Score (NPS)
of 5 out of a maximum score of 8 (with a unilateral score of at least 2 for each nostril) at V1, and
continuously maintained at V2 to meet the randomisation criterion, as determined by the study
Imaging Core Lab; ongoing symptoms for at least 12 weeks prior to V1; patient-reported moderate
to severe nasal blockage score (NBS) 2 or 3 over the 2 weeks prior to V1 (2-week recall assessment
of symptoms, scores 0 = none to 3 = severe)
2. SNOT-22 total score ≥ 30 at enrolment. Patient must meet the following criteria at the randomi-
sation visit:
• At least 8 days of evaluable daily diary data in the 14-day period prior to randomisation (baseline
bi-weekly mean score collected from study Day -13 to study Day 0)
• At randomisation, a bi-weekly mean NBS ≥ 1.5
• SNOT-22 total score ≥ 30 at randomisation
• At least 70% compliance with INCS during the run-in period based on daily diary
OSTRO 
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Interventions Benralizumab 30 mg subcutaneous
Outcomes Primary outcome measures:
1. Effect of benralizumab on nasal polyp burden (time frame: week 56 (visit 11)). Change from base-
line in endoscopic total nasal polyp score (NPS). NPS (maximum 8) is the sum of the right and leO
nostril scores
2. Effect of benralizumab on patient-reported nasal blockage (NB) (time frame: week 56 (visit 11)).
Change from baseline in mean nasal blockage score (NBS). NBS is assessed in daily diary by asking
patients to rate the severity of their worst nasal blockage over the past 24 hours using the following
response options: 0 = none; 1 = mild; 2 = moderate; 3 = severe
Secondary outcome measures:
1. Effect of benralizumab on disease specific health-related quality of life (HRQL) (time frame: week
56 (visit 11)). Change from baseline in SinoNasal Outcome Test (SNOT-22) score. SNOT-22 cap-
tures patient-reported physical problems, functional limitations and emotional consequences of
sinonasal condition. Its patient-reported symptom severity and symptom impact over the past 2
weeks and are captured via a 6-point scale (0 = no problem to 5 = problem as bad as it can be).
The total score is the sum of item scores and has a range from 0 to 110.
2. Effect of benralizumab on nasal polyp surgery (time frame: by week 56 (visit 11)). Time to first
nasal polyp surgery.
3. Proportion of nasal polyp surgery (time frame: by week 56 (visit 11)). Proportion of patients with
surgery for nasal polyps.
4. Systemic corticosteroids (SCS) use for relief of nasal symptoms (time frame: by week 56 (visit 11)).
Proportion of patients with SCS use for nasal polyps.
5. Systemic corticosteroids (SCS) use for relief of nasal symptoms (time frame: by week 56 (visit 11)).
Time to first SCS course for nasal polyps.
6. Symptoms associated with nasal polyps (time frame: week 56 (visit 11)). Change from baseline in
nasal symptom score(s) as captured in the daily diary. Patients report the severity of symptom
related to nasal polyps at its worst using a 4-point verbal rating scale (0 = none to 3 = severe).
7. Symptoms associated with nasal polyps (time frame: week 56 (visit 11)). Sense of smell captured
as change from baseline in University of Pennsylvania Smell Identification Test (UPSIT) score. It is
a quantitative test of olfactory function which uses microencapsulated odorants that are released
by scratching standardised odour-impregnated test booklets. Four booklets each with 10 odor-
ants each are used for the test. Patients are asked to identify the odour using multiple choice for-
mat which lists different possibilities. Scores are based on number of correctly identified odours
(score range 0 to 40).
8. Sinus opacification by computed tomography (CT) scan (subset of patients) (time frame: week 56
(visit 11)). Change from baseline in Lund Mackay score.
9. Patient-reported general health status (time frame: week 56 (visit 11)). Change from baseline in
Short Form 36-item Health survey, Version 2 (SF-36v2).
10.Systemic corticosteroids (SCS) use for relief of nasal symptoms (time frame: by week 56 (visit 11)).
Total SCS dose used.
11.Systemic corticosteroids (SCS) use for relief of nasal symptoms (time frame: by week 56 (visit 11)).
Number of courses of SCS for nasal polyps.
12.Systemic corticosteroids (SCS) use for relief of nasal symptoms (time frame: by week 56 (visit 11)).
Total duration of SCS use for nasal polyps.
13.Sinus opacification by computed tomography (CT) scan (subset of patients) (time frame: week 56
(visit 11)). Change from baseline in sinus severity score by Quantitative CT analysis.
Starting date January 2018
Contact information —
Notes Expected completion date: August 2020
Expected publication date: August 2021
OSTRO  (Continued)
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Trial name or title POLYP 1 (NCT03280550)
Methods Randomised controlled trial
Participants Adults (18 to 75 years) with:
• Nasal polyp score (NPS) ≥ 5, with a unilateral score of ≥ 2 for each nostril, at screening (Day -35)
and on Day -7
• Sino-Nasal Outcome Test-22 (SNOT-22) score ≥ 20 at screening (Day -35) and at randomisation
(Day 1)
• Treatment with at least nasal mometasone 200 µg per day, or equivalent daily dosing of INCS for
at least 4 weeks before screening (Day -35)
• Treatment with nasal mometasone 200 µg twice a day (or once a day if intolerant to twice daily)
during the run-in period with an adherence rate of at least 70%
• Presence of nasal blockage/congestion with NCS ≥ 2 (1-week recall) at Day -35 and an average
of the daily NCS score over the 7 days prior to randomization of NCS >1 with at least one of the
following symptoms prior to screening: nasal discharge (anterior/posterior nasal drip) and/or re-
duction or loss of smell
Interventions Omalizumab
Outcomes Primary outcome measures:
1. Change from baseline in average daily nasal congestion score (NCS) at week 24 (time frame: base-
line, week 24)
2. Change from baseline in nasal polyp score (NPS) to week 24 (time frame: baseline, week 24)
Secondary outcome measures:
1. Change from baseline in average daily total nasal symptom score (TNSS) at week 24 (time frame:
baseline, week 24)
2. Change from baseline in average daily sense of smell score at week 24 (time frame: baseline, week
24)
3. Change from baseline in average daily posterior rhinorrhoea score at week 24 (time frame: base-
line, week 24)
4. Change from baseline in average daily anterior rhinorrhoea score at week 24 (time frame: baseline,
week 24)
5. Change from baseline in participant reported health-related quality of life (HRQL) as assessed by
the total Sino-Nasal Outcome Test (SNOT)-22 at week 24 (time frame: baseline, week 24)
6. Change from baseline in sense of smell, as assessed by the University of Pennsylvania Smell Iden-
tification Test (UPSIT) at week 24 (time frame: baseline, week 24)
7. Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) of ≥ 0.5 (in participants with
comorbid asthma only) at week 24 (time frame: baseline, week 24)
8. Change from baseline in average daily NCS at week 16 (time frame: baseline, week 16)
9. Change from baseline in NPS at week 16 (time frame: baseline, week 16)
10.Percentage of participants with reduction in the need for surgery by week 24, as defined by a NPS
of ≤ 4 (unilateral score of ≤ 2 on each side) and improvement in SNOT-22 score of ≥ 8.9 (time frame:
up to week 24)
11.Percentage of participants requiring of rescue treatment (systemic corticosteroid for ≥ 3 consec-
utive days) or having had surgery for nasal polyps through week 24 (time frame: up to week 24)
12.Percentage of participants requiring of rescue treatment (systemic corticosteroid for ≥ 3 consec-
utive days) through week 24 (time frame: up to week 24)
POLYP 1 
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13.Percentage of participants having had surgery for nasal polyps through week 24 (time frame: up
to week 24)
14.Percentage of participants with adverse events (time frame: up to week 28)
15.Percentage of participants with serious adverse events (time frame: up to week 28)
16.Percentage of participants with adverse events leading to omalizumab/placebo discontinuation
(time frame: up to week 28)
17.Percentage of participants with clinically significant change in laboratory values (time frame: up
to week 28)
18.Serum concentration of omalizumab at specified time points (time frame: Day 1, Day 112, Day 168,
Day 196)
19.Serum concentration of total and free immunoglobulin E (IgE) at specified time points (time
frame: screening (Day -35), Day 1, Day 112, Day 168, Day 196)
Starting date November 2017
Contact information —
Notes Actual completion date: March 2019
Expected publica ton date: March 2020




Trial name or title POLYP 2 (NCT03280537)
Methods Randomised controlled trial
Participants Adults (18 to 75 years)
Interventions Omalizumab
Outcomes Primary outcome measures:
1. Change from baseline in average daily nasal congestion score (NCS) at week 24 (time frame: base-
line, week 24)
2. Change from baseline in nasal polyp score (NPS) to week 24 (time frame: baseline, week 24)
Secondary outcome measures:
1. Change from baseline in average daily total nasal symptom score (TNSS) at week 24 (time frame:
baseline, week 24)
2. Change from baseline in average daily sense of smell score at week 24 (time frame: baseline, week
24)
3. Change from baseline in average daily posterior rhinorrhoea score at week 24 (time frame: base-
line, week 24)
4. Change from baseline in average daily anterior rhinorrhoea score at week 24 (time frame: baseline,
week 24)
5. Change from baseline in participant-reported health-related quality of life (HRQL) as assessed by
the total Sino-Nasal Outcome Test (SNOT)-22 at week 24 (time frame: baseline, week 24)
6. Change from baseline in sense of smell, as assessed by the University of Pennsylvania Smell Iden-
tification Test (UPSIT) at week 24 (time frame: baseline, week 24)
7. Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) of ≥ 0.5 (in participants with
comorbid asthma only) at week 24 (time frame: baseline, week 24)
8. Change from baseline in average daily NCS at week 16 (time frame: baseline, week 16)
POLYP 2 
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9. Change from baseline in NPS at week 16 (time frame: baseline, week 16)
10.Percentage of participants with reduction in the need for surgery by week 24, as defined by a NPS
of ≤ 4 (unilateral score of ≤ 2 on each Side) and improvement in SNOT-22 score of ≥ 8.9 (time frame:
up to week 24)
11.Percentage of participants requiring of rescue treatment (systemic corticosteroid for ≥ 3 consec-
utive days) or having had surgery for nasal polyps through week 24 (time frame: up to week 24)
12.Percentage of participants requiring of rescue treatment (systemic corticosteroid for ≥ 3 consec-
utive days) through week 24 (time frame: up to week 24)
13.Percentage of participants having had surgery for nasal polyps through week 24 (time frame: up
to week 24)
14.Percentage of participants with adverse events (time frame: up to week 28)
15.Percentage of participants with serious adverse events (time frame: up to week 28)
16.Percentage of participants with adverse events leading to omalizumab/placebo discontinuation
(time frame: up to week 28)
17.Percentage of participants with clinically significant change in laboratory values (time frame: up
to week 28)
18.Serum concentration of omalizumab at specified time points (time frame: Day 1, Day 112, Day 168,
Day 196)
19.Serum concentration of total and free immunoglobulin E (IgE) at specified time points (time
frame: screening (Day -35), Day 1, Day 112, Day 168, Day 196)
Starting date November 2019
Contact information —
Notes Actual completion date: March 2019
Expected publication date: March 2020




Trial name or title SYNAPSE (NCT03085797)
Methods Randomised controlled trial
Participants Adults (over 18 years) with:
• Participants who have had at least one previous surgery in the previous 10 years for the removal of
nasal polyps. Nasal polyp surgery is defined as any procedure involving instruments with resulting
incision (cutting open) and removal of polyp tissue from the nasal cavity (polypectomy). For the
purpose of inclusion into this study, any procedure involving instrumentation in the nasal cavity
resulting in dilatation of the nasal passage such as balloon sinuplasty, insertion of coated stents
or direct injection of steroids or other medication without any removal of nasal polyp tissue is not
accepted.
• Bilateral nasal polyps as diagnosed by endoscopy or computed tomography (CT) scan. The pres-
ence of at least 2 of the following symptoms one of which should be either nasal blockage/ob-
struction/congestion or nasal discharge (anterior/posterior nasal drip) and either nasal discharge
(anterior/posterior nasal drip); facial pain/pressure; reduction or loss of smell for at least 12 weeks
prior to screening
• Presence of at least 2 of the following symptoms one of which should be either nasal blockage/ob-
struction/congestion or nasal discharge (anterior/posterior nasal drip) and either nasal discharge
(anterior/posterior nasal drip); facial pain/pressure; reduction or loss of smell for at least 12 weeks
prior to screening.
• Severe nasal polyp symptoms defined as an obstruction VAS symptom score of > 5.
SYNAPSE 
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• Severity consistent with a need for surgery as described by: participants with an overall VAS symp-
tom score > 7, participants with an endoscopic bilateral nasal polyp score of at least 5 out of a
maximum score of 8 (with a minimum score of 2 in each nasal cavity).
Interventions Mepolizumab injection 100 mg/mL
Outcomes Primary outcome measures:
1. Change from baseline in total endoscopic nasal polyp score at week 52 (time frame: baseline and
week 52). Each nostril was assessed for polyps and graded at week 0, 4, 8, 12, 16, 20, 24, 28, 32, 36
and 52. The grading was based on nasal polyp size and recorded as the sum of the right and leO
nostril scores. Total score ranges from 0 to 8; higher scores indicate worse status. Individual score
ranges from 0 (no polyps) to 4 (large polyps causing almost complete congestion/obstruction of
the inferior meatus).
2. Change from baseline in mean nasal obstruction visual analogue scale (VAS) score during the 4
weeks prior to week 52 (time frame: baseline and up to week 52). VAS is an instrument that mea-
sures a characteristic or attitude that is believed to range across a continuum of values and can-
not easily be directly measured. The participant will be asked to indicate on a VAS (0 to 100 units
on an electronic device which corresponds to a 0 to 10 score) the severity of 5 nasal polyposis
symptoms, one VAS for each symptom (1) nasal obstruction; 2) nasal discharge; 3) mucus in the
throat; 4) loss of smell; 5) facial pain) and overall VAS symptoms score. The leO hand side of the
scale (0) represents "None" and the right hand side of the scale (100) represents "As bad as you
can imagine". The VAS score will be collected daily in morning from screening up to week 52.
Secondary outcome measures:
1. Time to first nasal surgery up to week 52 (time frame: up to week 52). Nasal polyp surgery is defined
as any procedure involving instruments resulting in incision and removal of tissue (polypectomy)
or dilatation of the air passages (e.g. balloon sinuplasty) in the nasal cavity. Time to first nasal
surgery up to week 52 will be assessed.
2. Change from baseline in mean overall VAS symptom score during the 4 weeks prior to week 52
(time frame: baseline and up to week 52). The mean VAS score over the last 7 days before Visit 2
(week 0) will be used to determine the baseline value. The participant will be asked to indicate on
a VAS (0 to 100 units on an electronic device which corresponds to 0 to 10 score) the severity of 5
nasal polyposis symptoms, one VAS for each symptom (1) nasal obstruction; 2) nasal discharge;
3) mucus in the throat; 4) loss of smell; 5) facial pain) and overall VAS symptoms score. The leO
hand side of the scale (0) represents "None" and the right hand side of the scale (100) represents
"As bad as you can imagine". The VAS score will be collected daily in morning from screening up
to week 52.
3. Change from baseline in Sino-Nasal Outcome Test (SNOT)-22 total score at week 52 (time frame:
baseline and week 52). The SNOT-22 is a health-related quality of life questionnaire and has been
shown to be a reliable outcome measure for successful septal surgery and in chronic rhinosinusitis
management. It is also a tool to evaluate outcomes in nasal polyposis. Participants will be asked
to rate the severity of their condition on each of the 22 items over the previous 2 weeks using a 6-
point rating scale of 0 to 5 including: 0 = not present/no problem; 1 = very mild problem; 2 = mild
or slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem as "bad as it can be".
The theoretical total score range for the SNOT-22 is 0 to 110, where lower scores imply less severe
symptoms and higher scores represent a worse quality of life. The SNOT-22 questionnaire will be
completed by participants at weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 52.
4. Number of mg per year of prednisolone-equivalent oral corticosteroid dose up to week 52 (time
frame: up to week 52). The number of courses of systemic steroids as well as the dose and dura-
tion of the courses will be recorded. The dose for a course of oral corticosteroids will be accord-
ing to the participants SoC for oral corticosteroid use for its nasal polyps condition. A course of
systemic corticosteroids is considered continuous if treatment is separated by less than 7 days.
Various doses of intravenous and oral steroids will be converted to prednisolone-equivalent oral
corticosteroid.
Starting date May 2017
SYNAPSE  (Continued)
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Contact information —
Notes Expected study completion date: December 2019
Expected publication: December 2020
GSK intend to make IPD available 6 months after publication of the primary endpoints. Publication





NBS: nasal blockage score
NCS: nasal congestion score
NP: nasal polyposis
NPS: nasal polyp score
SCS: systemic corticosteroids
SNOT-22: Sino-Nasal Outcome Test-2
TEAE: treatment-emergent adverse event
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Anti-IL-4Rα mAb (dupilumab) versus placebo (on top of topical steroids)





Statistical method Effect size
1 HRQL - disease-specific  (SNOT-22,
0 to 110, lower = better)
3   Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Up to 24 weeks 3 784 Mean Difference (IV, Random, 95% CI) -19.61 [-22.54, -16.69]
1.2 At 52 weeks 1 303 Mean Difference (IV, Random, 95% CI) -22.38 [-27.10, -17.66]
2 Disease severity - VAS (0 to 10,
lower = better)
3 784 Mean Difference (IV, Random, 95% CI) -3.00 [-3.47, -2.53]
3 Serious adverse events 3 782 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.28, 0.75]
4 Avoidance of surgery - number of
patients who had surgery as rescue
treatment
2 725 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.05, 0.52]
5 Extent of disease - endoscopy
('nasal polyps score', 0 to 8, higher =
worse)
3   Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Up to 24 weeks 3 784 Mean Difference (IV, Random, 95% CI) -1.80 [-2.25, -1.35]
5.2 Up to 52 weeks 1 303 Mean Difference (IV, Random, 95% CI) -2.34 [-2.77, -1.91]
6 Extent of disease - CT scan (Lund
Mackay, 0 to 24, higher = worse)
3 784 Mean Difference (IV, Random, 95% CI) -7.00 [-9.61, -4.39]
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Statistical method Effect size
7 HRQL - generic (EQ-5D VAS, 0 to
100, higher = better)
2 706 Mean Difference (IV, Random, 95% CI) -8.59 [-11.86, -5.31]
8 Adverse events - nasopharyngitis,
including sore throat (longest avail-
able data)
3 783 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.25]
 
 
Analysis 1.1.   Comparison 1 Anti-IL-4Rα mAb (dupilumab) versus placebo (on top of
topical steroids), Outcome 1 HRQL - disease-specific  (SNOT-22, 0 to 110, lower = better).
Study or subgroup Dupilumab Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.1.1 Up to 24 weeks  
Bachert 2016 30 12.8 (11) 30 30.2 (19.6) 13.21% -17.4[-25.44,-9.36]
LIBERTY SINUS 24 143 18.6 (14.9) 133 40.5 (23.1) 40.05% -21.91[-26.53,-17.29]
LIBERTY SINUS 52 295 23.9 (18.8) 153 42.2 (23.4) 46.73% -18.27[-22.55,-13.99]
Subtotal *** 468   316   100% -19.61[-22.54,-16.69]
Heterogeneity: Tau2=0; Chi2=1.62, df=2(P=0.44); I2=0%  
Test for overall effect: Z=13.15(P<0.0001)  
   
1.1.2 At 52 weeks  
LIBERTY SINUS 52 150 21.7 (19.2) 153 44.1 (22.7) 100% -22.38[-27.1,-17.66]
Subtotal *** 150   153   100% -22.38[-27.1,-17.66]
Heterogeneity: Not applicable  
Test for overall effect: Z=9.29(P<0.0001)  
Test for subgroup differences: Chi2=0.95, df=1 (P=0.33), I2=0%  
Favours dupilumab 5025-50 -25 0 Favours placebo
 
 
Analysis 1.2.   Comparison 1 Anti-IL-4Rα mAb (dupilumab) versus placebo (on top
of topical steroids), Outcome 2 Disease severity - VAS (0 to 10, lower = better).
Study or subgroup Dupilumab Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bachert 2016 30 -4.3 (2.9) 30 -2.2 (3.5) 8.34% -2.1[-3.73,-0.47]
LIBERTY SINUS 24 143 -4.5 (2.8) 133 -1.3 (2.8) 52.35% -3.2[-3.85,-2.55]
LIBERTY SINUS 52 295 -4.3 (3.3) 153 -1.4 (4.1) 39.31% -2.93[-3.68,-2.18]
   
Total *** 468   316   100% -3[-3.47,-2.53]
Heterogeneity: Tau2=0; Chi2=1.56, df=2(P=0.46); I2=0%  
Test for overall effect: Z=12.48(P<0.0001)  
Favours dupilumab 105-10 -5 0 Favours placebo
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Analysis 1.3.   Comparison 1 Anti-IL-4Rα mAb (dupilumab) versus
placebo (on top of topical steroids), Outcome 3 Serious adverse events.
Study or subgroup Dupilumab Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Bachert 2016 2/30 4/30 9.15% 0.5[0.1,2.53]
LIBERTY SINUS 24 6/143 19/132 45.22% 0.29[0.12,0.71]
LIBERTY SINUS 52 18/297 15/150 45.62% 0.61[0.31,1.17]
   
Total (95% CI) 470 312 100% 0.45[0.28,0.75]
Total events: 26 (Dupilumab), 38 (Placebo)  
Heterogeneity: Tau2=0; Chi2=1.72, df=2(P=0.42); I2=0%  
Test for overall effect: Z=3.11(P=0)  
Favours dupilumab 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.4.   Comparison 1 Anti-IL-4Rα mAb (dupilumab) versus placebo (on top of topical steroids),
Outcome 4 Avoidance of surgery - number of patients who had surgery as rescue treatment.
Study or subgroup Dupilumab Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
LIBERTY SINUS 24 3/143 10/133 55.66% 0.28[0.08,0.99]
LIBERTY SINUS 52 2/295 12/154 44.34% 0.09[0.02,0.38]
   
Total (95% CI) 438 287 100% 0.17[0.05,0.52]
Total events: 5 (Dupilumab), 22 (Placebo)  
Heterogeneity: Tau2=0.19; Chi2=1.38, df=1(P=0.24); I2=27.37%  
Test for overall effect: Z=3.09(P=0)  
Favours dupilumab 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.5.   Comparison 1 Anti-IL-4Rα mAb (dupilumab) versus placebo (on top of topical
steroids), Outcome 5 Extent of disease - endoscopy ('nasal polyps score', 0 to 8, higher = worse).
Study or subgroup Dupilumab Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.5.1 Up to 24 weeks  
Bachert 2016 30 4 (1.9) 30 5.4 (1.5) 17.93% -1.4[-2.27,-0.53]
LIBERTY SINUS 24 143 3.8 (2) 133 5.9 (1.4) 37.57% -2.19[-2.6,-1.78]
LIBERTY SINUS 52 295 4.5 (1.9) 153 6.1 (1.2) 44.5% -1.63[-1.92,-1.34]
Subtotal *** 468   316   100% -1.8[-2.25,-1.35]
Heterogeneity: Tau2=0.1; Chi2=5.7, df=2(P=0.06); I2=64.89%  
Test for overall effect: Z=7.87(P<0.0001)  
   
1.5.2 Up to 52 weeks  
LIBERTY SINUS 52 150 3.8 (2.2) 153 6.1 (1.5) 100% -2.34[-2.77,-1.91]
Subtotal *** 150   153   100% -2.34[-2.77,-1.91]
Heterogeneity: Not applicable  
Test for overall effect: Z=10.75(P<0.0001)  
Test for subgroup differences: Chi2=2.94, df=1 (P=0.09), I2=65.95%  
Favours dupilumab 105-10 -5 0 Favours placebo
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Analysis 1.6.   Comparison 1 Anti-IL-4Rα mAb (dupilumab) versus placebo (on top of topical
steroids), Outcome 6 Extent of disease - CT scan (Lund Mackay, 0 to 24, higher = worse).
Study or subgroup Dupilumab Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bachert 2016 30 9.4 (5.1) 30 17.9 (5.7) 26.98% -8.5[-11.24,-5.76]
LIBERTY SINUS 24 143 10.9 (4.8) 133 19 (4.5) 35.87% -8.08[-9.18,-6.98]
LIBERTY SINUS 52 295 12.9 (3.9) 153 17.7 (3.8) 37.15% -4.87[-5.62,-4.12]
   
Total *** 468   316   100% -7[-9.61,-4.39]
Heterogeneity: Tau2=4.64; Chi2=25.69, df=2(P<0.0001); I2=92.21%  
Test for overall effect: Z=5.25(P<0.0001)  
Favours dupilumab 2010-20 -10 0 Favours placebo
 
 
Analysis 1.7.   Comparison 1 Anti-IL-4Rα mAb (dupilumab) versus placebo (on top of
topical steroids), Outcome 7 HRQL - generic (EQ-5D VAS, 0 to 100, higher = better).
Study or subgroup Placebo Dupilumab Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
LIBERTY SINUS 24 130 1.7 (1.5) 136 12 (1.5) 49.93% -10.26[-10.62,-9.9]
LIBERTY SINUS 52 151 3.9 (1.5) 289 10.8 (1.2) 50.07% -6.92[-7.19,-6.65]
   
Total *** 281   425   100% -8.59[-11.86,-5.31]
Heterogeneity: Tau2=5.55; Chi2=206.95, df=1(P<0.0001); I2=99.52%  
Test for overall effect: Z=5.14(P<0.0001)  
Favours dupilumab   2010-20 -10 0 Favours placebo
 
 
Analysis 1.8.   Comparison 1 Anti-IL-4Rα mAb (dupilumab) versus placebo (on top of topical steroids),
Outcome 8 Adverse events - nasopharyngitis, including sore throat (longest available data).
Study or subgroup Dupilumab Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bachert 2016 14/30 10/30 19.02% 1.4[0.74,2.64]
LIBERTY SINUS 24 19/143 20/133 22.61% 0.88[0.49,1.58]
LIBERTY SINUS 52 61/297 36/150 58.37% 0.86[0.6,1.23]
   
Total (95% CI) 470 313 100% 0.95[0.72,1.25]
Total events: 94 (Dupilumab), 66 (Placebo)  
Heterogeneity: Tau2=0; Chi2=1.83, df=2(P=0.4); I2=0%  
Test for overall effect: Z=0.39(P=0.7)  
Favours dupilumab 1000.01 100.1 1 Favours placebo
 
 
Biologics for chronic rhinosinusitis (Review)









Cochrane Database of Systematic Reviews
Comparison 2.   Anti-IL-5 mAb (mepolizumab) versus placebo (on top of topical steroids)





Statistical method Effect size
1 HRQL - SNOT-22 (1 to 100, lower = better) up
to 25 weeks




2 Disease severity - VAS (0 to 10, lower = bet-
ter)
1 72 Mean Difference (IV, Random, 95%
CI)
-2.03 [-3.65, -0.41]
3 Severe adverse events 2 135 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [0.07, 35.46]
4 Avoidance of surgery - patients no longer
meeting criteria for surgery at end of fol-
low-up
2 135 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.64, 0.94]
4.1 Patients still meeting criteria for surgery
at 24 weeks 
1 105 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.64, 0.95]
4.2 Patients requiring 'rescue' surgery during
trial
1 30 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.18, 2.42]
5 Extent of disease - endoscopic score 2 137 Mean Difference (IV, Random, 95%
CI)
-1.23 [-1.79, -0.68]
6 HRQL - generic measured using EQ-5D VAS
(range 0 to 100;  0 = worst, 100 = best imagin-
able health state) at week 25
1 105 Mean Difference (IV, Random, 95%
CI)
5.68 [-1.18, 12.54]
7 Adverse events - nasopharyngitis, including
sore throat
2 135 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.36, 1.47]
 
 
Analysis 2.1.   Comparison 2 Anti-IL-5 mAb (mepolizumab) versus placebo (on top of
topical steroids), Outcome 1 HRQL - SNOT-22 (1 to 100, lower = better) up to 25 weeks.
Study or subgroup Mepolizumab Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bachert 2017 54 27.1 (21.8) 51 40.4 (24.2) 100% -13.26[-22.08,-4.44]
   
Total *** 54   51   100% -13.26[-22.08,-4.44]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.95(P=0)  
Favours mepolizumab 10050-100 -50 0 Favours placebo
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Analysis 2.2.   Comparison 2 Anti-IL-5 mAb (mepolizumab) versus placebo (on top
of topical steroids), Outcome 2 Disease severity - VAS (0 to 10, lower = better).
Study or subgroup Mepolizumab Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bachert 2017 41 4.2 (3.6) 31 6.2 (3.4) 100% -2.03[-3.65,-0.41]
   
Total *** 41   31   100% -2.03[-3.65,-0.41]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.45(P=0.01)  
Favours mepolizumab 10050-100 -50 0 Favours placebo
 
 
Analysis 2.3.   Comparison 2 Anti-IL-5 mAb (mepolizumab) versus
placebo (on top of topical steroids), Outcome 3 Severe adverse events.
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Bachert 2017 1/20 0/10 100% 1.57[0.07,35.46]
Gevaert 2011 0/53 0/52   Not estimable
   
Total (95% CI) 73 62 100% 1.57[0.07,35.46]
Total events: 1 (Mepolizumab), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.28(P=0.78)  
Favours mepolizumab 1000.01 100.1 1 Favours placebo
 
 
Analysis 2.4.   Comparison 2 Anti-IL-5 mAb (mepolizumab) versus placebo (on top of topical steroids),
Outcome 4 Avoidance of surgery - patients no longer meeting criteria for surgery at end of follow-up.
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.4.1 Patients still meeting criteria for surgery at 24 weeks   
Bachert 2017 38/54 46/51 97.76% 0.78[0.64,0.95]
Subtotal (95% CI) 54 51 97.76% 0.78[0.64,0.95]
Total events: 38 (Mepolizumab), 46 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.49(P=0.01)  
   
2.4.2 Patients requiring 'rescue' surgery during trial  
Gevaert 2011 4/20 3/10 2.24% 0.67[0.18,2.42]
Subtotal (95% CI) 20 10 2.24% 0.67[0.18,2.42]
Total events: 4 (Mepolizumab), 3 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.62(P=0.54)  
   
Total (95% CI) 74 61 100% 0.78[0.64,0.94]
Total events: 42 (Mepolizumab), 49 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.8); I2=0%  
Test for overall effect: Z=2.56(P=0.01)  
Favours mepolizumab 1000.01 100.1 1 Favours placebo
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Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for subgroup differences: Chi2=0.06, df=1 (P=0.81), I2=0%  
Favours mepolizumab 1000.01 100.1 1 Favours placebo
 
 
Analysis 2.5.   Comparison 2 Anti-IL-5 mAb (mepolizumab) versus placebo
(on top of topical steroids), Outcome 5 Extent of disease - endoscopic score.
Study or subgroup Mepolizumab Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bachert 2017 54 -1.9 (1.8) 53 -0.7 (1.8) 65.54% -1.2[-1.89,-0.51]
Gevaert 2011 20 -1.3 (1.7) 10 0 (0.9) 34.46% -1.3[-2.25,-0.35]
   
Total *** 74   63   100% -1.23[-1.79,-0.68]
Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.87); I2=0%  
Test for overall effect: Z=4.33(P<0.0001)  
Favours mepolizumab 105-10 -5 0 Favours placebo
 
 
Analysis 2.6.   Comparison 2 Anti-IL-5 mAb (mepolizumab) versus placebo (on top of topical steroids), Outcome 6
HRQL - generic measured using EQ-5D VAS (range 0 to 100;  0 = worst, 100 = best imaginable health state) at week 25.
Study or subgroup Mepolizumab Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bachert 2017 54 81.1 (16.9) 51 75.5 (18.9) 100% 5.68[-1.18,12.54]
   
Total *** 54   51   100% 5.68[-1.18,12.54]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.62(P=0.1)  
Favours mepolizumab 10050-100 -50 0 Favours placebo
 
 
Analysis 2.7.   Comparison 2 Anti-IL-5 mAb (mepolizumab) versus placebo (on top of
topical steroids), Outcome 7 Adverse events - nasopharyngitis, including sore throat.
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bachert 2017 10/53 14/52 94.99% 0.7[0.34,1.43]
Gevaert 2011 1/20 0/10 5.01% 1.57[0.07,35.46]
   
Total (95% CI) 73 62 100% 0.73[0.36,1.47]
Total events: 11 (Mepolizumab), 14 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%  
Test for overall effect: Z=0.89(P=0.38)  
Favours mepolizumab 1000.01 100.1 1 Favours placebo
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Comparison 3.   Anti-IgE mAb (omalizumab) versus placebo (on top of topical steroids)





Statistical method Effect size
1 Severe adverse events 3 64 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Extent of disease - endoscopic score 2 47 Std. Mean Difference (IV, Random, 95% CI) -1.51 [-4.22, 1.21]
3 Extent of disease - CT scan (lower
score = better)
2 47 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-1.55, 1.14]
4 Adverse events - nasopharyngitis,
including sore throat
3 64 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 3.1.   Comparison 3 Anti-IgE mAb (omalizumab) versus
placebo (on top of topical steroids), Outcome 1 Severe adverse events.
Study or subgroup Omalizumab Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Gevaert 2013 0/15 0/8   Not estimable
NCT01066104 0/13 0/14   Not estimable
Pinto 2010 0/7 0/7   Not estimable
   
Total (95% CI) 35 29 Not estimable
Total events: 0 (Omalizumab), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Omalizumab 1000.01 100.1 1 Placebo
 
 
Analysis 3.2.   Comparison 3 Anti-IgE mAb (omalizumab) versus placebo (on
top of topical steroids), Outcome 2 Extent of disease - endoscopic score.
Study or subgroup Omalizumab Placebo Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Gevaert 2013 15 -2.7 (1) 8 -0.1 (0.4) 48.37% -2.94[-4.21,-1.67]
NCT01066104 12 -0.3 (2.1) 12 0.1 (2.3) 51.63% -0.17[-0.97,0.63]
   
Total *** 27   20   100% -1.51[-4.22,1.21]
Heterogeneity: Tau2=3.55; Chi2=13.12, df=1(P=0); I2=92.38%  
Test for overall effect: Z=1.09(P=0.28)  
Omalizumab 10050-100 -50 0 Placebo
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Analysis 3.3.   Comparison 3 Anti-IgE mAb (omalizumab) versus placebo (on top
of topical steroids), Outcome 3 Extent of disease - CT scan (lower score = better).
Study or subgroup Omalizumab Placebo Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Gevaert 2013 15 13.6 (5) 8 18.3 (5) 48.92% -0.91[-1.81,-0]
NCT01066104 12 4.2 (25.6) 12 -8.9 (28.2) 51.08% 0.47[-0.34,1.28]
   
Total *** 27   20   100% -0.2[-1.55,1.14]
Heterogeneity: Tau2=0.75; Chi2=4.91, df=1(P=0.03); I2=79.64%  
Test for overall effect: Z=0.3(P=0.77)  
Omalizumab 10050-100 -50 0 Placebo
 
 
Analysis 3.4.   Comparison 3 Anti-IgE mAb (omalizumab) versus placebo (on top of
topical steroids), Outcome 4 Adverse events - nasopharyngitis, including sore throat.
Study or subgroup Omalizumab Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gevaert 2013 0/15 0/8   Not estimable
NCT01066104 0/13 0/14   Not estimable
Pinto 2010 0/7 0/7   Not estimable
   
Total (95% CI) 35 29 Not estimable
Total events: 0 (Omalizumab), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Omalizumab 1000.01 100.1 1 Placebo
 
 
A D D I T I O N A L   T A B L E S
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Publications Publications Publication Publication NCT record (no
publications)
Table 1.   Summary of characteristics of included studies  (Continued)
aWorst aKected nostril ≥ 3 (on a 4-point scale), and symptoms score > 7 on 10 cm VAS despite intranasal steroids and/or previous oral corticosteroids.
bSNOT-22, scale 0 to 110, higher = worse, minimal clinically important diKerence (MID) ≥ 8.9 points.
cRSOM-31; AQLQ.
dVisual analogue scale for rhinosinusitis: "how troublesome are your symptoms?", scale 0 to 10 cm, higher = worse.
eTotal symptom severity score (including nasal congestion, rhinorrhoea and sense of smell, each rated between 0 and 3), total scale 0 to 9, higher = worse.
fFour individual symptoms were measured (anterior rhinorrhoea, nasal obstruction, postnasal drip and loss of sense of smell); reported only as narrative summary.
gTotal nasal symptom score (TNSS): nasal obstruction, nasal discharge, facial pain and hyposmia) each recorded on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe);
total scores summed.
hOnly reported as 'no significant diKerence' - no data presented.
iDisease severity symptom score: nasal and asthma symptoms (patient-reported, daily 'absent, mild, moderate or severe' (scores 0, 1, 2, 3).
jSeverity scores for individual symptoms (nasal congestion, anterior and posterior rhinorrhoea, loss in sense of smell, nocturnal awakenings), range 0 to 3, higher = worse.
kNCT record states that a total symptom score (TSS) and chronic rhinosinusitis facial pain/headache questionnaire were recorded daily; no outcome data presented in NCT record.
lNumber of participants requiring rescue with nasal polyp surgery - no definition for eligibility provided.























































































































nOutcome measured but not reported (pooled data with SINUS 24 only, specific data for this trial not reported on trial registry or publication).
oAt study endpoint, participants with a nasal polyp score of ≥ 3 were deemed as continuing to need surgery (regardless of VAS score). In addition, participants with a nasal polyp
score of 2, who had a VAS score of > 7 were also viewed as requiring surgery.
pLund Mackay CT score, range 0 to 24, higher = worse.
qPublication reports proportion of participants who showed improvement in CT score during the study. Shown separately for three independent raters, with no summary measure
reported.
rMucosal thickness on CT scan.
sCT scan scored using the Zinreich modification of the Lund Mackay scoring system.
tBilateral "endoscopic nasal polyps score" (NPS) or total polyps score (TPS), range 0 to 8, higher = worse.
uImprovement by at least one point in endoscopic nasal polyp score.
vNasal endoscopy score (0 to 4). Unclear which scoring system used.
wEQ-5D visual analogue scale, range 0 to 100 (100 = best imaginable).
xEQ-5D index score, range 0 to 1, higher = better.
ySF-36.
zOutcome not specifically mentioned, paper just states "No side eKects or adverse events occurred during the study".
 
 
Eligibility for surgery: defined at
randomisation?























  x Criteria not defined but one outcome was "Proportion of
patients during study treatment receiving oral corticos-









x   Offered when there was worsening of signs and/or symptoms
during the study
Criteria not applied at baseline
































































































































  x Criteria not defined but one outcome was "Proportion of
patients during study treatment receiving oral corticos-
teroid (OCS) for NP and/or planned to under surgery for nasal
polyps"
Han 2019   x Not
men-
tioned
  x Full text not available but one outcome was "Reduction of
surgery for nasal polyps"




































x   Criteria for endoscopic nasal polyp score of ≥ 3, or nasal
polyp score of 2 and a VAS symptom score of > 7
Criteria different from what applied at baseline
Who: not mentioned
80% qualified for surgery




































































































































































x   Criteria endoscopic nasal polyp score of ≥ 3, or nasal polyp
score of 2 and a VAS symptom score of > 7
Criteria different from what applied at baseline
Who: not mentioned
75% qualified for surgery








































































































































































Included studies (not published)
































































































































x   No need for surgery when a nasal polyps score ≤ 4 (unilateral
score of ≤ 2
on each side) and improvement in SNOT-22 score of ≥ 8.9
Criteria not applied at baseline
Who: not mentioned
Completed. Results not available
POLYP 1
(NCT03280550)
NCT03280550   x Not
men-
tioned
x   No need for surgery when an NPS of ≤ 4 (unilateral score of ≤
2 on each side)
and improvement in SNOT-22 score of ≥ 8.9
Criteria not applied at baseline
Who: not mentioned
Completed. Results not available
























    Ongoing study








































































































































































































































































































































































































































































































    Ongoing study



























































































































































































































































































NCT03450083 NCT03450083   x Not
men-
tioned
  x Criteria not defined but one outcome was time to nasal polyp
surgery
Table 2.   Eligibility for surgery  (Continued)
NP: nasal polyps
NPS: nasal polyp score
SNOT-22: Sino-Nasal Outcome Test-22
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A P P E N D I C E S
Appendix 1. Search strategies (main electronic sources)
 
CENTRAL (via CRS) ENT Register (via CRS) MEDLINE (Ovid) Embase (Ovid)
1 MESH DESCRIPTOR Sinusitis EX-
PLODE ALL AND CENTRAL:TARGET
2 MESH DESCRIPTOR Rhinitis AND
CENTRAL:TARGET
3 MESH DESCRIPTOR Rhinitis, Atroph-
ic AND CENTRAL:TARGET
4 MESH DESCRIPTOR Rhinitis, Vaso-
motor AND CENTRAL:TARGET
5 MESH DESCRIPTOR Paranasal Sinus
Diseases AND CENTRAL:TARGET
6 MESH DESCRIPTOR Paranasal
Sinuses EXPLODE ALL AND CEN-
TRAL:TARGET
7 (rhinosinusitis or nasosinusitis or
pansinusitis or ethmoiditis or sphe-
noiditis):AB,EH,KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
8 (kartagener* near syndrome*):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
9 (inflamm* near sinus*):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
10 ((maxilla* or frontal*) near si-
nus*):AB,EH,KW,KY,MC,MH,TI,TO AND
CENTRAL:TARGET
11 #1 or #2 or #3 or #4 or #5 or #6
or #7 or #8 or #9 or #10 AND CEN-
TRAL:TARGET
12 MESH DESCRIPTOR Chronic
Disease EXPLODE ALL AND CEN-
TRAL:TARGET
13 MESH DESCRIPTOR Recurrence
EXPLODE ALL AND CENTRAL:TARGET
14 (chronic or persis* or recur*):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
15 #12 or #13 or #14 AND CEN-
TRAL:TARGET
16 #11 and #15 AND CENTRAL:TAR-
GET
1 MESH DESCRIPTOR Si-















PLODE ALL AND IN-
REGISTER
7 (rhinosinusitis or na-
sosinusitis or pansi-
















11 #1 or #2 or #3 or #4 or
#5 or #6 or #7 or #8 or #9
or #10 AND INREGISTER
12 MESH DESCRIPTOR
Chronic Disease EX-
PLODE ALL AND IN-
REGISTER
1 exp Sinusitis/
2 paranasal sinus dis-
eases/ or rhinitis/ or
rhinitis, atrophic/ or
rhinitis, vasomotor/
3 exp Paranasal Sinuses/
4 (rhinosinusitis or na-
sosinusitis or pansi-
nusitis or ethmoiditis or
sphenoiditis).ab,ti.
5 (kartagener* adj3 syn-
drome*).ab,ti.
6 (inflamm* adj5 si-
nus*).ab,ti.
7 ((maxilla* or frontal*)
adj3 sinus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6
or 7
9 exp chronic disease/
10 exp Recurrence/
11 (chronic or persis* or
recur*).ab,ti.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.ab,ti.
15 ((sinusitis or rhinitis)
adj3 (chronic or persis*
or recur*)).ab,ti.
16 13 or 14 or 15
17 exp Nasal Polyps/
18 exp Nose/ or exp Nose
Diseases/
19 exp Polyps/
20 18 and 19
21 ((nose or nasal or rhi-
no* or rhinitis or sinus*
1 exp sinusitis/ or paranasal sinus
disease/
2 rhinitis/ or atrophic rhinitis/ or
chronic rhinitis/ or rhinosinusitis/
or vasomotor rhinitis/
3 exp paranasal sinus/
4 (rhinosinusitis or nasosinusitis
or pansinusitis or ethmoiditis or
sphenoiditis).tw.
5 (kartagener* adj3 syn-
drome*).tw.
6 (inflamm* adj5 sinus*).tw.
7 ((maxilla* or frontal*) adj3 si-
nus*).tw.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp recurrent disease/
11 (chronic or persis* or recur*).tw.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.tw.
15 ((sinusitis or rhinitis) adj3
(chronic or persis* or recur*)).tw.
16 13 or 14 or 15
17 exp nose polyp/
18 exp nose disease/ or exp nose/
19 exp polyp/
20 18 and 19
21 ((nose or nasal or rhino* or
rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).tw.
22 (rhinopolyp* or CRSwNP).tw.
23 16 or 17 or 20 or 21 or 22
24 exp antiidiotypic antibody/
 
Biologics for chronic rhinosinusitis (Review)









Cochrane Database of Systematic Reviews
17 (CRSsNP):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
18 ((sinusitis or rhinitis) near (chronic
or persis* or recur*)):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
19 #16 or #17 or #18 AND CEN-
TRAL:TARGET
20 MESH DESCRIPTOR Nasal Polyps
EXPLODE ALL AND CENTRAL:TARGET
21 MESH DESCRIPTOR Nose EXPLODE
ALL AND CENTRAL:TARGET
22 MESH DESCRIPTOR Nose Diseases
EXPLODE ALL AND CENTRAL:TARGET
23 #21 or #22 AND CENTRAL:TARGET
24 MESH DESCRIPTOR Polyps EX-
PLODE ALL AND CENTRAL:TARGET
25 #23 and #24 AND CENTRAL:TAR-
GET
26 ((nose or nasal or rhino* or rhini-
tis or sinus* or sinonasal) near (pa-
pilloma* or polyp*)):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
27 (rhinopolyp* or CRSwNP):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
28 #19 or #20 or #25 or #26 or #27
AND CENTRAL:TARGET
29 MESH DESCRIPTOR Antibodies,
Monoclonal EXPLODE ALL AND CEN-
TRAL:TARGET
30 MESH DESCRIPTOR Antibodies,
Anti-Idiotypic EXPLODE ALL AND CEN-
TRAL:TARGET
31 MESH DESCRIPTOR Immunoglob-
ulin E EXPLODE ALL AND CEN-
TRAL:TARGET
32 MESH DESCRIPTOR Interleukins
EXPLODE ALL AND CENTRAL:TARGET
33 MESH DESCRIPTOR Receptors,
Interleukin EXPLODE ALL AND CEN-
TRAL:TARGET
34 MESH DESCRIPTOR Biological









15 #12 or #13 or #14 AND
INREGISTER





18 ((sinusitis or rhini-















23 #21 or #22 AND IN-
REGISTER
24 MESH DESCRIPTOR
Polyps EXPLODE ALL AND
INREGISTER
25 #23 and #24 AND IN-
REGISTER
26 ((nose or nasal or rhi-
no* or rhinitis or sinus*












23 16 or 17 or 20 or 21 or
22
24 exp Antibodies, Mono-
clonal/





28 exp Receptors, Inter-
leukin/







32 exp Etanercept/ or exp
Alefacept/
33 (Antibod* adj3 mono-
clonal).ab,ti.




35 (anti adj3 (globulin* or
idiotyp* or immunoglob-
ulin* or M1 or CCR4 or





ab or Certolizumab or
Cetuximab or Deno-
sumab or Ipilimumab
or Natalizumab or Oma-
lizumab or Palivizum-
ab or Ranibizumab or
Trastuzumab or stek-
inumab or mepolizumab
or Nucala or SB240563
or "SB 240563" or
dupilumab or REGN668
or AMG317 or "AMG 317"
25 biological product/
26 exp immunoglobulin e/
27 exp interleukin derivative/
28 exp interleukin receptor/
29 exp monoclonal antibody/




33 exp cytokine receptor antago-
nist/
34 (Antibod* adj3 monoclon-
al).ab,ti.
35 (Interleukin* or IgE or "im-
munoglobulin E" or Antiglobulin*
or antiidiotyp*).ab,ti.
36 (anti adj3 (globulin* or idio-
typ* or immunoglobulin* or M1
or CCR4 or "LFA 1" or "GATA 3" or
OX40L)).ab,ti.
37 (ralokimumab or Adalimumab
or Alemtuzumab or Bevacizum-
ab or Certolizumab or Cetuximab
or Denosumab or Ipilimumab
or Natalizumab or Omalizum-
ab or Palivizumab or Ranibizum-
ab or Trastuzumab or stekinum-
ab or mepolizumab or Nucala
or SB240563 or "SB 240563" or
dupilumab or REGN668 or AMG317
or "AMG 317" or AMG827 or "AMG
827" or DNAzyme or antiTSLP
or CSL311 or "CSL 311" or "AMG
761" or AMG761 or "AMG 837" or
KW0761 or "KW 0761" or "CSF 2" or
"CSF GM").ab.
38 (siliq or D2E7 or humira or cam-
path or Lemtrada or avastin or
cimzia or CDP870 or "CDP 870" or
Erbitux or C225 or Xgeva or prolia
or "AMG 162" or AMG162 or Yervoy
or Tysabri or Antegren or Xolair*
or Synagis or RhuFab or lucentis
or Herceptin or stelara or CNTO or
ASM8 or granulocyte-macrophage
or GM-CSF or QGE031 or Raptiva or
AK001 or "AK 001").ab,ti.
  (Continued)
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35 MESH DESCRIPTOR Granulo-
cyte-Macrophage Colony-Stimulat-
ing Factor EXPLODE ALL AND CEN-
TRAL:TARGET
36 MESH DESCRIPTOR Cytokines EX-
PLODE ALL AND CENTRAL:TARGET
37 MESH DESCRIPTOR Etanercept EX-
PLODE ALL AND CENTRAL:TARGET
38 MESH DESCRIPTOR Immunoglob-
ulin G EXPLODE ALL AND CEN-
TRAL:TARGET
39 (Antibod* adj3 monoclonal):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
40 (Interleukin* or IgE or "im-
munoglobulin E" or Antiglobulin*
or antiidiotyp*):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
41 (anti adj3 (globulin* or idiotyp* or
immunoglobulin* or M1 or CCR4 or
"LFA 1" or "GATA 3" or OX40L)):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
42 (ralokimumab or Adalimumab or
Alemtuzumab or Bevacizumab or
Certolizumab or Cetuximab or Deno-
sumab or Ipilimumab or Natalizum-
ab or Omalizumab or Palivizumab
or Ranibizumab or Trastuzumab or
stekinumab or mepolizumab or Nu-
cala or SB240563 or "SB 240563" or
dupilumab or REGN668 or AMG317 or
"AMG 317" or AMG827 or "AMG 827"
or DNAzyme or antiTSLP or CSL311
or "CSL 311" or "AMG 761" or AMG761
or "AMG 837" or KW0761 or "KW
0761" or "CSF 2" or "CSF GM"):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
43 (siliq or D2E7 or humira or cam-
path or Lemtrada or avastin or cimzia
or CDP870 or "CDP 870" or Erbitux
or C225 or Xgeva or prolia or "AMG
162" or AMG162 or Yervoy or Tysabri
or Antegren or Xolair or Synagis or
RhuFab or lucentis or Herceptin or
stelara or CNTO or ASM8 or granu-
locyte-macrophage or GM-CSF or
QGE031 or Raptiva or AK001 or "AK
001"):AB,EH,KW,KY,MC,MH,TI,TO AND
CENTRAL:TARGET
44 ((B-cell or T-cell or Eosinophil or
"mast cell" or stimulating) adj3 fac-
28 #19 or #20 or #25












PLODE ALL AND IN-
REGISTER
























PLODE ALL AND IN-
REGISTER




40 (Interleukin* or IgE
or "immunoglobulin




or AMG827 or "AMG 827"
or DNAzyme or antiTSLP
or CSL311 or "CSL 311" or
"AMG 761" or AMG761 or
"AMG 837" or KW0761 or
"KW 0761" or "CSF 2" or
"CSF GM").ab,ti.
37 (siliq or D2E7 or humi-
ra or campath or Lemtra-
da or avastin or cimzia or
CDP870 or "CDP 870" or
Erbitux or C225 or Xge-
va or prolia or "AMG 162"
or AMG162 or Yervoy or
Tysabri or Antegren or
Xolair or Synagis or Rhu-
Fab or lucentis or Her-
ceptin or stelara or CN-
TO or ASM8 or granu-
locyte-macrophage or
GM-CSF or QGE031 or
Raptiva or AK001 or "AK
001").ab,ti.
38 ((B-cell or T-cell or
Eosinophil or "mast cell"
or stimulating) adj3 fac-
tor).ab,ti.
39 (CD23 or CD2 or CD11a
or CD20 or CD25 opr
CD252 or (receptor* adj3
apsilon)).ab,ti.
40 (CD adj3 ("23" or anti-
gen* or "2" or 11a or "20"
or "25" or "252")).ab,ti.
41 ((antigamma or "an-
ti gamma") adj3 Anti-
bod*).ab,ti.
42 (IgEid or "55700" or
SCH55700 or CEP38072
or "CEP 38072" or cinqair
or DCP835 or "DCP 835"
or GM-CSF or TNF or
TSLP or OX40L).ab,ti.
43 (IL adj3 ("5" or five or
"4" or four or "13" or thir-
teen or "1" or one or "10"
or ten or "11" or eleven
or "12" or twelve or "15"
or fifteen or "16" or six-
teen or "17" or seventeen
or "18" or eighteen or "2"
or two or "23" or "twenty
three" or "12" or twelve
39 ((B-cell or T-cell or Eosinophil
or "mast cell" or stimulating) adj3
factor).ab,ti.
40 (CD23 or CD2 or CD11a or CD20
or CD25 opr CD252 or (receptor*
adj3 apsilon)).ab,ti.
41 (CD adj3 ("23" or antigen*
or "2" or 11a or "20" or "25" or
"252")).ab,ti.
42 ((antigamma or "anti gamma")
adj3 Antibod*).ab,ti.
43 (IgEid or "55700" or SCH55700
or CEP38072 or "CEP 38072" or
cinqair or DCP835 or "DCP 835"
or GM-CSF or TNF or TSLP or
OX40L).ab,ti.
44 (IL adj3 ("5" or five or "4" or four
or "13" or thirteen or "1" or one
or "10" or ten or "11" or eleven or
"12" or twelve or "15" or fifteen or
"16" or sixteen or "17" or seven-
teen or "18" or eighteen or "2" or
two or "23" or "twenty three" or
"12" or twelve or "27" or "twenty
seven" or "3" or three or "33" or
"thirty three" or "6" or six or "7"
or seven or "8" or eight or "9" or
nine or 5R* or 1R1 or 4R* or 12p40
or IL-23p40 or 17A or 17RA or "22"
or "twenty two" or "31" or "thirty
one" or 31R)).ab,ti.
45 (IL5 or IL4 or IL13 or IL1 or IL10
or IL11 or IL12 or IL15 or IL15 or
IL16 or IL17 or IL18 or IL2 or IL23
or IL12 or IL27 or IL3 or IL33 or
IL6 or IL7 or IL8 or IL9 or IL22 or
IL31).ab,ti.
46 (biologic or biologics or biother-
ap*).ab,ti.
47 (biologic* adj3 therap*).ab,ti.
48 (mAB or mepo or MDX or MEDI
or siglec* or "lectin 8").ab,ti.
49 (SAR231893 or reslizumab or
siglec8 or benralizumab or le-
brikizumab or brodalumab or
Tralokinumab or Quilizumab or
Ligelizumab or Mogamulizum-
ab or Efalizumab or Pitrakinra or
Odulimomab or Mogamulizuma-
bor or BCGF or binetrakin or "anti
antibod*").ab,ti.
  (Continued)
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tor):AB,EH,KW,KY,MC,MH,TI,TO AND
CENTRAL:TARGET
45 (CD23 or CD2 or CD11a or CD20 or
CD25 opr CD252 or (receptor* adj3
apsilon)):AB,EH,KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
46 (CD adj3 ("23" or antigen* or "2"
or 11a or "20" or "25" or "252")):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
47 ((antigamma or "anti gamma")
adj3 Antibod*):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
48 (IgEid or "55700" or SCH55700 or
CEP38072 or "CEP 38072" or cinqair
or DCP835 or "DCP 835" or GM-
CSF or TNF or TSLP or OX40L):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
49 (IL adj3 ("5" or five or "4" or four
or "13" or thirteen or "1" or one or
"10" or ten or "11" or eleven or "12"
or twelve or "15" or fifteen or "16" or
sixteen or "17" or seventeen or "18"
or eighteen or "2" or two or "23" or
"twenty three" or "12" or twelve or
"27" or "twenty seven" or "3" or three
or "33" or "thirty three" or "6" or six
or "7" or seven or "8" or eight or "9"
or nine or 5R* or 1R1 or 4R* or 12p40
or IL-23p40 or 17A or 17RA or "22" or
"twenty two" or "31" or "thirty one"
or 31R)):AB,EH,KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
50 (biologic or biologics or biothera-
p*):AB,EH,KW,KY,MC,MH,TI,TO AND
CENTRAL:TARGET
51 biologic* adj3 therap* AND CEN-
TRAL:TARGET
52 (mAB or mepo or MDX or MEDI or
siglec* or "lectin 8"):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
53 SAR231893 or reslizumab or
siglec8 or benralizumab or lebrik-
izumab or brodalumab or Tralok-
inumab or Quilizumab or Ligelizum-
ab or Mogamulizumab or Efalizum-
ab or Pitrakinra or Odulimomab or
Mogamulizumabor or BCGF or bine-
trakin or "anti antibod*" AND CEN-
TRAL:TARGET
54 (Canakinumab or Ilaris or Rilona-
cept or Arcalyst or Anakinra or
41 (anti adj3 (globu-
lin* or idiotyp* or im-
munoglobulin* or M1 or







ab or Certolizumab or
Cetuximab or Deno-
sumab or Ipilimumab
or Natalizumab or Oma-
lizumab or Palivizum-
ab or Ranibizumab or
Trastuzumab or stek-
inumab or mepolizumab
or Nucala or SB240563
or "SB 240563" or
dupilumab or REGN668
or AMG317 or "AMG 317"
or AMG827 or "AMG 827"
or DNAzyme or antiTSLP
or CSL311 or "CSL 311"
or "AMG 761" or AMG761
or "AMG 837" or KW0761




43 (siliq or D2E7 or humi-
ra or campath or Lemtra-
da or avastin or cimzia or
CDP870 or "CDP 870" or
Erbitux or C225 or Xge-
va or prolia or "AMG 162"
or AMG162 or Yervoy or
Tysabri or Antegren or
Xolair or Synagis or Rhu-
Fab or lucentis or Her-
ceptin or stelara or CN-
TO or ASM8 or granu-
locyte-macrophage or
GM-CSF or QGE031 or




44 ((B-cell or T-cell or
Eosinophil or "mast cell"




45 (CD23 or CD2 or CD11a
or CD20 or CD25 opr
CD252 or (receptor*
or "27" or "twenty seven"
or "3" or three or "33"
or "thirty three" or "6"
or six or "7" or seven or
"8" or eight or "9" or nine
or 5R* or 1R1 or 4R* or
12p40 or IL-23p40 or 17A
or 17RA or "22" or "twen-
ty two" or "31" or "thirty
one" or 31R)).ab,ti.
44 (IL5 or IL4 or IL13 or
IL1 or IL10 or IL11 or IL12
or IL15 or IL15 or IL16 or
IL17 or IL18 or IL2 or IL23
or IL12 or IL27 or IL3 or
IL33 or IL6 or IL7 or IL8 or
IL9 or IL22 or IL31).ab,ti.
45 (biologic or biologics
or biotherap*).ab,ti.
46 (biologic* adj3 thera-
p*).ab,ti.
47 (mAB or mepo or MDX
or MEDI or siglec* or
"lectin 8").ab,ti.
48 (SAR231893 or
reslizumab or siglec8 or
benralizumab or lebrik-
izumab or brodalumab
or Tralokinumab or Quil-
izumab or Ligelizumab or
Mogamulizumab or Efal-
izumab or Pitrakinra or
Odulimomab or Moga-
mulizumabor or BCGF or
binetrakin or "anti anti-
bod*").ab,ti.
49 (siglec8 or TPI ASM8 or
Rilonacept).rn.
50 (Canakinumab or
Ilaris or Rilonacept or
Arcalyst or Anakinra or
Kineret or Antril or Al-
trakincept or Nuvance
or Pascolizumab or SB
240683 or VAK694 or
QBX258 or VAK 694 or
VAK-694 or dectrekum-
ab QAX-576 or QAX576
or QAX 576 or aerovant
or AER-001 or AER001 or
"AER 001" or BAY-16-9996
or BAY 16-9996 or Bosa-
tria or Nucala or CDP 835
or CDP835 or CDP-835 or
CINQAIR or CTx55700 or
CTx 55700 or CTx-55700
50 (Canakinumab or Ilaris or
Rilonacept or Arcalyst or Anakinra
or Kineret or Antril or Altrakincept
or Nuvance or Pascolizumab or SB
240683 or VAK694 or QBX258 or
VAK 694 or VAK-694 or dectrekum-
ab QAX-576 or QAX576 or QAX 576
or aerovant or AER-001 or AER001
or "AER 001" or BAY-16-9996 or BAY
16-9996 or Bosatria or Nucala or
CDP 835 or CDP835 or CDP-835
or CINQAIR or CTx55700 or CTx
55700 or CTx-55700 or DCP 835 or
DCP-835 or DCP835 or SCH5570
or SCH 5570 SCH-5570 or TRFK-5
or TRFK 5 or TRFK5 or BIW-8405*
or BIW8405* or BIW 8405* or KHK
4563 or KHK-4563 or KHK4563 or
Enokizumab or 7F3com-2H2 or
Ustekinumab or Stelara or CN-
TO-1275 or CNTO1275 or CNTO
1275 or Anrukinzuma* or IMA-638
or PF-05230917 or GSK679586
or GSK-679586 or GDK 679586 or
IMA026 or IMA-026 or "IMA 026"
or IMA638 or IMA 638 MILR1444A
or MILR 1444A or MILR-1444A
or PRO-301444 or PRO301444
or PRO 301444 or RG-3637 or
RG3637 or RG 3637 or RO-5490255
or RO5490255 or RO 5490255 or
TNX-650 or TNX650 or TNX 650 or
RPC-4046 or ABT-308 or RPC4046
or ABT308 or RPC 4046 or ABT 308
or CAT-354 or CAT354 or CAT 354
or Secukinumab or Cosentyx or
AIN-457 or KB-03303A or NVP-AIN
457 or AIN457 or KB03303A or NVP-
AIN457 or AIN 457 or KB 03303A
or NVP-AIN-457 or KHK-4827 or
KHK4827 or KHK 4827 or fezak-
inumab * or ILV-094 or PF-5212367
or ILV094 or PF5212367 or "ILV
094" or PF 5212367 or BMS-981164
or BMS981164 or BMS 981164 or
Nemolizumab or CIM331 or CIM
331 or CIM-331 or Lenzilumab or
KB003 or "KB 003" or KB-003 or
ABT-D2E7 or D2E7 or LU 200134
or ABTD2E7 or LU200134 or ABT
D2E7 or LU 200134 or Golimum-
ab or Simponi or CNTO-148 or CN-
TO148 or CNTO 148 or Inflixima
or cA2 or CenTNF or Remicade
or TA-650 or TA650 or TA 650 or
Etanercept or Enbrel or p75TN-
FR-Ig or rhu TNFR-Fc or TNFR-Fc-
p75 or TNR-001 or TNR001 or "TNR
001" or AMG-157 or MEDI-9929 or
AMG157 or AMG 157 MEDI4212 or
MEMP1972A or RG7449 or MEMP
1972A or RG 7449 or MEMP-1972A
or RG-7449 or Mogamulizumab or
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Kineret or Antril or Altrakincept or
Nuvance or Pascolizumab or SB
240683 or VAK694 or QBX258 or
VAK 694 or VAK-694 or dectrekum-
ab QAX-576 or QAX576 or QAX 576
or aerovant or AER-001 or AER001
or "AER 001" or BAY-16-9996 or
BAY 16-9996 or Bosatria or Nucala
or CDP 835 or CDP835 or CDP-835
or CINQAIR or CTx55700 or CTx
55700 or CTx-55700 or DCP 835 or
DCP-835 or DCP835 or SCH5570 or
SCH 5570 SCH-5570 or TRFK-5 or
TRFK 5 or TRFK5 or BIW-8405* or
BIW8405* or BIW 8405* or KHK 4563
or KHK-4563 or KHK4563 or Enok-
izumab or 7F3com-2H2 or Ustek-
inumab or Stelara or CNTO-1275 or
CNTO1275 or CNTO 1275 or Anruk-
inzuma* or IMA-638 or PF-05230917
or GSK679586 or GSK-679586 or
GDK 679586 or IMA026 or IMA-026 or
"IMA 026" or IMA638 or IMA 638 MIL-
R1444A or MILR 1444A or MILR-1444A
or PRO-301444 or PRO301444 or PRO
301444 or RG-3637 or RG3637 or RG
3637 or RO-5490255 or RO5490255
or RO 5490255 or TNX-650 or TNX650
or TNX 650 or RPC-4046 or ABT-308
or RPC4046 or ABT308 or RPC 4046
or ABT 308 or CAT-354 or CAT354 or
CAT 354 or Secukinumab or Cosentyx
or AIN-457 or KB-03303A or NVP-AIN
457 or AIN457 or KB03303A or NVP-
AIN457 or AIN 457 or KB 03303A or
NVP-AIN-457 or KHK-4827 or KHK4827
or KHK 4827 or fezakinumab * or
ILV-094 or PF-5212367 or ILV094 or
PF5212367 or "ILV 094" or PF 5212367
or BMS-981164 or BMS981164 or BMS
981164 or Nemolizumab or CIM331
or CIM 331 or CIM-331 or Lenzilum-
ab or KB003 or "KB 003" or KB-003
or ABT-D2E7 or D2E7 or LU 200134 or
ABTD2E7 or LU200134 or ABT D2E7
or LU 200134 or Golimumab or Sim-
poni or CNTO-148 or CNTO148 or CN-
TO 148 or Inflixima or cA2 or CenTNF
or Remicade or TA-650 or TA650 or TA
650 or Etanercept or Enbrel or p75TN-
FR-Ig or rhu TNFR-Fc or TNFR-Fc-p75
or TNR-001 or TNR001 or "TNR 001"
or AMG-157 or MEDI-9929 or AMG157
or AMG 157 MEDI4212 or MEMP1972A
or RG7449 or MEMP 1972A or RG
7449 or MEMP-1972A or RG-7449
or Mogamulizumab or KM8761 or
Poteligeo or KM-8761 or KM 8761 or
Alefacept or Amevive or "ASP 0485"
or BG 9273 or BG 9712 or ASP0485
or BG9273 or BG9712 or ASP-0485 or




46 (CD adj3 ("23" or anti-
gen* or "2" or 11a or "20"
or "25" or "252")):AB,E-
H,KW,KY,MC,MH,TI,TO
AND INREGISTER
47 ((antigamma or "an-




48 (IgEid or "55700" or
SCH55700 or CEP38072
or "CEP 38072" or cinqair
or DCP835 or "DCP 835"




49 (IL adj3 ("5" or five or
"4" or four or "13" or thir-
teen or "1" or one or "10"
or ten or "11" or eleven
or "12" or twelve or "15"
or fifteen or "16" or six-
teen or "17" or seventeen
or "18" or eighteen or "2"
or two or "23" or "twenty
three" or "12" or twelve
or "27" or "twenty seven"
or "3" or three or "33"
or "thirty three" or "6"
or six or "7" or seven or
"8" or eight or "9" or nine
or 5R* or 1R1 or 4R* or
12p40 or IL-23p40 or 17A
or 17RA or "22" or "twen-
ty two" or "31" or "thir-
ty one" or 31R)):AB,EH,K-
W,KY,MC,MH,TI,TO AND
INREGISTER




51 biologic* adj3 therap*
AND INREGISTER
52 (mAB or mepo or




or DCP 835 or DCP-835
or DCP835 or SCH5570
or SCH 5570 SCH-5570
or TRFK-5 or TRFK 5 or
TRFK5 or BIW-8405* or
BIW8405* or BIW 8405*
or KHK 4563 or KHK-4563
or KHK4563 or Enok-
izumab or 7F3com-2H2
or Ustekinumab or Ste-
lara or CNTO-1275 or CN-





679586 or IMA026 or
IMA-026 or "IMA 026"





301444 or RG-3637 or
RG3637 or RG 3637
or RO-5490255 or
RO5490255 or RO
5490255 or TNX-650 or
TNX650 or TNX 650 or
RPC-4046 or ABT-308
or RPC4046 or ABT308
or RPC 4046 or ABT 308
or CAT-354 or CAT354
or CAT 354 or Secuk-
inumab or Cosentyx or
AIN-457 or KB-03303A or
NVP-AIN 457 or AIN457
or KB03303A or NVP-
AIN457 or AIN 457 or KB
03303A or NVP-AIN-457
or KHK-4827 or KHK4827
or KHK 4827 or fezak-
inumab * or ILV-094 or
PF-5212367 or ILV094
or PF5212367 or "ILV




ab or CIM331 or CIM 331
or CIM-331 or Lenzilum-
ab or KB003 or "KB 003"
or KB-003 or ABT-D2E7
or D2E7 or LU 200134 or
ABTD2E7 or LU200134 or
ABT D2E7 or LU 200134
or Golimumab or Sim-
poni or CNTO-148 or CN-
TO148 or CNTO 148 or In-
flixima or cA2 or CenTNF
or Remicade or TA-650
KM8761 or Poteligeo or KM-8761 or
KM 8761 or Alefacept or Amevive
or "ASP 0485" or BG 9273 or BG
9712 or ASP0485 or BG9273 or
BG9712 or ASP-0485 or BG-9273
or BG-9712 or Xanelim or Ritux-
imab or Rituxan or Daclizumab or
Zenapax or Oxeluma* or huMAb or
OX40L or RG 4930 or RO4989991 or
RG4930 or RG-4930 or RO 4989991
or RO-4989991 or Bertilimumab or
Tezepeluma or Isunakinra or "Fu-
sion Protein*" or cytokine*).ab,ti.
51 or/24-50
52 23 and 51
53 (random* or factorial* or
placebo* or assign* or allocat* or
crossover*).tw.
54 (control* adj group*).tw.
55 (trial* and (control* or compar-
ative)).tw.
56 ((blind* or mask*) and (single or
double or triple or treble)).tw.
57 (treatment adj arm*).tw.
58 (control* adj group*).tw.
59 (phase adj (III or three)).tw.
60 (versus or vs).tw.
61 rct.tw.
62 crossover procedure/
63 double blind procedure/
64 single blind procedure/
65 randomization/
66 placebo/
67 exp clinical trial/
68 parallel design/
69 Latin square design/
70 53 or 54 or 55 or 56 or 57 or 58
or 59 or 60 or 61 or 62 or 63 or 64 or
65 or 66 or 67 or 68 or 69
71 exp ANIMAL/ or exp NONHU-
MAN/ or exp ANIMAL EXPERIMENT/
or exp ANIMAL MODEL/
72 exp human/
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uximab or Rituxan or Daclizumab or
Zenapax or Oxeluma* or huMAb or
OX40L or RG 4930 or RO4989991 or
RG4930 or RG-4930 or RO 4989991 or
RO-4989991 or Bertilimumab or Teze-
peluma or Isunakinra or "Fusion Pro-
tein*" or cytokine*):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
55 (IL5 or IL4 or IL13 or IL1 or IL10 or
IL11 or IL12 or IL15 or IL15 or IL16 or
IL17 or IL18 or IL2 or IL23 or IL12 or
IL27 or IL3 or IL33 or IL6 or IL7 or IL8
or IL9 or IL22 or IL31):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
56 #29 OR #30 OR #31 OR #32 OR #33
OR #34 OR #35 OR #36 OR #37 OR #38
OR #39 OR #40 OR #41 OR #42 OR #43
OR #44 OR #45 OR #46 OR #47 OR #48
OR #49 OR #50 OR #51 OR #52 OR #53
OR #54 OR #55
57 #56 AND #28
53 SAR231893 or
reslizumab or siglec8 or
benralizumab or lebrik-
izumab or brodalumab
or Tralokinumab or Quil-
izumab or Ligelizumab or
Mogamulizumab or Efal-
izumab or Pitrakinra or
Odulimomab or Moga-
mulizumabor or BCGF or
binetrakin or "anti anti-
bod*" AND INREGISTER
54 (Canakinumab or
Ilaris or Rilonacept or
Arcalyst or Anakinra or
Kineret or Antril or Al-
trakincept or Nuvance
or Pascolizumab or SB
240683 or VAK694 or
QBX258 or VAK 694 or
VAK-694 or dectrekum-
ab QAX-576 or QAX576
or QAX 576 or aerovant
or AER-001 or AER001 or
"AER 001" or BAY-16-9996
or BAY 16-9996 or Bosa-
tria or Nucala or CDP 835
or CDP835 or CDP-835 or
CINQAIR or CTx55700 or
CTx 55700 or CTx-55700
or DCP 835 or DCP-835
or DCP835 or SCH5570
or SCH 5570 SCH-5570
or TRFK-5 or TRFK 5 or
TRFK5 or BIW-8405* or
BIW8405* or BIW 8405*
or KHK 4563 or KHK-4563
or KHK4563 or Enok-
izumab or 7F3com-2H2
or Ustekinumab or Ste-
lara or CNTO-1275 or CN-





679586 or IMA026 or
IMA-026 or "IMA 026"





301444 or RG-3637 or
RG3637 or RG 3637
or RO-5490255 or
RO5490255 or RO
5490255 or TNX-650 or
TNX650 or TNX 650 or
RPC-4046 or ABT-308
or TA650 or TA 650 or
Etanercept or Enbrel or
p75TNFR-Ig or rhu TN-
FR-Fc or TNFR-Fc-p75 or
TNR-001 or TNR001 or
"TNR 001" or AMG-157
or MEDI-9929 or AMG157
or AMG 157 MEDI4212 or
MEMP1972A or RG7449
or MEMP 1972A or RG
7449 or MEMP-1972A
or RG-7449 or Moga-
mulizumab or KM8761 or
Poteligeo or KM-8761 or
KM 8761 or Alefacept or
Amevive or "ASP 0485"
or BG 9273 or BG 9712 or
ASP0485 or BG9273 or
BG9712 or ASP-0485 or
BG-9273 or BG-9712 or
Xanelim or Rituximab or
Rituxan or Daclizumab
or Zenapax or Oxeluma*
or huMAb or OX40L or RG
4930 or RO4989991 or
RG4930 or RG-4930 or RO
4989991 or RO-4989991
or Bertilimumab or Teze-
peluma or Isunakinra or
"Fusion Protein*" or cy-
tokine*).ab,ti.
51 or/24-50
52 23 and 51
53 randomized con-
trolled trial.pt.








61 53 or 54 or 55 or 56 or
57 or 58 or 59 or 60
62 exp animals/ not hu-
mans.sh.
63 61 not 62
64 52 and 63
73 71 not 72
74 70 not 73
75 52 and 74
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or RPC4046 or ABT308
or RPC 4046 or ABT 308
or CAT-354 or CAT354
or CAT 354 or Secuk-
inumab or Cosentyx or
AIN-457 or KB-03303A or
NVP-AIN 457 or AIN457
or KB03303A or NVP-
AIN457 or AIN 457 or KB
03303A or NVP-AIN-457
or KHK-4827 or KHK4827
or KHK 4827 or fezak-
inumab * or ILV-094 or
PF-5212367 or ILV094
or PF5212367 or "ILV




ab or CIM331 or CIM 331
or CIM-331 or Lenzilum-
ab or KB003 or "KB 003"
or KB-003 or ABT-D2E7
or D2E7 or LU 200134 or
ABTD2E7 or LU200134 or
ABT D2E7 or LU 200134
or Golimumab or Sim-
poni or CNTO-148 or CN-
TO148 or CNTO 148 or In-
flixima or cA2 or CenTNF
or Remicade or TA-650
or TA650 or TA 650 or
Etanercept or Enbrel or
p75TNFR-Ig or rhu TN-
FR-Fc or TNFR-Fc-p75 or
TNR-001 or TNR001 or
"TNR 001" or AMG-157
or MEDI-9929 or AMG157
or AMG 157 MEDI4212 or
MEMP1972A or RG7449
or MEMP 1972A or RG
7449 or MEMP-1972A
or RG-7449 or Moga-
mulizumab or KM8761 or
Poteligeo or KM-8761 or
KM 8761 or Alefacept or
Amevive or "ASP 0485"
or BG 9273 or BG 9712 or
ASP0485 or BG9273 or
BG9712 or ASP-0485 or
BG-9273 or BG-9712 or
Xanelim or Rituximab or
Rituxan or Daclizumab
or Zenapax or Oxeluma*
or huMAb or OX40L or RG
4930 or RO4989991 or
RG4930 or RG-4930 or RO
4989991 or RO-4989991
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55 (IL5 or IL4 or IL13 or
IL1 or IL10 or IL11 or IL12
or IL15 or IL15 or IL16 or
IL17 or IL18 or IL2 or IL23
or IL12 or IL27 or IL3 or
IL33 or IL6 or IL7 or IL8 or
IL9 or IL22 or IL31):AB,E-
H,KW,KY,MC,MH,TI,TO
AND INREGISTER
56 #29 OR #30 OR #31 OR
#32 OR #33 OR #34 OR
#35 OR #36 OR #37 OR
#38 OR #39 OR #40 OR
#41 OR #42 OR #43 OR
#44 OR #45 OR #46 OR
#47 OR #48 OR #49 OR
#50 OR #51 OR #52 OR
#53 OR #54 OR #55 AND
INREGISTER
57 #56 AND #28 AND IN-
REGISTER
Web of Science (Web of Knowledge) ClinicalTrials.gov (via
clinicaltrials.gov)
ICTRP (via the WHO
platform)
ClinicalTrials.gov and ICTRP (via
CRS)
#1 TOPIC: (rhinosinusitis or nasosi-
nusitis or pansinusitis or ethmoiditis
or sphenoiditis)
Indexes=SCI-EXPANDED, CPCI-S, CCR-
EXPANDED, IC Timespan=All years
#2 TOPIC: (kartagener* NEAR/3 syn-
drome*)
Indexes=SCI-EXPANDED, CPCI-S, CCR-
EXPANDED, IC Timespan=All years
#3 TOPIC: (inflamm* NEAR/5 sinus*)
#4 TOPIC: ((maxilla* or frontal*)
NEAR/3 sinus*)
#5 #4 OR #3 OR #2 OR #1
#6 TOPIC: (chronic or persis* or re-
cur*)
#7 #6 AND #5
#8 TOPIC: (CRSsNP)
#9 TOPIC: ((sinusitis or rhinitis)
NEAR/3 (chronic or persis* or recur*))
Search 1
( rhinosinusitis OR CRS
OR CRSsNP OR CRSwNP
OR rhinopolypy) AND
( biologics OR biologic
OR biotherapy OR Inter-
leukins OR interleukin
OR IgE OR immunoglob-
ulin OR Antiglobulin OR
antiidiotype OR mAB OR
mepo OR "IL-4" OR "IL-5"
OR M1 OR "CCR4 LFA-1"
OR "IL-13" OR "IL-4α" OR
Dupilumab OR Reslizum-
ab OR Benralizumab OR
Mepolizumab OR Oma-
lizumab OR Quilizum-
ab OR Ligelizumab OR
Mogamulizumab OR Efal-
izumab OR AMG317 OR
Pitrakinra OR Lebrik-
izumab OR Tralokinum-
ab OR GATA-3 OR siglec
OR AK001 OR OX40L OR
TNF OR TSLP OR CSL311
OR "IL-3" OR GM-CSF





tis AND biotherap* OR
Rhinosinusitis AND Inter-
leukin* OR Rhinosinusitis
AND IgE OR Rhinosinusi-
tis AND immunoglobu-





AND mepo OR Rhinosi-





ab OR Rhinosinusitis AND
Mepolizumab OR Rhinos-
inusitis AND Omalizum-
ab OR Rhinosinusitis AND
Rhinosinusitis AND Quil-
izumab OR Rhinosinusitis




1 rhinosinusitis or nasosinusitis
or pansinusitis or ethmoiditis or
sphenoiditis AND CENTRAL:TAR-
GET
2 kartagener* near syndrome* AND
CENTRAL:TARGET
3 inflamm* and sinus AND CEN-
TRAL:TARGET
4 (maxilla* or frontal*) and sinus*
AND CENTRAL:TARGET
5 CRSsNP or sinusitis or rhinitis or
rhinopolyp* or CRSwNP AND CEN-
TRAL:TARGET
6 (nose or nasal or rhino* or rhini-
tis or sinus* or sinonasal) and
(papilloma* or polyp*) AND CEN-
TRAL:TARGET
7 #1 OR #2 OR #3 OR #4 OR #5 OR
#6 AND CENTRAL:TARGET
8 (Antibod* and monoclonal):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
9 (Interleukin* or IgE or im-
munoglobulin or Antiglobulin*
  (Continued)
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#10 TOPIC: ((nose or nasal or rhi-
no* or rhinitis or sinus* or sinonasal)
NEAR/3 (papilloma* or polyp*))
#11 TOPIC: (rhinopolyp* or CRSwNP)
#12 #11 OR #10 OR #9 OR #8 OR #7
#13 TOPIC: (Antibod* NEAR/3 mono-
clonal)
#14 TOPIC: (Interleukin* or IgE or "im-
munoglobulin E" or Antiglobulin* or
antiidiotyp*)
#15 TOPIC: (anti NEAR/3 (globulin*
or idiotyp* or immunoglobulin* or
M1 or CCR4 or "LFA 1" or "GATA 3" or
OX40L))
#16 TOPIC: (ralokimumab or Adal-
imumab or Alemtuzumab or Beva-
cizumab or Certolizumab or Cetux-
imab or Denosumab or Ipilimum-
ab or Natalizumab or Omalizum-
ab or Palivizumab or Ranibizumab
or Trastuzumab or stekinumab or
mepolizumab or Nucala or SB240563
or "SB 240563" or dupilumab or
REGN668 or AMG317 or "AMG 317" or
AMG827 or "AMG 827" or DNAzyme or
antiTSLP or CSL311 or "CSL 311" or
"AMG 761" or AMG761 or "AMG 837"
or KW0761 or "KW 0761" or "CSF 2" or
"CSF GM")
#17 TOPIC: (siliq or D2E7 or humira
or campath or Lemtrada or avastin
or cimzia or CDP870 or "CDP 870" or
Erbitux or C225 or Xgeva or prolia or
"AMG 162" or AMG162 or Yervoy or
Tysabri or Antegren or Xolair or Sy-
nagis or RhuFab or lucentis or Her-
ceptin or stelara or CNTO or ASM8 or
granulocyte-macrophage or GM-CSF
or QGE031 or Raptiva or AK001 or "AK
001")
#18 TOPIC: ((B-cell or T-cell or
Eosinophil or "mast cell" or stimulat-
ing) NEAR/3 factor)
#19 TOPIC: (CD23 or CD2 or CD11a or
CD20 or CD25 opr CD252 or (recep-
tor* NEAR/3 apsilon))
#20 TOPIC: (CD NEAR/3 ("23" or anti-
gen* or "2" or 11a or "20" or "25" or
"252"))
#21 TOPIC: ((antigamma or "anti
gamma") NEAR/3 Antibod*)
#22 TOPIC: (IgEid or "55700" or
SCH55700 or CEP38072 or "CEP
38072" or cinqair or DCP835 or "DCP
OR monoclonal AND anti-
bodies )
Search 2
( rhinitis OR sinusitis )
AND ( recurrence OR
recurrent OR chronic
OR persistant OR per-
sistance ) AND ( biolog-
ics OR biologic OR bio-
therapy OR Interleukins
OR interleukin OR IgE
OR immunoglobulin OR
Antiglobulin OR antiidio-
type OR mAB OR mepo
OR "IL-4" OR "IL-5" OR
M1 OR "CCR4 LFA-1" OR
"IL-13" OR "IL-4α" OR
Dupilumab OR Reslizum-
ab OR Benralizumab OR
Mepolizumab OR Oma-
lizumab OR Quilizum-
ab OR Ligelizumab OR
Mogamulizumab OR Efal-
izumab OR AMG317 OR
Pitrakinra OR Lebrik-
izumab OR Tralokinum-
ab OR GATA-3 OR siglec
OR AK001 OR OX40L OR
TNF OR TSLP OR CSL311
OR "IL-3" OR GM-CSF
OR "IL-25" OR "IL-5" OR
granulocyte-macrophage
OR monoclonal AND anti-
bodies )
Search 3
( nose OR nasal OR si-
nus OR sinonasal ) AND
( polyp OR polyps ) AND
( biologics OR biologic
OR biotherapy OR Inter-
leukins OR interleukin
OR IgE OR immunoglob-
ulin OR Antiglobulin OR
antiidiotype OR mAB OR
mepo OR "IL-4" OR "IL-5"
OR M1 OR "CCR4 LFA-1"
OR "IL-13" OR "IL-4α" OR
Dupilumab OR Reslizum-
ab OR Benralizumab OR
Mepolizumab OR Oma-
lizumab OR Quilizum-
ab OR Ligelizumab OR
Mogamulizumab OR Efal-
izumab OR AMG317 OR
Pitrakinra OR Lebrik-
izumab OR Tralokinum-
ab OR GATA-3 OR siglec
OR AK001 OR OX40L OR




ab OR Rhinosinusitis AND
Tralokinumab OR Rhi-





ic AND Biologic* OR Si-
nusitis AND chronic AND
biotherap* OR Sinusi-
tis AND chronic AND In-
terleukin* OR Sinusitis
AND chronic AND IgE OR
Sinusitis AND chronic
AND immunoglobulin
OR Sinusitis AND chron-
ic AND Antiglobulin OR
Sinusitis AND chronic
AND antiidiotype OR Si-
nusitis AND chronic AND
mAB OR Sinusitis AND
chronic AND mepo OR
Sinusitis AND chronic
AND IL OR Sinusitis AND
chronic AND Dupilumab
OR Sinusitis AND chron-




AND Mepolizumab OR Si-
nusitis AND chronic AND
Omalizumab OR Sinusitis
AND chronic AND Sinusi-
tis AND chronic AND Quil-
izumab OR Sinusitis AND
chronic AND Ligelizumab
OR Sinusitis AND chron-
ic AND Mogamulizumab
OR Sinusitis AND chron-
ic AND Efalizumab OR
Sinusitis AND chronic
AND Pitrakinra OR Sinusi-
tis AND chronic AND Le-
brikizumab OR Sinusitis
AND chronic AND Tralok-
inumab OR Sinusitis AND
chronic AND siglec OR Si-
nusitis AND chronic AND
monoclonal AND anti-






10 (anti adj3 (globulin* or id-
iotyp* or immunoglobulin* or
M1 or CCR4 or "LFA 1" or "GATA
3" or OX40L)):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
11 (ralokimumab or Adalimumab
or Alemtuzumab or Bevacizum-
ab or Certolizumab or Cetuximab
or Denosumab or Ipilimumab
or Natalizumab or Omalizum-
ab or Palivizumab or Ranibizum-
ab or Trastuzumab or stekinum-
ab or mepolizumab or Nucala
or SB240563 or "SB 240563" or
dupilumab or REGN668 or AMG317
or "AMG 317" or AMG827 or "AMG
827" or DNAzyme or antiTSLP
or CSL311 or "CSL 311" or "AMG
761" or AMG761 or "AMG 837" or
KW0761 or "KW 0761" or "CSF 2"
or "CSF GM"):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
12 (siliq or D2E7 or humira or cam-
path or Lemtrada or avastin or
cimzia or CDP870 or "CDP 870" or
Erbitux or C225 or Xgeva or prolia
or "AMG 162" or AMG162 or Yervoy
or Tysabri or Antegren or Xolair or
Synagis or RhuFab or lucentis or
Herceptin or stelara or CNTO or
ASM8 or granulocyte-macrophage
or GM-CSF or QGE031 or Rapti-
va or AK001 or "AK 001"):AB,E-
H,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
13 ((B-cell or T-cell or Eosinophil
or "mast cell" or stimulating) adj3
factor):AB,EH,KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
14 (CD23 or CD2 or CD11a or CD20
or CD25 opr CD252 or (receptor*
adj3 apsilon)):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
15 (CD adj3 ("23" or antigen*
or "2" or 11a or "20" or "25" or
"252")):AB,EH,KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
16 ((antigamma or "anti gamma")
and Antibod*):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
17 (IgEid or "55700" or SCH55700
or CEP38072 or "CEP 38072" or
  (Continued)
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835" or GM-CSF or TNF or TSLP or
OX40L)
#23 TOPIC: (IL NEAR/3 ("5" or five or
"4" or four or "13" or thirteen or "1"
or one or "10" or ten or "11" or eleven
or "12" or twelve or "15" or fifteen
or "16" or sixteen or "17" or seven-
teen or "18" or eighteen or "2" or two
or "23" or "twenty three" or "12" or
twelve or "27" or "twenty seven" or
"3" or three or "33" or "thirty three"
or "6" or six or "7" or seven or "8" or
eight or "9" or nine or 1R1 or 12p40
or IL-23p40 or 17A or 17RA or "22" or
"twenty two" or "31" or "thirty one"
or 31R))
#24 TOPIC: (IL5 or IL4 or IL13 or IL1 or
IL10 or IL11 or IL12 or IL15 or IL15 or
IL16 or IL17 or IL18 or IL2 or IL23 or
IL12 or IL27 or IL3 or IL33 or IL6 or IL7
or IL8 or IL9 or IL22 or IL31 or "IL 4R*"
or "IL 5R*")
#25 TOPIC: (biologic or biologics or
biotherap*)
#26 TOPIC: (biologic* NEAR/3 ther-
ap*)
#27 TOPIC: (mAB or mepo or MDX or
MEDI or siglec* or "lectin 8")
#28 TOPIC: (SAR231893 or reslizum-
ab or siglec8 or benralizumab or le-
brikizumab or brodalumab or Tralok-
inumab or Quilizumab or Ligelizumab
or Mogamulizumab or Efalizumab or
Pitrakinra or Odulimomab or Moga-
mulizumabor or BCGF or binetrakin
or "anti antibod*")
#29 TOPIC: (Canakinumab or Ilaris
or Rilonacept or Arcalyst or Anakin-
ra or Kineret or Antril or Altrakin-
cept or Nuvance or Pascolizumab or
SB 240683 or VAK694 or QBX258 or
VAK 694 or VAK-694 or dectrekum-
ab QAX-576 or QAX576 or QAX 576
or aerovant or AER-001 or AER001
or "AER 001" or BAY-16-9996 or
BAY 16-9996 or Bosatria or Nucala
or CDP 835 or CDP835 or CDP-835
or CINQAIR or CTx55700 or CTx
55700 or CTx-55700 or DCP 835 or
DCP-835 or DCP835 or SCH5570 or
SCH 5570 SCH-5570 or TRFK-5 or
TRFK 5 or TRFK5 or BIW-8405* or
BIW8405* or BIW 8405* or KHK 4563
or KHK-4563 or KHK4563 or Enok-
izumab or 7F3com-2H2 or Ustek-
OR "IL-3" OR GM-CSF
OR "IL-25" OR "IL-5" OR
granulocyte-macrophage
OR monoclonal AND anti-
bodies )
Nasal AND polyp* AND
Biologic* OR Nasal AND
polyp* AND biotherap*
OR Nasal AND polyp*
AND Interleukin* OR
Nasal AND polyp* AND
IgE OR Nasal AND polyp*
AND immunoglobulin
OR Nasal AND polyp*
AND Antiglobulin OR
Nasal AND polyp* AND
antiidiotype OR Nasal
AND polyp* AND mAB
OR Nasal AND polyp*
AND mepo OR Nasal
AND polyp* AND IL OR
Nasal AND polyp* AND
Dupilumab OR Nasal AND
polyp* AND Reslizum-
ab OR Nasal AND polyp*
AND Benralizumab OR
Nasal AND polyp* AND
Mepolizumab OR Nasal
AND polyp* AND Oma-
lizumab OR Nasal AND
polyp* AND Nasal AND
polyp* AND Quilizum-
ab OR Nasal AND polyp*
AND Ligelizumab OR
Nasal AND polyp* AND
Mogamulizumab OR
Nasal AND polyp* AND
Efalizumab OR Nasal
AND polyp* AND Pitrakin-
ra OR Nasal AND polyp*
AND Lebrikizumab OR
Nasal AND polyp* AND
Tralokinumab OR Nasal
AND polyp* AND siglec
OR Nasal AND polyp*




AND Biologic* OR Rhini-
tis AND chronic AND bio-
therap* OR Rhinitis AND
chronic AND Interleukin*
OR Rhinitis AND chron-
ic AND IgE OR Rhinitis
AND chronic AND im-
munoglobulin OR Rhini-
tis AND chronic AND
Antiglobulin OR Rhini-
tis AND chronic AND an-
tiidiotype OR Rhinitis
AND chronic AND mAB
OR Rhinitis AND chron-
ic AND mepo OR Rhini-
tis AND chronic AND IL
cinqair or DCP835 or "DCP 835"
or GM-CSF or TNF or TSLP or
OX40L):AB,EH,KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
18 (IL adj3 ("5" or five or "4" or four
or "13" or thirteen or "1" or one
or "10" or ten or "11" or eleven or
"12" or twelve or "15" or fifteen or
"16" or sixteen or "17" or seven-
teen or "18" or eighteen or "2" or
two or "23" or "twenty three" or
"12" or twelve or "27" or "twenty
seven" or "3" or three or "33" or
"thirty three" or "6" or six or "7"
or seven or "8" or eight or "9" or
nine or 5R* or 1R1 or 4R* or 12p40
or IL-23p40 or 17A or 17RA or "22"
or "twenty two" or "31" or "thir-
ty one" or 31R)):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET
19 (biologic or biologics or biother-
ap*):AB,EH,KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
20 biologic* adj3 therap* AND
CENTRAL:TARGET
21 (mAB or mepo or MDX or MEDI
or siglec* or "lectin 8"):AB,EH,K-
W,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
22 SAR231893 or reslizumab or
siglec8 or benralizumab or le-
brikizumab or brodalumab or
Tralokinumab or Quilizumab or
Ligelizumab or Mogamulizum-
ab or Efalizumab or Pitrakinra or
Odulimomab or Mogamulizuma-
bor or BCGF or binetrakin or "anti
antibod*" AND CENTRAL:TARGET
23 (Canakinumab or Ilaris or
Rilonacept or Arcalyst or Anakinra
or Kineret or Antril or Altrakincept
or Nuvance or Pascolizumab or SB
240683 or VAK694 or QBX258 or
VAK 694 or VAK-694 or dectrekum-
ab QAX-576 or QAX576 or QAX 576
or aerovant or AER-001 or AER001
or "AER 001" or BAY-16-9996 or BAY
16-9996 or Bosatria or Nucala or
CDP 835 or CDP835 or CDP-835
or CINQAIR or CTx55700 or CTx
55700 or CTx-55700 or DCP 835 or
DCP-835 or DCP835 or SCH5570
or SCH 5570 SCH-5570 or TRFK-5
or TRFK 5 or TRFK5 or BIW-8405*
or BIW8405* or BIW 8405* or KHK
4563 or KHK-4563 or KHK4563 or
  (Continued)
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inumab or Stelara or CNTO-1275 or
CNTO1275 or CNTO 1275 or Anruk-
inzuma* or IMA-638 or PF-05230917
or GSK679586 or GSK-679586 or
GDK 679586 or IMA026 or IMA-026 or
"IMA 026" or IMA638 or IMA 638 MIL-
R1444A or MILR 1444A or MILR-1444A
or PRO-301444 or PRO301444 or PRO
301444 or RG-3637 or RG3637 or RG
3637 or RO-5490255 or RO5490255
or RO 5490255 or TNX-650 or TNX650
or TNX 650 or RPC-4046 or ABT-308
or RPC4046 or ABT308 or RPC 4046
or ABT 308 or CAT-354 or CAT354 or
CAT 354 or Secukinumab or Cosentyx
or AIN-457 or KB-03303A or NVP-AIN
457 or AIN457 or KB03303A or NVP-
AIN457 or AIN 457 or KB 03303A or
NVP-AIN-457 or KHK-4827 or KHK4827
or KHK 4827 or fezakinumab * or
ILV-094 or PF-5212367 or ILV094 or
PF5212367 or "ILV 094" or PF 5212367
or BMS-981164 or BMS981164 or BMS
981164 or Nemolizumab or CIM331
or CIM 331 or CIM-331 or Lenzilum-
ab or KB003 or "KB 003" or KB-003
or ABT-D2E7 or D2E7 or LU 200134 or
ABTD2E7 or LU200134 or ABT D2E7
or LU 200134 or Golimumab or Sim-
poni or CNTO-148 or CNTO148 or CN-
TO 148 or Inflixima or cA2 or CenT-
NF or Remicade or TA-650 or TA650
or TA 650 or Etanercept or Enbrel or
p75TNFR-Ig or rhu TNFR-Fc or TN-
FR-Fc-p75 or TNR-001 or TNR001 or
"TNR 001" or AMG-157 or MEDI-9929
or AMG157 or AMG 157 MEDI4212
or MEMP1972A or RG7449 or MEMP
1972A or RG 7449 or MEMP-1972A
or RG-7449 or Mogamulizumab or
KM8761 or Poteligeo or KM-8761 or
KM 8761 or Alefacept or Amevive or
"ASP 0485" or BG 9273 or BG 9712
or ASP0485 or BG9273 or BG9712 or
ASP-0485 or BG-9273 or BG-9712 or
Xanelim or Rituximab or Rituxan or
Daclizumab or Zenapax or Oxeluma*
or huMAb or OX40L or RG 4930 or
RO4989991 or RG4930 or RG-4930 or
RO 4989991 or RO-4989991 or Bertili-
mumab or Tezepeluma or Isunakinra
or "Fusion Protein*" or cytokine*)
#30 #29 OR #28 OR #27 OR #26 OR #25
OR #24 OR #23 OR #22 OR #21 OR #20
OR #19 OR #18 OR #17 OR #16 OR #15
OR #14 OR #13
#31 #30 AND #12
OR Rhinitis AND chron-
ic AND Dupilumab OR
Rhinitis AND chronic AND
Reslizumab OR Rhini-
tis AND chronic AND
Benralizumab OR Rhini-
tis AND chronic AND
Mepolizumab OR Rhinitis
AND chronic AND Omal-
izumab OR Rhinitis AND
chronic AND Rhinitis
AND chronic AND Quil-
izumab OR Rhinitis AND
chronic AND Ligelizumab
OR Rhinitis AND chron-
ic AND Mogamulizumab
OR Rhinitis AND chron-
ic AND Efalizumab OR
Rhinitis AND chronic
AND Pitrakinra OR Rhini-
tis AND chronic AND Le-
brikizumab OR Rhinitis
AND chronic AND Tralok-
inumab OR Rhinitis AND
chronic AND siglec OR
Rhinitis AND chronic AND
monoclonal AND anti-
bod*
Enokizumab or 7F3com-2H2 or
Ustekinumab or Stelara or CN-
TO-1275 or CNTO1275 or CNTO
1275 or Anrukinzuma* or IMA-638
or PF-05230917 or GSK679586
or GSK-679586 or GDK 679586 or
IMA026 or IMA-026 or "IMA 026"
or IMA638 or IMA 638 MILR1444A
or MILR 1444A or MILR-1444A
or PRO-301444 or PRO301444
or PRO 301444 or RG-3637 or
RG3637 or RG 3637 or RO-5490255
or RO5490255 or RO 5490255 or
TNX-650 or TNX650 or TNX 650 or
RPC-4046 or ABT-308 or RPC4046
or ABT308 or RPC 4046 or ABT 308
or CAT-354 or CAT354 or CAT 354
or Secukinumab or Cosentyx or
AIN-457 or KB-03303A or NVP-AIN
457 or AIN457 or KB03303A or NVP-
AIN457 or AIN 457 or KB 03303A
or NVP-AIN-457 or KHK-4827 or
KHK4827 or KHK 4827 or fezak-
inumab * or ILV-094 or PF-5212367
or ILV094 or PF5212367 or "ILV
094" or PF 5212367 or BMS-981164
or BMS981164 or BMS 981164 or
Nemolizumab or CIM331 or CIM
331 or CIM-331 or Lenzilumab or
KB003 or "KB 003" or KB-003 or
ABT-D2E7 or D2E7 or LU 200134
or ABTD2E7 or LU200134 or ABT
D2E7 or LU 200134 or Golimum-
ab or Simponi or CNTO-148 or CN-
TO148 or CNTO 148 or Inflixima
or cA2 or CenTNF or Remicade
or TA-650 or TA650 or TA 650 or
Etanercept or Enbrel or p75TN-
FR-Ig or rhu TNFR-Fc or TNFR-Fc-
p75 or TNR-001 or TNR001 or "TNR
001" or AMG-157 or MEDI-9929 or
AMG157 or AMG 157 MEDI4212 or
MEMP1972A or RG7449 or MEMP
1972A or RG 7449 or MEMP-1972A
or RG-7449 or Mogamulizumab or
KM8761 or Poteligeo or KM-8761 or
KM 8761 or Alefacept or Amevive
or "ASP 0485" or BG 9273 or BG
9712 or ASP0485 or BG9273 or
BG9712 or ASP-0485 or BG-9273
or BG-9712 or Xanelim or Ritux-
imab or Rituxan or Daclizumab or
Zenapax or Oxeluma* or huMAb or
OX40L or RG 4930 or RO4989991 or
RG4930 or RG-4930 or RO 4989991
or RO-4989991 or Bertilimumab or
Tezepeluma or Isunakinra or "Fu-
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#32 TOPIC: ((randomised OR random-
ized OR randomisation OR randomi-
sation OR placebo* OR (random*
AND (allocat* OR assign*)) OR (blind*
AND (single OR double OR treble OR
triple))))
#33 #32 AND #31
24 (IL5 or IL4 or IL13 or IL1 or IL10
or IL11 or IL12 or IL15 or IL15 or
IL16 or IL17 or IL18 or IL2 or IL23
or IL12 or IL27 or IL3 or IL33 or
IL6 or IL7 or IL8 or IL9 or IL22 or
IL31):AB,EH,KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
25 #24 OR #23 OR #22 OR #21 OR
#20 OR #19 OR #18 OR #17 OR #16
OR #15 OR #14 OR #13 OR #12 OR
#11 OR #10 OR #9 OR #8
26 #25 AND #7
27 nct:AU OR http*:SO AND CEN-
TRAL:TARGET
28 #26 AND #27
  (Continued)
 
Appendix 2. Data extraction form
 
REF ID: Study title:








Flow chart of trial




No. of people screened    
No. of participants randomised - all    
No. randomised to each group    
No. receiving treatment as allocated    




No. dropped out    
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(no follow-up data for any outcome available)




Number analysed    
1This should be the people who received the treatment and were therefore not considered 'dropouts' but were excluded from all




Information to go into 'Characteristics of included studies' table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/cross-over/cluster-RCT, with x du-
ration of treatment and x duration of follow-up
Participants Location: country, no of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison




• Main diagnosis: [as stated in paper]
• Polyps status: x % with polyps/no information [add info on mean polyps score if available]
• Previous sinus surgery status: [x% with previous surgery]
• Previous courses of steroids: [add info on mean number of courses if available
Other important effect modifiers, if applicable (e.g. aspirin sensitivity, comorbidities of asthma):
Inclusion criteria: [state diagnostic criteria used for CRS, polyps score if available]
Exclusion criteria:
Interventions Intervention (n = x): drug name, method of administration, dose per day/frequency of administra-
tion, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment arms):
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific
• Disease severity symptom score
• Significant adverse effects: local reaction at the injection site, including swelling, redness
Secondary outcomes:
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• Health-related quality of life, generic
• Nasopharyngitis, including sore throat
• Endoscopy (polyps size or overall score)
• CT scan
Funding sources 'No information provided'/'None declared'/State source of funding





Bias (ROB 1.0) Authors' judge-
ment
Support for judgement
Random sequence generation (selection bias)   Quote: "…"
Comment:
Allocation concealment (selection bias)   Quote: "…"
Comment:
Blinding of participants and personnel (performance bias)   Quote: "…"
Comment:
Blinding of outcome assessment (detection bias)   Quote: "…"
Comment:
Incomplete outcome data (attrition bias)   Quote: "…"
Comment:
Selective reporting (reporting bias)   Quote: "…"
Comment:
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Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other sum-
mary stats/
Notes















             
Added total - if scores reported separately for each symptom
(range)
Time point:
             
Nasal blockage/obstruction/congestion
(instrument name/range)
             
Nasal discharge
(instrument name/range)
             




























































































































             
Headache
(instrument name/range)
             
Cough (in children)
(instrument name/range)
             
               
Endoscopy score (nasal polyp size score or Lund Kennedy)
(instrument name/range)
             
CT score
(instrument name/range)
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Results (dichotomous data table)
















P values, RR (95% CI),
OR (95% CI)
Local reaction at the injection site, including
swelling, redness
         




Appendix 3. Search strategies for Clinical Study Reports
 
EUCTR Novartis (searched via Google) GlaxoSmithKlein (searched
via Google)
Other
( rhinosinusitis OR CRS OR CRSs-
NP OR CRSwNP OR rhinopolypy)
AND ( biologics OR biologic OR
biotherapy OR Interleukins OR in-
terleukin OR IgE OR immunoglob-
ulin OR Antiglobulin OR anti-
idiotype OR mAB OR mepo OR
"IL-4" OR "IL-5" OR M1 OR "CCR4
LFA-1" OR "IL-13" OR "IL-4α" OR
Dupilumab OR Reslizumab OR
Benralizumab OR Mepolizumab
OR Omalizumab OR Quilizum-
ab OR Ligelizumab OR Moga-
mulizumab OR Efalizumab OR
AMG317 OR Pitrakinra OR Le-
brikizumab OR Tralokinumab
OR GATA-3 OR siglec OR AK001
OR OX40L OR TNF OR TSLP OR
CSL311 OR "IL-3" OR GM-CSF OR
"IL-25" OR "IL-5" OR granulo-
cyte-macrophage OR "monoclon-
al antibodies" )
( rhinitis OR sinusitis ) AND ( re-
currence OR recurrent OR chron-
ic OR persistant OR persistance )
AND ( biologics OR biologic OR
biotherapy OR Interleukins OR in-
terleukin OR IgE OR immunoglob-
ulin OR Antiglobulin OR anti-
idiotype OR mAB OR mepo OR
"IL-4" OR "IL-5" OR M1 OR "CCR4
site:novctrd.com ( rhinosinusitis OR CRS
OR CRSsNP OR CRSwNP OR rhinopolypy)
( biologics OR biologic OR biotherapy OR
Interleukins OR interleukin OR IgE OR im-
munoglobulin OR Antiglobulin OR anti-
idiotype OR mAB OR mepo OR "IL-4" OR
"IL-5" OR M1 OR "CCR4 LFA-1" OR "IL-13" OR
"IL-4α" OR Dupilumab OR Reslizumab OR
Benralizumab OR Mepolizumab)
site:novctrd.com ( rhinosinusitis OR CRS OR
CRSsNP OR CRSwNP OR rhinopolypy) (Oma-
lizumab OR Quilizumab OR Ligelizumab OR
Mogamulizumab OR Efalizumab OR AMG317
OR Pitrakinra OR Lebrikizumab OR Tralok-
inumab OR GATA-3 OR siglec OR AK001 OR
OX40L OR TNF OR TSLP OR CSL311 OR "IL-3"
OR GM-CSF OR "IL-25" OR "IL-5" OR granulo-
cyte-macrophage)
site:novctrd.com ( rhinosinusitis OR CRS OR
CRSsNP OR CRSwNP OR rhinopolypy) (mon-
oclonal AND antibodies)
site:novctrd.com ( rhinitis OR sinusitis ) ( re-
currence OR recurrent OR chronic OR per-
sistant OR persistance) ( biologics OR bio-
logic OR biotherapy OR Interleukins OR in-
terleukin OR IgE OR immunoglobulin OR
Antiglobulin OR antiidiotype OR mAB OR
mepo OR "IL-4" OR "IL-5" OR M1 OR "CCR4
LFA-1" OR "IL-13" OR "IL-4α" OR Dupilumab
OR Reslizumab)
site:gsk-studyregister.com ( rhi-
nosinusitis OR CRS OR CRSsNP
OR CRSwNP OR rhinopolypy)
( biologics OR biologic OR
biotherapy OR Interleukins
OR interleukin OR IgE OR im-
munoglobulin OR Antiglobu-
lin OR antiidiotype OR mAB OR
mepo OR "IL-4" OR "IL-5" OR
M1 OR "CCR4 LFA-1" OR "IL-13"




nosinusitis OR CRS OR CRSsNP
OR CRSwNP OR rhinopolypy)
(Omalizumab OR Quilizum-
ab OR Ligelizumab OR Moga-
mulizumab OR Efalizumab OR
AMG317 OR Pitrakinra OR Le-
brikizumab OR Tralokinumab
OR GATA-3 OR siglec OR AK001
OR OX40L OR TNF OR TSLP OR
CSL311 OR "IL-3" OR GM-CSF OR
"IL-25" OR "IL-5" OR granulo-
cyte-macrophage)
site:gsk-studyregister.com ( rhi-
nosinusitis OR CRS OR CRSsNP

















• EMA - ap-
prove
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LFA-1" OR "IL-13" OR "IL-4α" OR
Dupilumab OR Reslizumab OR
Benralizumab OR Mepolizumab
OR Omalizumab OR Quilizum-
ab OR Ligelizumab OR Moga-
mulizumab OR Efalizumab OR
AMG317 OR Pitrakinra OR Le-
brikizumab OR Tralokinumab
OR GATA-3 OR siglec OR AK001
OR OX40L OR TNF OR TSLP OR
CSL311 OR "IL-3" OR GM-CSF OR
"IL-25" OR "IL-5" OR granulo-
cyte-macrophage OR "monoclon-
al antibodies" )
( nose OR nasal OR sinus OR
sinonasal ) AND ( polyp OR
polyps ) AND ( biologics OR bi-
ologic OR biotherapy OR Inter-
leukins OR interleukin OR IgE OR
immunoglobulin OR Antiglob-
ulin OR antiidiotype OR mAB
OR mepo OR "IL-4" OR "IL-5" OR
M1 OR "CCR4 LFA-1" OR "IL-13"
OR "IL-4α" OR Dupilumab OR
Reslizumab OR Benralizumab
OR Mepolizumab OR Omalizum-
ab OR Quilizumab OR Ligelizum-
ab OR Mogamulizumab OR Efal-
izumab OR AMG317 OR Pitrakin-
ra OR Lebrikizumab OR Tralok-
inumab OR GATA-3 OR siglec OR
AK001 OR OX40L OR TNF OR TSLP
OR CSL311 OR "IL-3" OR GM-CSF
OR "IL-25" OR "IL-5" OR granulo-
cyte-macrophage OR "monoclon-
al antibodies" )
site:novctrd.com ( rhinitis OR sinusitis ) ( re-
currence OR recurrent OR chronic OR persis-
tant OR persistance) (Omalizumab OR Quil-
izumab OR Ligelizumab OR Mogamulizum-
ab OR Efalizumab OR AMG317 OR Pitrakinra
OR Lebrikizumab OR Tralokinumab OR GA-
TA-3 OR siglec OR AK001 OR OX40L OR TNF
OR TSLP OR CSL311 OR "IL-3" OR GM-CSF OR
"IL-25")
site:novctrd.com ( rhinitis OR sinusitis ) ( re-
currence OR recurrent OR chronic OR per-
sistant OR persistance) (Benralizumab OR
Mepolizumab OR granulocyte-macrophage
OR "IL-5" OR (monoclonal AND antibodies)
site:novctrd.com ( nose OR nasal OR si-
nus OR sinonasal ) ( polyp OR polyps) (Ben-
ralizumab OR Mepolizumab OR granulo-
cyte-macrophage OR "IL-5" OR (monoclonal
AND antibodies)
site:novctrd.com ( nose OR nasal OR sinus
OR sinonasal ) ( polyp OR polyps) ( biologics
OR biologic OR biotherapy OR Interleukins
OR interleukin OR IgE OR immunoglobulin
OR Antiglobulin OR antiidiotype OR mAB OR
mepo OR "IL-4" OR "IL-5" OR M1 OR "CCR4
LFA-1" OR "IL-13" OR "IL-4α" OR Dupilumab
OR Reslizumab)
site:novctrd.com ( nose OR nasal OR sinus
OR sinonasal ) ( polyp OR polyps) (O1mal-
izumab OR Quilizumab OR Ligelizumab OR
Mogamulizumab OR Efalizumab OR AMG317
OR Pitrakinra OR Lebrikizumab OR Tralok-
inumab OR GATA-3 OR siglec OR AK001 OR
OX40L OR TNF OR TSLP OR CSL311 OR "IL-3"
OR GM-CSF OR "IL-25")
site:gsk-studyregister.com
( rhinitis OR sinusitis ) ( recur-
rence OR recurrent OR chron-
ic OR persistant OR persis-
tance) ( biologics OR biologic
OR biotherapy OR Interleukins
OR interleukin OR IgE OR im-
munoglobulin OR Antiglobu-
lin OR antiidiotype OR mAB OR
mepo OR "IL-4" OR "IL-5" OR
M1 OR "CCR4 LFA-1" OR "IL-13"
OR "IL-4α" OR Dupilumab OR
Reslizumab)
site:gsk-studyregister.com
( rhinitis OR sinusitis ) ( recur-
rence OR recurrent OR chronic
OR persistant OR persistance)
(Omalizumab OR Quilizum-
ab OR Ligelizumab OR Moga-
mulizumab OR Efalizumab OR
AMG317 OR Pitrakinra OR Le-
brikizumab OR Tralokinumab
OR GATA-3 OR siglec OR AK001
OR OX40L OR TNF OR TSLP OR
CSL311 OR "IL-3" OR GM-CSF OR
"IL-25")
site:gsk-studyregister.com
( rhinitis OR sinusitis ) ( recur-
rence OR recurrent OR chronic
OR persistant OR persistance)
(Benralizumab OR Mepolizumab
OR granulocyte-macrophage OR
"IL-5" OR (monoclonal AND anti-
bodies)
site:gsk-studyregister.com
( nose OR nasal OR sinus OR
sinonasal ) ( polyp OR polyps)
(Benralizumab OR Mepolizumab
OR granulocyte-macrophage OR
"IL-5" OR (monoclonal AND anti-
bodies)
site:gsk-studyregister.com
( nose OR nasal OR sinus OR
sinonasal ) ( polyp OR polyps)
( biologics OR biologic OR
biotherapy OR Interleukins
OR interleukin OR IgE OR im-
munoglobulin OR Antiglobu-
lin OR antiidiotype OR mAB OR
mepo OR "IL-4" OR "IL-5" OR
M1 OR "CCR4 LFA-1" OR "IL-13"
OR "IL-4α" OR Dupilumab OR
Reslizumab)
site:gsk-studyregister.com
( nose OR nasal OR sinus OR
sinonasal ) ( polyp OR polyps)
(O1malizumab OR Quilizum-
  (Continued)
Biologics for chronic rhinosinusitis (Review)









Cochrane Database of Systematic Reviews
ab OR Ligelizumab OR Moga-
mulizumab OR Efalizumab OR
AMG317 OR Pitrakinra OR Le-
brikizumab OR Tralokinumab
OR GATA-3 OR siglec OR AK001
OR OX40L OR TNF OR TSLP OR




Appendix 4. Responses to requests for data
Email from Kyowa Kirin RE: NCT02772419 (8 January 2020)
Dear Ms. Cox,
Thank you for your prompt reply.
Unfortunately, we cannot share the study date of KHK4563-005 with you.
As AstraZeneca now has global rights to Benralizumab for all current and future indication, Kyowa Kirin cannot provide study data without
AstraZeneca’s permission.
Please refer our Press Release on Mar. 25, 2019.
https://www.kyowakirin.com/media_center/news_releases/2019/e20190325_01.html
We appreciate it if you could wait for our paper to be published.
Best regards,
Kyowa Kirin Co., Ltd.
C O N T R I B U T I O N S   O F   A U T H O R S
Lee-Yee Chong: scoped the review, and designed and wrote the protocol. Screened the search results and selected studies, carried out
statistical analyses, and reviewed and edited the text of the review.
Patorn Piromchai: commented on the draO protocol and agreed the final version. Screened the search results and selected studies, carried
out data checking of statistical analysis, reviewed the analyses of results and provided clinical guidance at all stages of the review, reviewed
and edited the text of the review.
Steve Sharp: advised on the search strategy, commented on the draO protocol and agreed the final version. Screened the search results
and selected studies. Carried out tasks related to searching for other resources.
Kornkiat Snidvongs: commented on the draO protocol and agreed the final version. Selected studies, reviewed the analyses and reviewed
and edited the text of the review.
Carl Philpott: clinical guidance at all stages of the review; reviewed the analyses and reviewed and edited the text of the review.
Claire Hopkins: clinical guidance at all stages of the review; reviewed the analyses and reviewed and edited the text of the review.
Martin J Burton: clinical guidance at all stages of the review; screened the search results and selected studies, carried out data extraction,
reviewed the analyses, wrote, reviewed and edited the text of the review.
D E C L A R A T I O N S   O F   I N T E R E S T
Lee-Yee Chong: none known.
Patorn Piromchai: none known.
Steve Sharp: Steve Sharp's employer, the National Institute for Health and Care Excellence (NICE), has produced guidance on related topics
such as sinusitis, which he has not contributed to.
Kornkiat Snidvongs: none known.
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Carl Philpott: Carl Philpott has previously received consultancy fees for Acclarent, Navigant, Aerin Medical and Entellus, and is a trustee of
the patient charity FiOh Sense. He is an investigator on a clinical trial that may be included in this review, but will have no role in the data
extraction, risk of bias assessment or data analysis for this study.
Claire Hopkins: Claire Hopkins has participated in advisory boards for Olympus, Chordate, Smith & Nephew and Sanofi to provide expertise
with regards to study design and outcome assessment, and interpretation of trial data. She is an investigator on a clinical trial that is
included in this review, but had no role in the data extraction, risk of bias assessment or data analysis for this study (LIBERTY SINUS 24;
LIBERTY SINUS 52).
Martin J Burton: Professor Martin Burton is joint Co-ordinating Editor of Cochrane ENT, but had no role in the editorial process for this
review.
S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
Infrastructure funding for Cochrane ENT
• National Institute for Health Research, UK.
Cochrane-NIHR Incentive Award 2019
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
As planned we identified completed trials that have not been published, but we did not contact the principal investigator or pharmaceutical
company to obtain original data or clinical study reports, because the studies identified were not yet due to be published. We plan to make
these contacts over the coming months and to incorporate any data into the next published version of this living systematic review.
Clinical study reports (CSRs) and other sources of evidence
We planned to request data from various sources beyond those listed above under electronic searches. We ran the searches as listed above
and did not identify any additional reports of known trials, or trials not identified via the electronic searches. We did not, therefore, proceed
to make contact but we plan to make additional eKorts in this area for the first update of this living systematic review.
We did not search Clinical Study Data Request (CSDR) (https://clinicalstudydatarequest.com), AllTrials (http://www.alltrials.net) or the
TrialsTracker website (https://trialstracker.ebmdatalab.net), because we determined that they were not useful for the identification of
clinical study reports and other sources of evidence.
We searched the European Medicines Agency (EMEA) (http://www.emea.europa.eu), but did not make a formal request for all relevant
clinical study reports (CSRs) to the European Medicines Agency (EMA) under the Access to Documents Policy (0043). We plan to pursue this
as part of the planned update of this living systematic review. We did not search the UK Medicine and Healthcare Regulatory Authority
(UK MHRA), as there is no database of trials to search. We plan to contact the UK MHRA to request clinical study reports for identified trials
regulated by them, as part of the planned update of this living systematic review.
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